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ABSTRACT OF DISSERTATION

DEVELOPMENT OF NOVEL CHEMICAL TOOLS FOR PROTEASOME BIOLOGY
& A NEW APPROACH TO 1-AZASPIROCYCLIC RING SYSTEM
The proteasome, a multiprotease complex, is clinically validated as an anticancer
target by the FDA approval of bortezomib and carfilzomib for the treatment of multiple
myeloma. The emergence of resistance to proteasome inhibitors however remains a major
clinical challenge. Recently, distinct types of proteasomes termed ‘intermediate
proteasomes’, which contain unconventional mixtures of catalytic subunits, have been
implicated with drug resistance of tumor cells. In elucidating the role of intermediate
proteasomes in drug resistance, a crucial step is to unequivocally determine the subunit
composition of intermediate proteasomes in cells. With this in mind, the goal of the
studies reported in this dissertation is to develop novel chemical tools which can facilitate
the investigation of intermediate proteasomes via two complementary approaches: a
FRET-based approach and a bifunctional cross-linking approach.
Chapter 2 describes the structure-based design, synthesis, and characterization of
a peptide epoxyketone-based fluorescent probe, named as LKS01-B650, which
selectively targets the immunoproteasome subunit β5i/LMP7. In addition to its utility in
determining the identity of intermediate proteasomes as FRET-based probe, this imaging
agent may also serve as a valuable tool in visualizing the immunoproteasome in living
cells.
Chapter 3 describes the design and synthesis of various epoxyketone-based
bifunctional agents. The ability of these bifunctional agents to cross-link different
catalytic subunits within a proteasome complex is shown by mobility shift assays.

These bifunctional agents may provide important information in determining the subunit
composition of proteasomes.
Chapter 4 describes a systematic study of the relationship between the proteasome
inhibitor structure and the inhibitory activity against critical subunits of the proteasome.
Given the reported role of β5i/LMP7 in autoimmune diseases, this study may provide
useful insights in developing therapeutic agents for autoimmune diseases as well as other
diseases.
Chapter 5 describes a separate study which is not related to proteasome biology.
A concise approach to synthesize 1-azaspirocyclic ring systems is developed by utilizing
a novel semi-pinacol/Beckmann rearrangement. Additionally, an environmentally benign,
microwave-assisted, and solvent-free self-condensation of carbonyl compounds is
reported.
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Chapter 1: Introduction & Objective of the Study
1.1. Intracellular Protein Degradation
Intracellular protein synthesis and protein degradation are two complementary processes
which play important roles in maintaining biological homeostasis. The dynamic state of
intracellular protein turnover is not only regulated by the rate of protein synthesis, but
also by the rate of proteolysis. As cellular processes depend on active proteins,
uncontrolled or inaccurate protein synthesis or degradation is potentially harmful to cells.
Even a small imbalance in the rate of protein synthesis and degradation can result in
cellular and tissue atrophy (loss of proteins from cells) or hypertrophy (increase in
protein contents of cells), which in turn can cause the deregulation of several cellular
processes (Mitch et al. 1996). To prevent promiscuous protein degradation, cells contain
complex proteolytic active sites that are carefully compartmentalized either in the
macromolecular complex known as the proteasome or in organelles such as lysosomes.
In all eukaryotic cells, the ubiquitin proteasome pathway (UPP) is responsible for
the degradation of the majority of intracellular proteins. However, some extracellular
proteins and cell surface proteins are degraded within lysosomes. The selection of
proteins to be degraded by lysosomes generally occurs during endocytosis (Lardeux et al.
1987; Baehrecke et al. 2005). Lysosomes contain several proteases such as cathepsins B,
H, and D for the degradation of proteins. In mammalian cells, there are other proteolytic
processes that involve the calpains and caspases. The calpains are cysteine proteases that
are activated during cellular injury and require Ca2+ for their activity (Goll et al. 2003).
On the other hand, caspases are aspartate-specific cysteine proteases that are required for
the degradation of cellular components during apoptosis (Salvesen et al. 1997).
1.2. Ubiquitin proteasome pathway (UPP)
The importance of the ubiquitin proteasome pathway (UPP) is evident from the 2004
Noble Prize in Chemistry, which was awarded to Aaron Chiechanover, Avram Hershko,
and Irwin Rose for their contributions to the discovery of ubiquitin and the understanding
1

of its role in protein degradation. The UPP is responsible for selective ATP-dependent
degradation of more than 80% of the intracellular proteins in eukaryotes (Adams, J.
2004). The primary functions of the UPP are degradation of damaged or unneeded
proteins and maintaining turnover of short-lived proteins that are essential for many
cellular regulatory mechanisms. For example, cell growth and gene expression are
controlled by the proteasomal degradation of transcriptional regulators, e.g. c-Jun, E2F-1
and β-catenin (Hershko et al. 1998). The degradation of cyclins and inhibitors of cyclindependent kinases is required for the regulation of cell cycle progression (Koepp et al.
1999). Similarly, the termination of certain transduction cascades is regulated by
proteasomal degradation of activated protein kinases such as protein kinase C and Src
tyrosine kinase (Lu et al. 1998; Harris et al. 1999). Furthermore, the ubiquitin proteasome
pathway (UPP) plays an important role in maintaining other cellular processes such as
inflammation (Palombella et al. 1998), muscle atrophy (Mitch et al. 1996), immune
responses (Rock et al.1999) and metabolic pathways (Hampton et al. 1996; Murakami et
al. 1992). Also, the UPP selectively breaks down mutant and misfolded proteins
(Schubert et al. 2000).
The whole process of protein degradation by the UPP involves two consecutive
and distinct steps. The first step involves the labeling of a protein for degradation by
covalent attachment of ubiquitin to the protein target (ubiquitination). In the second step,
a complex proteolytic system known as the proteasome degrades the ubiquitinated
protein into smaller peptides (degradation).
1.2.1. Ubiquitination
The key player in the ubiquitination process is ubiquitin (Ub) which is a highly conserved
protein of 76 amino acids. Ubiquitin contains a glycine residue (G76) at its C-terminal
end that serves as the site of covalent conjugation with the nucleophilic Ԗ-amino group of
a Lys residue of the target substrate (Vijay-Kumar et al. 1985).
A cascade of three enzymes (E1, E2 and E3) is required for the conjugation of a
ubiquitin (Ub) monomer or a polyubiquitin (poly-Ub) chain onto the protein destined for
degradation (Figure 1.1). This process is initiated by the activation of the C-terminal G76
of ubiquitin by the ubiquitin-activation enzyme, E1. This single E1 enzyme uses one ATP
2

to generate a highly reactive E1-Ub thioester intermediate (Handley et al. 1991). After
activation, the Ub thioester is transferred to the ubiquitin-conjugating enzyme E2 (Jentsch
et al. 1992; Scheffner et al. 1993; Zheng et al. 2000). E3 enzymes bind to protein
substrate and thus these ligases are mainly responsible for substrate specificity (Hershko
et al. 1986). The E2 enzyme conjugates with E3 ligase, which catalyses the transfer of Ub
chain to the substrate and forms an isopeptide bond between the Lys of the protein
substrate and G76 of Ub (Hershko et al. 1986; Reiss et al. 1989, Huang et al. 1999).

Figure 1.1 Conjugation of ubiquitin to a protein substrate by the E1-E2-E3
enzymatic cascade.
Ub also contains seven lysine residues (K63, K48, K33, K29, K27, K11 and K6)
that are used to create polyubiquitin chains. The covalent linkage between the C-terminal
G76 and lysine residue of the previous ubiquitin results in ubiquitin polymerization. The
nature of this linkage decides the fate of the substrate (Spence et al. 2000). For example,
only G76-K48-linked chains are destined for degradation by proteasome (Chau et al.
1989). On the other hand, K63-G76-linked chains are believed to play an important role
in DNA repair, endocytosis and translational regulation (Hofmann et al. 1999).
1.2.2. Protein Degradation by the 26S Proteasome
In the second step of the ubiquitin proteasome pathway (UPP), the polyubiquitinated
protein substrate is recognized and degraded by the 26S proteasome. The crystal structure
of the 26S proteasome from the archaeon Thermoplasma acidophilum showed that it is
composed of two substructures: the central barrel-shaped 20S proteasome that contains
3

multiple proteolytic sites and the 19S regulatory particles assembled at either or both
ends of the 20S proteasome (Lowe et al. 1995) (Figure 2). Each 19S regulatory particle
(RP) is composed of 18 subunits. Two subunits of the 19S RP with poly-ubiquitin chain
binding domains are responsible for recognition of polyubiquitinated substrates
(Deveraux et al. 1994; Lam et al. 2002). The 19S RP also contains six ATPases that assist
in recognition of the ubiquitin-tagged protein and provide the energy required to unfold
the protein (Kohler et al. 2001). After partial unfolding of the protein substrate, it is
translocated to the central core of the 26S proteasome that contains the active sites
responsible for protein degradation.
The 20S core of the 26S proteasome is a hollow cylinder and it is made up of four
stacked rings each comprising of α- and β-type subunits arranged in αββα stoichiometry
(Figure 1.2A). The outer two rings are each made up of seven α-subunits. The α-rings
play an important role in regulating substrate entry into the 20S core for proteolysis. The
inner two rings are also each made up of seven β-subunits. In prokaryotic proteasomes,
all the 14 β-subunits have identical proteolytic activity. While in case of eukaryotic
proteasome, only β1(Y), β2(Z) and β5(X) of each β-ring are catalytically active, each
having a unique proteolytic activity (Lowe et al. 1995) (Figure 1.2B).

Figure 1.2 (A) Structural composition of the 26S proteasome and (B) cross-sectional
view of subunits of a β-rings.

4

Structural and mutational studies revealed that the β5-subunit is responsible for
chymotrypsin-like (CT-L) activity and cleaves peptide bonds preferentially after bulky
hydrophobic residues (Groll et al. 1997; Heinemeyer et al. 1997; Groll et al. 1999). The
β1-subunit has caspase-like (C-L) activity i.e. it cleaves peptide bonds after acidic
residues; and β2 cleaves after basic residues, consistent with trypsin-like (T-L) activity.
Because of these three activities, the proteasome has the ability to degrade most of the
amino acid sequences found in intracellular proteins (Orlowski et al. 1990; Orlowski et
al. 2000, Arendt et al. 1997). The substrate specificity of different catalytic sites was
explained by structural analysis of their substrate specific (S1) pockets (Groll et al. 1997).
Residue 45 in the S1-pocket of each catalytic subunit mainly contributes to its cleavage
preference. The presence of Arg45 in the β1 S1 pocket provides it with a basic character,
which in turn favors the cleavage of peptide bonds after the acidic residues. The Gly
residue at position 45 makes a wide β2 S1 pocket, resulting in broad substrate specificity
and preferred cleavage after large basic residues. The β5 subunit contains Met45 in its S1
pocket, which explains its CT-L activity.
Cocrystallization of the Thermoplasma proteasome with the inhibitor Ac-LLnL-al
showed the covalent attachment of the N-terminal threonine of the catalytic β-subunits
with the aldehyde of Ac-LLnL-al (Lowe et al. 1995). This, in addition to mutational
studies, identified the N-terminal Thr1 as the key catalytic residue (Groll et al. 1997,
Groll et al. 1999). Mechanistically, the hydroxyl group on the N-terminal threonine
(Thr1-Oγ) is activated by the free amino group (NH2) (Scheme 1.1). The nucleophilic
attack by this activated hydroxyl then initiates hydrolysis of the peptide bond and thereby
forms a tetrahedral intermediate. This intermediate is then collapsed into an acyl-enzyme
ester and the first hydrolysis product. The hydrolysis of the ester bond is catalyzed by a
neighboring water molecule to produce the C-terminal peptide fragment, thereby
regenerating the Thr1-Oγ for another reaction. Based on this mechanism, which was
originally proposed by Groll et. al.1997, the proteasome was classified as a N-terminal
nucleophilic (Ntn) hydrolase. Aside from Thr1, Asp/Glu17 and Lys33 are also important
active site residues. Other neighboring side chains such as Ser129, Asp166, and Ser169
are also required for structural integrity of the proteolytic sites (Lowe et al. 1995;
Seemuller et al. 1995).
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Scheme 1.1 The proposed proteolytic mechanism of catalytically active proteasome
subunit.

1.3. Immunoproteasome
In addition to the standard/constitutive proteasome, mammalian cells are also capable of
producing an alternate form of proteasome known as the immunoproteasome, which
contains a different set of catalytic subunits: β1i /LMP2 (low molecular mass polypeptide
2), β2i/ MECL1 (multicatalytic endopeptidase complex 1) and β5i/LMP7 (low-molecular
mass polypeptide 7). The immunoproteasome is normally expressed in immune cells, but
can also be induced in non-hematopoietic cells following exposure to cytokines such as
interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α). The exposure of mammalian
cells to these cytokines induces the synthesis of immunoproteasome-specific catalytic
subunits β1i/LMP2, β2i/MECL1 and β5i/LMP7 which are preferentially incorporated
during proteasome assembly to create the immunoproteasome (Strehl et al. 2005) (Figure
1.3). Several cytokine-independent regulations of immunoproteasomes have also been
reported. One of them is nitric oxide (NO) which has been shown to upregulate immunosubunit expression in endothelial cells (Kotamraju et al. 2006). Other reported regulators
of immunoproteasomes include heat shock (Callahan et al. 2006), H2O2 (Ding et al. 2003)
and hyperglycemia (Zu et al. 2010).
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Figure 1.3 Formation of Immunoproteasome
The catalytic subunits of immunoproteasome have been associated with enhanced
chymotrypsin like (CT-L) and trypsin like (T-L) activities and reduced caspase like (C-L)
activity. This leads to the production of a completely different spectrum of degraded
peptides as compared to what result from the constitutive proteasome. Initially, the main
function of immunoproteasome in the cells was thought to be the generation of peptides
required for the major histocompatibility complex (MHC) class I antigen presentation.
However, studies in mice lacking LMP2 and LMP7 have suggested that the
immunoproteasome plays only a minor role in antigen presentation (Fehling et al. 1994,
Van Kaer et al. 1994). Recent studies have demonstrated the involvement of
immunoproteasomes in regulating of cytokine production in immune cells (Hensley et al.
2010).

Additionally,

several

studies

have

also

suggested

a

key

role

of

immunoproteasomes in T-cell differentiation (Muchamuel et al. 2009), survival (Chen et
al. 2001; Basler et al. 2006), and proliferation (Caudill et al. 2006).
In addition to its roles in the immune system, recent studies have revealed the
non-immune functions of immunoproteasome, such as anti-oxidative stress (Pickering et
al. 2010), prevention of protein aggregation (Seifert et al. 2010) and muscle remolding
(Cai et al. 2008, Zu et al. 2010). Importantly, recent studies have associated the
immunoproteasome to cells with disease states such as cancer (Altun et al. 2005),
neurodegenerative disease (Diaz-Hernandez et. al. 2004; Mishto et al. 2006), autoimmune
diseases (Basler et al. 2010; Muchamuel et al. 2009), and cardiovascular disease (Yang et
al. 2009; Zu et al. 2010). In line with these reports, the immunoproteasome is currently
being investigated as a therapeutic target in cancer, and autoimmune diseases.
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1.4. Assembly of the Proteasome & the Concept of Intermediate Proteasome
In vertebrates, proteasome assembly is a highly ordered process and involves the
formation of two symmetrical half proteasomes, each containing one α and one β-ring.
Studies in Trypanosoma brucei and E. coli suggested that the process of proteasome
assembly begins with α-ring formation (Yao et al. 1999; Gerards et al. 1997). Two
dimeric proteasome assembly chaperones (PAC1-PAC2 and PAC3-PAC4) assist in this
process. Knockdown experiments showed that PAC1-PAC2 complex not only assists in
α-ring assembly but also prevents dimerization of α-rings (Hirano et al. 2005). The
PAC1-PAC2 heterodimer has been shown to stick to the proteasome precursor (α1-7PAC1-PAC2) until the formation of the fully matured 20S proteasome (Hirano et al.
2005). The primary role of the PAC3-PAC4 complex is to maintain the correct subunit
orientation of the α-ring by inhibiting inappropriate binding of α-subunits (Yashiroda et
al. 2008).
The α-ring directly serves as a platform for the binding of β subunits. The three
catalytic subunits (β1, β2 and β5) and non-catalytic β6 and β7 are synthesized as
precursors having a propeptides at their N-termini. These propeptides are only removed
at the final stage of the proteasome assembly to expose the catalytic Thr of β1, β2 and β5.
The β subunits are recruited onto the α ring in an ordered set of steps, which is directed
by the mutual interactions of their propeptides (Hirano et al. 2008). β ring formation is
initiated by proteasome maturation protein (POMP) (Ramos et al. 1998; Witt et al. 2000).
First, the β2 subunit is recruited to the α ring and is followed by the sequential addition of
β3 and β4 subunits to form the 13S proteasome complex. Next, β5 is added, followed by
the β6-subunit. β1 can be recruited at any time after incorporation of β2 and β3. Finally,
β7-subunit is added to complete the assembly of the β ring and thereby construct the 16S
proteasome (α1-7β1-7-PAC1-PAC2-POMP) (Hirano et al. 2008).
The dimerization of two 16S half proteasomes is triggered by the incorporation of
β7 and insertion of its C-terminal tail into a groove between β1 and β2 of the opposite
ring (Marques et al. 2007; Hirano et al. 2008). After the correct dimerization of the half
proteasomes, the propeptides at the N-terminus of β subunits are removed by an
intramolecular autolysis mechanism. This step results in activation of the N-terminal Thr
residues of catalytic subunits (β1, β2 and β5), which degrade POMP and PAC1-PAC2 to
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complete the formation of the mature 20S proteasome (α1-7β1-7β1-7α1-7) (Hirano et al.
2005; Ramos et al. 1998). To protect unregulated protein degradation by the matured
catalytic subunits in the 20S proteasome, the propeptides on α-subunits serve as a gate for
entry into the chamber.
Similar to the constitutive proteasome, the immunoproteasome subunits are also
assembled in a defined order. However, in immunoproteasome assembly, there is an early
incorporation of β1i subunit on to the α-ring (Nandi et al. 1997). Subunit β1i is required
for the incorporation of β2i, although β1i can be incorporated in the absence of β2i
(Groettrup et al. 1997). The propeptide of β5i was found to be necessary for cleaving the
propeptide of β1i and β2i (Kingsbury et al. 2000). Therefore, after the addition of β3 and
β4, β5i (LMP7) is preferentially incorporated over β5 (Griffin et al. 1998). This
cooperative assembly of the three inducible subunits (β1i, β2i and β5i) favors their
common incorporation to form the immunoproteasome.
Recently, there have been several reports which suggest the formation of
proteasomes having a non-standard mixture of catalytic subunits of the constitutive- and
immuno-proteasome (Figure 1.4). The existence of these so called “intermediate
proteasomes” was first reported by Burkhardt et al. (2000). In this study, subtypes of the
20S proteasome were purified and separated by chromatographic means. Analysis of the
rat spleen suggested the presence of small amounts of intermediate proteasomes (β1-β2β5i and β1-β2i-β5i). The activity of these subtypes against fluorogenic proteasome
substrates was found to be different, suggesting the unique activities and/or function of
these subtypes in vivo (Burkhardt et al. 2000). Later, another study suggested the
formation of proteasome subtype β1-β2i-β5i, although the existence of proteasomes
containing β2i without β1i does not agree with the proposed model of cooperative
proteasome assembly (De et al. 2003). Also, β5i was found to be expressed in β1i- and
β2i-deficient cells, suggesting the formation of subtype β1-β2-β5i (De et al. 2003; Basler
et al. 2006). In 2007, Drews et al. developed a new protocol for in-solution isoelectric
focusing of multiprotease complexes. They observed differences in pI values of cardiac
and hepatic proteasomes and noted: “These data suggest the possibility of mixed 20S
proteasome assembly, a departure from the currently hypothesized two subpopulations:
constitutive and immuno forms.” More recently, Guillaume et al. (2010) isolated two
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major intermediate proteasomes (β1-β2-β5i and β1i-β2-β5i), which are found to be
responsible for the processing of certain tumor antigens of clinical interest.
As a matured 20S proteasome is made up of two β-rings, we cannot rule out the
existence of two rings with different subunit composition (i.e. asymmetric intermediate
proteasome). As Klare et al. noted in 2007: “Our study showed that subunit replacement
can be confined to one half of the proteasome cylinder, resulting in the formation of
intermediate-type proteasomes with “asymmetric” subunit composition.” Given that β5i
is required for the existence of β1i and β2i, theoretically there are 13 subtypes of
proteasome possible as suggested by Klare et al. 2007.

Figure 1.4. Different proteasome subtypes
1.5. History of proteasome inhibitors
Initially, proteasome inhibitors were developed to understand the functional role of the
proteasomes in the cell. As explained earlier, the key step in protein degradation by the
proteasome is the nucleophilic attack of the hydroxyl group of Thr1 (Thr1-Oγ) on peptide
bonds of proteins (Scheme 1.1). Therefore, most of the proteasome inhibitors developed
so far target the N-terminal Thr1 of the catalytic subunits of the proteasome (Figure 1.5).
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The most important proteasome inhibitors can be classified into five different classes:
peptide aldehydes, peptide vinyl sulfones, peptide boronates, β-lactones and peptide
epoxyketones.
Peptide aldehydes were the first class of proteasome inhibitors to be developed.
Because of the similar catalytic activities of serine/cysteine protease and the proteasome,
initially known inhibitors of these proteases were explored as proteasome inhibitors. A
serine and cysteine protease, Leupeptin (1), was shown to inhibit the T-L activity of the
proteasome (Wilk et al. 1983). Later, calpain inhibitors I/II were found to inhibit the CTL activity of the proteasome (Orlowski et al. 1990). Co-crystallization of caplain inhibitor
I (Ac-Leu-Leu-nLeu-CHO) with the yeast proteasome showed hemiacetal bond
formation between the active Thr1-Oγs and the aldehyde group of inhibitor (Scheme 2A)
(Groll et al. 1997). Many peptide aldehydes have been developed so far, and MG115 (ZLeu-Leu-nVal-CHO, 2), MG132 (Z-Leu-Leu-Leu-CHO) and PSI (Z-Ile-Glu(OtBu)-AlaLeu-CHO) were found to be selective and potent inhibitors of CT-L activity of the
proteasome (Lee et al. 1996, Rock et al. 1994). All of these aldehyde pharmacophorebased inhibitors also target other proteases in cells and thus they have limited therapeutic
potential. Still, peptide aldehydes are the most widely used inhibitors for studying
proteasome biology.
Several additional electrophilic groups were explored as a pharmacophores for
proteasome inhibitors. The ability of the vinyl sulfone group, acting as a Michael
acceptor, to bind to the hydroxyl group of Thr1 was first explored by Bogyo’s lab
(Scheme 1.2B). Bogyo and co-workers showed that peptide vinyl sulfones, Nip-LeuLeu-Leu-VS (9) and Tyr-Leu-Leu-Leu-VS, bind to catalytic β-subunits of the proteasome
(Bogyo et al. 1997 and 1998). Later, Ada-Ahx3-Leu-Leu-Leu-VS (10) was found to be
the most potent vinyl sulfone-based inhibitor of the proteasome and was shown to inhibit
all the catalytically active sites of both the constitutive and immunoproteasome. This
compound was further labeled with a radioisotope, biotin, and fluorescent groups and the
resulting derivatives were successfully used to study the mechanism of proteasome action
(Kessler et al. 2001). However, the peptide vinyl sulfones are also known to target the
thiol groups of cysteine proteases, limiting their applications as molecular probes in
proteasome biology.
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Peptide boronic acids were known to inhibit serine proteases such as
chymotrypsin (Kettner et al. 1984; Weber et al. 1995), so it was postulated that they
might potentially inhibit the chymotrypsin- like (CT-L) activity of the proteasome. Adam
and co-workers investigated a few peptide boronates such as MG262 (Z-Leu-Leu-Leuboronate, 8) and found them to be very potent inhibitors with much slower dissociation
rates as compared to aldehyde-based inhibitors (Adams et al. 1998). Interestingly, these
peptide boronates were found to inhibit the proteasome reversibly (Gardner et al. 2000).
As compared to aldehyde and vinyl sulfones, the peptide boronates were found to be poor
inhibitors of cysteine proteases (Adams et al. 1998). The selectivity of boronates towards
the proteasome was postulated to arise from the interaction between the lone pair of the
hydroxyl group of Thr1-Oγ and the empty p-orbital on the boron atom of the inhibitor
(Scheme 1.2C). This selectivity of boronates made them attractive targets for drug
development. Further medicinal efforts resulted into the development of the first-in-class
proteasome inhibitor drug, bortezomib, which was subsequently approved by the FDA
for the treatment of multiple myeloma (see Sec. 1.6 for detail).
Lactacystin (3) was the first natural product reported as a selective inhibitor of the
proteasome with a non-peptide backbone. It was originally discovered as a metabolite of
Streptomyces lactacystinaeus and found to induce neuritogenesis in neuroblastoma cells
(Omura et al. 1991). Later, radiolabeled derivatives of lactacystin demonstrated its ability
to bind predominantly to the β5 subunit of mammalian proteasomes, irreversibly
inhibiting CT-L activity. The T-L and C-L activities were also found to be blocked, but at
much slower rates (Fenteany et al. 1995). However, in vivo studies demonstrated that
lactacystin itself does not inhibit proteasomal activites (Corey et al. 1999). Kinetic
analysis suggested that lactacystin is hydrolysed into clasto-lactacystin β-lactone (4) at
pH 8, and then the β-lactone reacts with the catalytic Thr1 of the proteasome (Scheme
1.2D) (Dick, L. R. 1996). This mechanism of action of lactacystin was confirmed by Xray diffraction analysis of the yeast proteasome complexed with clasto-lactacystin βlactone (Groll et al. 1997). Even though the β-lactones were found to be more selective
inhibitors of proteasomes compared to peptide aldehydes, their unstable nature at neutral
pH, complex synthesis, and ability to bind to other proteases discouraged further
medicinal chemistry efforts.
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Figure 1.5. Classification of proteasome inhibitors based on their pharmacophores
(blue).
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Scheme 1.2 Mechanism of proteasome inhibition by different classes of inhibitors.
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Another important class of proteasome inhibitors are the peptidyl epoxyketones.
Crews and coworkers reported eponemycin (5) and epoxomicin (6), two peptidyl α’,β’epoxyketone natural products, as selective inhibitors of the proteasome (Meng et al. 1999
and 1999b). Eponemycin was originally isolated from Streptomyces hygroscopicus and
was later found to bind to the β1i, β5i and β5 subunits of the proteasome (Meng et al.
1999). On the other hand, epoxomicin was found to primarily target the CT-L activity of
the proteasome and bind to β2, β2i, β5 and β5i. Further studies demonstrated that
epoxomicin does not inhibit other proteases such as papin, calpin, trypsin, chymotrypsin
or cathepsins (Meng et al. 1999b). The unusually high specificity of epoxomicin was
explained by crystal structure analysis. Co-crystallization of epoxomicin with the yeast
proteasome showed the formation of a six-membered morpholine ring system between
the epoxyketone pharmacophore of epoxomicin and the N-terminal Thr1 of proteasome
catalytic subunits (Groll et al. 2000). Mechanistically, the formation of this unique
morpholino ring can be explained by the nucleophilic attack of Thr1-Oγ on the carbonyl
group of the epoxyketone to form a hemiacetal intermediate. This positions the free
amine group at N-terminus perfectly to carry out ring opening of the epoxide to form the
morpholino ring (Scheme 1.2D). The high specificity of epoxomicin towards the 20S
proteasome encouraged the synthesis of second generation α’,β’-epoxyketones. One of
the most promising compounds, PR-171 or carfilzomib, has been recently approved by
the FDA for the treatment of relapsed multiple myeloma (see Sec. 1.6 for detail).
1.6. Clinically Relevant Proteasomes Inhibitors
Increased understanding of the ubiquitin proteasome pathway (UPP) resulted into the
identification of the proteasome as a target for cancer treatment. Proteasome inhibitors
were found to induce cell death in malignant cell lines (Imajoh-Ohmi et al. 1995;
Shinohara et al. 1996), which was not surprising given that the proteasome-mediated
degradation of proteins helps regulate a veriety of cellular processes. Interestingly,
malignant cells were found to be preferentially affected by proteasome inhibition,
suggesting a higher dependence of tumor cells on the UPP (An et al. 1998; Orlowski et
al. 1998; Masdehors et al. 2000). These studies provided the rational for the development
of proteasome inhibitors as anti-cancer drugs.
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1.6.1 Reversible Inhibitors
After building on strong preclinical rational and encouraging results from clinical trials,
bortezomib (PS-341 or VelcadeTM) became the first proteasome inhibitor to be approved
by US Food and Drug Administration (FDA) for the treatment of relapsed multiple
myeloma and mantle cell lymphoma (Figure 1.6). During clinical trials, bortezomib
alone caused an overall response rate of 41-43% in relapsed and refractory multiple
myeloma (Richardson et al. 2007; Orlowski et al. 2007). Several phase II clinical trials
confirmed the activity of bortezomib in non-Hodgkin’s lymphoma (O’Connor et al. 2005;
Goy et al. 2005; Belch et al. 2007). Currently, bortezomib is being tested in combinations
with other drugs for the treatment of other types of cancer.

Figure 1.6. Classification of proteasome inhibitors under clinical trials based on
their mode of action.
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Structurally, bortezomib (11) is a dipeptide boronate proteasome inhibitor that
targets, specifically and reversibly, the CT-L activity of the 20S proteasome (Lightcap et
al. 2000). It has also been shown to target the C-L activity of the proteasome, but with
lower affinity (Demo et al. 2007). A recent study using subunit-specific fluorogenic
substrates showed that bortezomib inhibits the β1i, β5 and β5i subunits of the proteasome
with IC50 values of 5.5 nM, 8.2 nM and 3.3 nM, respectively (Blackburn et al. 2010).
Despite its clinical success in myeloma and mantle cell lymphoma, bortezomib
therapy has several disadvantages. First, due to the poor bioavailability of bortezomib, it
requires twice-weekly or weekly intravenous administration and thus patients must go to
special clinics regularly. Additionally, some serious side effects of bortezomib have been
observed, such as thrombocytopenia, neutroprnia, and gastrointestinal disorders. The
development of reversible but severe peripheral neuropathy has also been observed in
more than one-third of bortezomib-treated patients. These side effects are mainly
associated with off-target activity of bortezomib. Arastu-Kapur et. al. (2011) recently
demonstrated that some serine proteases, such as cathepsin A/G, chymase, HtrA2/omi
and dipeptidyl peptidase II, are inhibited by bortezomib. These proteases are required for
neuronal cell survival, and their inhibition by bortezomib treatment causes neurotoxicity,
tremor, and reduced nerve conduction velocity. Furthermore, despite encouraging
preclinical data, the response to bortezomib treatment in patients with non-small cell lung
cancer (NSCLC) and other solid tumors has been very disappointing. In addition to this
inherent resistance, acquired resistance to bortezomib treatment is also a major clinical
concern.
The limitations of bortezomib treatment have provided a wide range of
opportunities for the development of a second generation of proteasome inhibitordrugs.
Currently, there are two additional boronic acid-based proteasome inhibitors under
clinical trials, namely Delanzomib/CEP-18770 (12) and Ixazomib/MLN9074 (13)
(Kupperman et al. 2010, Sanchez et al. 2010, Piva et al. 2008). Preclinical studies with
these proteasome inhibitors have demonstrated their enhanced anti-tumor activity
compared to bortezomib. Additionally, an advantage of these drug candidates is their oral
route of administration, which offers more flexible dosing and convenience for the
patient. However, since the mechanism of action of both of these second-generation
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boronates is similar to that of bortezomib, it is unlikely that these inhibitors will
overcome bortezomib resistance.
1.6.2 Irreversible Inhibitors
As previously mentioned, α’,β’-epoxyketones inhibit proteasome activity in a highly
selective manner because of the unique interaction of the epoxyketone pharmacophore
and the N-terminal Thr residues of the catalytic subunits of the proteasome (Scheme
1.2E). An extensive medicinal chemistry effort led to the development of the first
epoxyketone based drug, Carfilzomib (14) (Figure 1.6). Carfilzomib is a tetrapeptide
derivative of the natural product epoxomycin (Figure 4). Compared to bortezomib,
carfilzomib is a more selective and potent inhibitor of the CT-L activity of the
proteasome (Parlati et al. 2009, Kuhn et al. 2007). It has been shown that carfilzomib
binds to both β5 and β5i catalytic subunits of the proteasome (Parlati et al. 2009). Several
studies have shown the ability of carfilzomib to induce cell death in bortezomib-resistant
cells (Kuhn et al. 2007; Demo et al. 2007). After successful Phase 3 clinical trials,
carfilzomib was approved by the FDA for the treatment of relapsed multiple myeloma in
July, 2012.
Carfilzomib’s increased specificity results in decreased off-target activity in
comparison with bortezomib. The most common side effects of carfilzomib treatment
include pneumonia, thrombocytopenia, pyrexia and GradeI/II gastrointestinal problems,
but, importantly, no peripheral neurotoxicity was observed. Another major limitation of
carfilzomib is its poor bioavailability and therefore its requirement of intravenous or
subcutaneous routes of administration. To address these limitations, an orally
bioavailable proteasome inhibitor (ONX0912 or Oprozomib or PR-047) is already in
phase 1 clinical trials. ONX0912 (15) is a tripeptide epoxyketone-based inhibitor that
inhibits both β5 and β5i with IC50 values of 36nM and 82nM (Zhau et al. 2009).
ONX0912 is now being evaluated as a monotherapy for the treatment of hematological
malignancies and some solid tumors.
Since most of these proteasome inhibitors are peptide-based, they can be degraded
by endogenous peptidases and proteases. Thus, researchers are also developing
proteasome inhibitors without peptide backbones. One such irreversible non-peptidyl
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proteasome inhibitor is NPI-0052/Marizomib (16). The pharmacophore of NPI-0052 is a
β-lactone, and the mechanism of action is the same as explained earlier (Scheme 1.2D).
NPI-0052 has been shown to inhibit the CT-L and T-L activities of the proteasome faster
than bortezomib (Chauhan et al. 2005). Additionally, NPI-0052 showed activity in
bortezomib-resistant tumor cells (Chauhan et al. 2005). Currently, NPI-0052 is under
evaluation in Phase I clinical trials for the treatment of multiple myeloma and solid
tumors. Despite encouraging preclinical and phase I clinical studies, the half-life of NPI0052 is less than 5 minutes, which may limit its therapeutic potential.
Another interesting approach to overcome side effects of proteasome inhibitors is
to target the immunoproteasomes. All of the proteasome inhibitors currently under
clinical trials target both the constitutive and immunoproteasome. Although
immunoproteasome expression is predominantly limited to immune cells, recent studies
have demonstrated high expression levels of immunoproteasome catalytic subunits (β1i,
β2i and β5i) in various cancer cell lines. Therefore, it is possible that immunoproteasomespecific inhibitors could improve the side effects by sparing most noncancerous cells
which do not contain immunoproteasomes.
1.7. Intermediate Proteasomes and Drug Resistance
The approval of the proteasome inhibitors, bortezomib and carfilzomib, by the FDA has
validated the proteasome as an anticancer target. Even though these two drugs have
shown very encouraging clinical responses, intrinsic and acquired resistance to
proteasome inhibitors has remained a major clinical concern. Despite multiple
mechanisms so far identified, there appears no major unifying mechanism which can
account for intrinsic or acquired resistance to proteasome inhibitors. A better
understanding of the mechanism of this resistance would be helpful in developing more
effective therapies. Interestingly, there are some reports which have associated
intermediate proteasomes with resistance to proteasome inhibitors. For example, unique
subtypes of intermediate proteasomes with differential sensitivities to proteasome
inhibitors have been identified in the murine heart and liver (Gomes et al. 2009; Kloss et
al. 2010). Additionally, when treated with proteasome inhibitors, cancer cells were found
to alter the expression of certain proteasome catalytic subunits (Fuchs et al. 2008; Busse
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et al. 2008, Ruchrich et al. 2009), indicating the formation of different proteasome
subtypes in response to proteasome inhibitors. Recently, specific intermediate
proteasomes have been identified in cancer cells of differing sensitivity to proteasome
inhibitors (Wang et al. 2011, Guillaume et al. 2010).
All these previous reports and preliminary experiments conduct in ou lab (data not
reported in this dissertation) have suggested that the presence and/or formation of
different intermediate proteasomes may underlie a unique mechanism of resistance to
proteasome inhibitors. With this in mind, we hypothesize that intermediate
proteasomes contribute to cellular adaptation to adverse conditions, such as
exposure to proteasome inhibitors. A major challenge in testing our hypothesis is that
there is no appropriate means currently available to identify different proteasome
subtypes in cells.
1.8. Our Approaches to Identify Intermediate Proteasome
Most of the current research in proteasome biology is focused on two conventional forms
of the proteasome (constitutive- and immuno-proteasomes). Despite growing interest in
intermediate proteasomes, there is a significant knowledge gap in understanding the role
of intermediate proteasomes in cells. A crucial step to study the role of intermediate
proteasomes in drug-resistant cells is to determine proteasome subunit composition and
specific subtypes present in these cells. Traditional techniques, such as western blotting
and ELISA, can only assess the overall subunit levels in a preparation of proteasomes
rather than actual composition or the specific proteasome subtypes present in cells.
Recently, Guillaume et al. (2010) have reported the first method to identify intermediate
proteasomes using a set of subunit-specific antibodies. Although this method directly
shows the existence of intermediate proteasomes, the procedure has serious limitations.
First, it requires three sequential immunoprecipitation steps, which are difficult to
perform for each and every cell line. Also, this procedure may identify only a subpopulation of intermediate proteasomes present in cells. Therefore, there is a need to
develop novel chemical tools/approaches to identify intermediate proteasomes. The
identification of these proteasome subtypes in a series of cancer cell lines will allow us to
investigate whether specific subtypes are associated with intrinsic and acquired resistance
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to proteasome inhibitors. Currently, Dr. Kim’s lab is investigating two complementary
approaches to identify intermediate proteasomes: a FRET-based approach and a chemical
cross-linking approach utilizing bifunctional agents.
1.8.1. FRET Approach
Fluorescence resonance energy transfer or Fӧrster resonance energy transfer (FRET) has
emerged as a sensitive tool for elucidating the various structures and dynamics of
different biomolecular systems. FRET is a spectroscopic process which involves a nonradiative transfer of energy from an excited donor fluorophore to an acceptor fluorophore
over long distances (10-100 Å) (Figure 1.7). This energy transfer requires a resonance
between singlet-singlet electronic transitions of the two fluorophores, generated by
dipolar coupling between the transition moments of donor and acceptor. The efficiency of
energy transfer during the FRET process depends on the distance and relative orientation
of the donor and acceptor, as well as the spectral properties of the two fluorophores. The
first practical description of FRET was reported by Theodor Fӧrster in 1946. Since then,
due to its relative simplicity and ability to follow the dynamics of individual complexes
with high sensitivity, FRET has been extensively used for studying protein structures,
protein-nucleic acids interactions, DNA structures, RNA folding and many other systems.

Figure 1.7 (A) Utilization of FRET to study proteasome biology and (B) molecular
assembly of the 20S proteasome.
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As FRET provides a unique tool for studying molecular interactions with subnanometer sensitivity, we envisioned that a FRET-based method could also be used for
determining different proteasome subtypes in cells. The X-ray structural analysis of the
yeast 20S proteasome revealed the intermolecular distances between Thr1Oϒ residues of
the catalytic subunits of the 20S proteasome complex (Figure 1.7B).

These

intermolecular distances are within the range (<100 Å) of FRET detection. Additionally,
the confinement of the catalytic residues on the interior of the proteasome will facilitate
the detection of FRET only when the two targeted subunits are present within the same
proteasome complex (Figure 1.7A). Therefore, if we label the catalytic subunits with
different fluorescent probes, the identity of non-standard mixtures of catalytic subunits
(intermediate proteasomes) can be easily detected utilizing the FRET process.
The application of a FRET-based approach in proteasome biology requires the
specific labeling of different catalytic subunits of proteasomes with donor/acceptor
fluorescent pairs. However, the lack of appropriate fluorescent probes selective for the
different catalytic subunits of proteasomes limits our options. Therefore, to explore the
utility of a FRET-based method in the context of proteasome biology, there is a need to
develop activity-based fluorescent probes targeting specific proteasome subunits.
1.8.2 Chemical Cross-linking Approach Utilizing Bifunctional Agents
Complementary to the FRET-based method, we decided to use a more traditional
chemical cross-linking approach to analyze the subunit composition of proteasomes. This
approach involves the formation of a covalent bridge between two different proteins in
close proximity. It utilizes bifunctional agents containing two chemical groups that are
reactive towards specific functional groups on proteins. The bifunctional cross-linking
agents have proved to be very useful to study the tertiary and quaternary structure of
proteins and to identify the spatial arrangements of subunits in oligomeric proteins.
Over a period of time, Dr. Kim’s lab has developed epoxyketone based inhibitors
selective for different catalytic subunits of proteasomes. These selective inhibitors could
be used to design and synthesize several bifunctional agents. Based on the previouslydetermined intermolecular distances between catalytic subunits within the 20S
proteasome complex (Figure 1.7B), bifunctional agents with appropriate spacer arm
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lengths to covalently cross-link two different catalytic subunits within the same
proteasome complex could be developed. Western blotting analysis of the reaction
products of the proteasome and these bifunctional reagents could provide a direct and
rapid method to identify different proteasome.

Figure 1.8 Our approach to cross-link to different catalytic subunits within a
proteasome complex utilizing bifunctional probes.
1.9. Specific Aims
Aim 1. To develop fluorescently labeled molecular probes selectively targeting the
catalytically active immunoproteasome subunits. This study will require structurebased design, synthesis, and characterization of activity-based fluorescent probes capable
of labeling catalytic subunits of the immunoproteasome. Given the implication of
immunoproteasomes in cancer and inflammatory diseases, these imaging probes will
provide a valuable tool to analyze the functions and dynamics of the immunoproteasome
in disease states. Additionally, these fluorescent probes can be used in FRET studies to
identify different intermediate proteasome subtypes. The details of these studies are
reported in chapter 2.
Aim 2. To develop bifunctional agents capable of cross-linking two catalytic
subunits within the 20S proteasome complex. In this study, we will design and
synthesize a few epoxyketone pharmacophore-based bifunctional molecules by utilizing
the knowledge gained by inhibitor screening in our lab. The ability of these bifunctional
agents to cross-link different catalytic subunits of the proteasome will be tested using
mobility shift assays. The results obtained will provide a proof of concept of cross23

linking two proteasome catalytic subunits using bifunctional agents, which may serve as
a direct and convincing method to identify intermediate proteasomes. The details of these
studies are reported in chapter 3.
Aim 3. To develop a selective inhibitor of the β5i/LMP7 subunit of the
immunoproteasome. In this study, we plan to synthesize a small library of peptidylepoxyketone-based compounds based on the reference compound IPSI, with the goal of
identifying a selective inhibitor of the LMP7 subunit of the immunoproteasome. The
synthesized compounds will be screened for their ability to selectively target LMP7 using
proteasome activity assays. As recent studies have associated elevated levels of the
LMP7-subunits with some pathological disorders such as cancer and autoimmune
disease, a selective inhibitor of LMP7-subunit may provide a therapeutic potential for
targeting LMP7 in cancer and rheumatoid arthritis. The details of these studies are
reported in chapter 4.
Aim 4. To develop a new and concise approach to synthesize 1-azaspirocyclic ring
systems. This is a completely different study which is not related to proteasomes (Aim 13). In this study, we will design and develop a new, concise and more flexible route for
the construction of 1-azaspirocyclic ring systems. These structural motifs are present in
various natural products that are structurally complex and show interesting biological
activities. We plan to utilize Lewis catalyzed semi-pinacol rearrangement and acid
mediated Beckmann rearrangement to synthesize 1-azaspriocyclic ring systems. Our
approach may lead to the development of new, novel, or more efficient synthetic
reactions. The details of these studies are reported in chapter 5.

Copyright © Lalit Kumar 2012
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Chapter 2: Development of activity-based fluorescent probes targeting the
β5i/LMP7 catalytic subunits of the immunoproteasome†
2.1 Overview of the Study
To investigate our FRET-based approach for the identification of intermediate
proteasomes, we require activity-based fluorescent probes which are selective towards
different catalytic subunits of the immunoproteasome. The primary goal of the study
reported in this chapter is to develop fluorescently-labeled molecular probes selective for
the immunoproteasome catalytic subunit β5i/LMP7. A structure-based design and
synthesis of the fluorescently-labeled compound LKS01-B650 is described here. The
western blot analysis and in-gel fluorescence assay demonstrates the ability of LKS01B650 to selectively label β5i/LMP7. The utility of this imaging agent to visualize
β5i/LMP7 in living cells is demonstrated in various localization studies. In addition to
their utility for FRET-based studies, these fluorescent probes may serve as valuable
imaging agents for the real-time investigation of immunoproteasome functions in living
cells.
2.2. Introduction
2.2.1. Activity Based Probes
Over the past 20-30 years, the advancement in the field of global genomics and
proteomics has allowed us to understand the functions of genes and proteins in complex
networks within a cell. The field of genomics includes the study of all of the genes of a
cell or tissue and the relationship of those genes with each other and with adverse
environmental effects (Venter et al. 2001). A raw genome sequence data is informative
____________________
† A report of this work has been published. Portions taken in part from: Lalit Kumar Sharma,
Na-Ra Lee, Eun-Ryoung Jang, Beilei Lei, Chang-Guo Zhan, Wooin Lee, Kyung Bo Kim.
ChemBioChem 2012, 13, 1899-1903.
† The work reported in this chapter was conducted in collaboration with Wooin Lee and
Chang-Guo Zhan at College of Pharmacy, University of Kentucky.
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(Reiss 2001), but it often fails to provide insight into the functional roles of specific gene
products.
To address the complexity arisen from genome sequences, the field of proteomics
was established. Proteomics is the analysis of the functional regulation of all of the
proteins in a given proteome (Wasinger et al. 1995). The traditional proteomics
methodology is based on two dimensional gel electrophoresis (2-DE) combined with
protein staining and mass spectrometry. Other techniques which are used for purification
and identification of proteins, include geLC-MS/MS, DIGE, MudPIT, ICAT etc. These
proteomic methods allow for global analysis of protein abundance but they are still
unable to analyze the activity and the function of the proteins/enzymes.
In cells, most enzymes are often synthesized as inactive zymogens that require
activation by proteolytic cleavage to carry out specific biological processes. To
differentiate the functions of active and inactive form of enzymes, a new division of
proteomics, known as activity-based proteomics, was established. This method utilizes
small molecules designed to target the active sites of enzymes. As these activity-based
probes (ABPs) are able to covalently label the active site of enzymes, they are highly
selective and allow specific labeling of active enzymes while inactive enzymes remain
unlabeled (Kidd et al. 2001).

Figure 2.1 General structure of activity-based probes (ABPs) having three basic
components: warhead (green), linker (blue) and tag (red).
ABPs are composed of three main structural elements: the reactive group
(warhead), linker and chemical tag (Figure 2.1) (Kidd et al. 2001). The warhead of the
ABPs consists of a reactive functional group which is capable of forming a covalent bond
with the active site of the enzyme. The linker is generally used to separate the reactive
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group from the tag and in some cases it also enhances the specificity of the probe. The
chemical tag of the ABPs enables the visualization and/or purification of the labeled
protein. The most commonly used chemical tags include radioisotopes, fluorescent dyes
and biotin.
The application of fluorophores as chemical tags was the most exciting
development in the field of activity-based proteomics. Fluorophores are generally safe as
compared to radioisotopes and show comparable sensitivity. Also, various types of
fluorophores are commercially available and span a long range of emission spectra from
blue to near-infra red (NIR). Fluorescently-labeled ABPs, being highly selective, allow
us to monitor the activity of enzymes in living cells or organisms, in real time and with
spatial resolution.
2.2.2. Activity Based Probes & Proteasome Biology
For proteasome biology, the application of activity based probes can be particularly
useful since there are two forms of β subunits present in cells: catalytically inactive,
immature precursor forms and active, mature forms (Chapter 1, Sec 1.4). Initially, the
catalytic β-subunits of proteasomes are genetically expressed with N-terminal
propeptides. These β-propeptides assist in subunit folding and molecular assembly of the
20S proteasome, but their presence directly blocks the proteolytic active sites (Figure
2.2). Only during the final step of assembly of the 20S proteasome, these propeptides are
cleaved off to expose the catalytic Thr residues of β1, β2 and β5.

Figure 2.2 Strucuture of N-terminal Thr1 in precursor and matured β-ubunits.
Thus, the immature β subunits undergo maturation only in the fully assembled
proteasome complex (Figure 2.2). Investigating the localization pattern of the
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catalytically active immunoproteasome using immunofluorescence labeling is very
difficult, since antibodies often detect both catalytically active and propeptide-containing
inactive forms of proteasome subunits
General proteasome inhibitors containing active-site-targeting pharmacophores,
such as the vinyl sulfone (Bogyo et. al. 1997) or epoxyketone functional groups (Groll et
al. 2000), can be used as activity-based probes because of their ability to target only the
catalytically active β subunits in the fully assembled proteasome. The use of these
pharmacophores led to the design of the first generation of activity-based fluorescent
probes targeting proteasomes. In 2006, Verdoes et. al. reported a BODIPY-labeled vinyl
sulfone-based ABP (MV151) (17), which

binds to all catalytic subunits of the

proteasome in living cells. The same research group designed a more selective
fluorescent probe, BODIPY-epoxomicin (18), which was shown to covalently modify β1
and β5 subunits of the proteasome.

Figure 2.3 Structures of commonly used proteasome targeting ABPs (MV151 and
BODIPY-labeled epoxomicin).
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Both of these fluorescently labeled proteasome targeting ABPs proved to be very
useful in functional studies of active proteasomes in tissues and for subunit-specific
inhibitor screening (Berkers et al. 2007, Ovaa et al. 2007). However, due to high
structural homology between the immunoproteasome and the constitutive proteasome
(Huber et al. 2012), these probes typically target both proteasome subtypes, adding to the
difficulty in deciphering the distinct functions of the immunoproteasome. Therefore, in
order to properly study the functional intricacies of the immunoproteasome, it is
necessary

to

develop a

new

generation

of

molecular

probes

specific

for

immunoproteasome subunits. The goal of the study described in this chapter is to
develop fluorescently-labeled ABPs that selectively bind the catalytically active
β5i/LMP7 subunit of the immunoproteasome to allow its visualization in living cells.
Given the implication of immunoproteasomes in cancer and inflammatory diseases
(Chapter 1, Sec. 1.3), these imaging probes can potentially be implemented as an imaging
agents to monitor the activity and subcellular localization of the immunoproteasome in
disease states. Also, these fluorescently labeled ABPs can be further used in FRET-based
studies to identify different intermediate proteasomes (as explained in Chapter 1,
Sec1.8.1).
2.3 Results and Discussion
2.3.1. Structure-based design of LMP7-specific fluorescent probe
In 2009, Parlati et. al. reported a peptide epoxy-ketone based molecular inhibitor (IPSI)
as a selective inhibitor of the LMP7 subunit in a dose-dependent manner. We decided to
use IPSI (19) to design a LMP7-specific fluorescent molecular probe. First, we needed to
understand the binding pattern of IPSI and LMP7 subunit of immunoproteasome. So, we
performed

in

silico

molecular

modeling

utilizing

the

3D

model

of

the

immunoproteasome.
Our molecular modeling studies of LMP7:IPSI complex structure indicated
that the tryptophan side chain at P2 site of IPSI is exposed towards the surface of LMP7
through the open channel extending from the active site. Therefore, the tryptophan group
at P2 segment of IPSI is most likely not involved in any specific interaction with LMP7,
thus providing a potential anchor to introduce a fluorophore without disrupting the
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specific IPSI:LMP7 interaction (Figure 2.4). Based on these predictions, we decided to
introduce a Lysine group at a P2 site of IPSI and the free amine functional group was
envisioned to derivatize with a fluorophore at the P2 position (Scheme 2.1).

(A)

(B)

Figure 2.4 Chemical structure of (A) IPSI and (B) its predicted LMP7 binding
mode. The LMP7:IPSI binding structure depicted here was the last snapshot of the
molecular dynamics (MD) simulation of the LMP7:IPSI complex in water. ‡ The blue or
white circle highlights the tryptophan group at P2, which is modified to yield LKS01.
(This figure is taken from our published work L. K. Sharma et al. ChemBioChem 2012,
13, 1899)

Scheme 2.1 Design strategy of LMP7-specific fluorescent probe based on molecular
modeling studies.
____________________

‡ Molecular modeling study was performed by Beilei Lei of Dr. Zhang’s group.
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2.3.2. Synthesis and Binding Selectivity of compound LKS01 (1)
As depicted in Scheme 2.2, the structure of LKS01 (20) can be retrosynthetically divided
into two fragments 21 and 22 that could be reassembled easily to the desired compound.
This convergent approach would allow us to synthesize material in large scale as
compared to linear approach. The left fragment 21 can be further dissected into three
amino-acid/acid precursors that could be coupled utilizing the well-established peptide
bond formation reaction. We envisioned that right fragment 22 could be assembled from
a readily available NH-protected L-phenylalanine derivative via sequential conversion of
acid to weinreb amide, then to α,β-unsaturated ketone and final epoxidation would give
the desired epoxide.

Scheme 2.2 Our retrosynthetic analysis to synthesize LKS01.
Based on the synthetic plan, we initially focused on the synthesis of tripeptide
(21). As indicated in Scheme 2.3, the tert-butyl protected derivative of tripeptide 21 was
assembled in three steps staring from H-Lys(Z)-OBut (23). HOBt/HBTU-promoted
coupling of 23 with Fmoc-D-Ala-OH afforded access to dipeptide 24 in 96% yield. Here,
HOBT and HBTU were used to control the racemization. Next, the sequential treatment
of 24 with 20% piperidine in DMF (Fmoc removal) followed by coupling with 3methylindene-2-carboxylic acid furnished the desired 25 in 95% isolated yield.
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Scheme 2.3 Synthesis of left fragment (25) of LKS01. Reagents and conditions: (a)
Fmoc-D-Ala-OH (1 equiv), HBTU (1.5 equiv), HOBt (1.5 equiv), DIPEA (5 equiv),
DCM, rt, 3 hr, 96%; (c) 20% piperidine, 2 hr; (g) 3-Methylindene-2-carboxylic acid (1
equiv), HBTU (1.5 equiv), HOBt (1.5 equiv), DIPEA (5 equiv), DCM, rt, 3 hr, 95% for 2
steps.

With tripeptide 25 in hand, we turned our attention towards the preparation of
epoxyketone fragment 22. The current procedure reported in the literature which was
generally used to synthesize the peptide epoxyketone is shown in Scheme 2.4. It involved
first the construction of enone

26, which was then reduced by sodium

borohydride/cerium chloride to get a mixture of two separable diastereomers. The
absolute configuration of desired allylic alcohol 27 was determined by treatment of 27
with 1M HCl/dioxane, followed by carbonyl diimidazole mediated cyclization. The
resulted oxazolidinone 30 is analyzed by Nuclear Overhauser Effect (NOE) and absolute
configuration is assigned accordingly.
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Scheme 2.4 Current procedure to synthesize epoxyketone and determination the
absolute stereochemistry using NMR.
The epoxidation of 27 was achieved by VO(acac)2-TBHP system or MCPBA to
get epoxyalcohol 28 as a single diastereomer in low yield. Finally, oxidation of 28
yielded the desired epoxyketone 29. To determine the absolute configuration of the
epoxide, nucleophilic ring opening of epoxide in epoxyalcohol 28 was done and the
resulted diol 31 was cyclized with diimidazole. The cyclic carbonate 32 thus obtained is
analyzed by spectroscopic means to assign the absolute configuration.
Due to the lack of an efficient method for the synthesis of epoxy-ketone and a
complex procedure for determination of absolute configuration, we decided to modify the
current procedure. We began the synthesis of required epoyketone derivative with the
reaction of Boc-Phe-OH (33) with N,O-dimethylhydroxylamine hydrochloride which
provided Weinreb amide 34 in 98% yield. Treatment of 34 with isopropenyl magnesium
bromide delivered the corresponding α,β-unsaturated ketone 35 in 84% yield. Several
epoxidation methods such as H2O2/NaOH, mcpba, HBO3 etc., were investigated and the
best conversion (98%) was observed with dimethyldioxirane (DMDO) which afforded a
mixture of diastereomers 36a and 36b in 98% yield (2.5:1 ratio). The absolute
stereochemistry of 36b was assigned utilizing single crystal X-ray. However,
epoxyketone 36a was not crystalline, so a nucleophilic ring opening of 36a was
performed with thiophenol to obtain alcohol 37. Again, the absolute configuration of 37
was assigned using X-ray structure.
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After having the required epoxyketone in hand, TFA mediated boc-deprotection
was performed to obtain 22. To construct the final compound LKS01, tripeptide 25 was
treated with TFA and the resulting product 21 was coupled with epoxyketone 22 to yield
LKS01 (20).

Scheme 2.5 Synthesis of right hand epoxyketone fragment (36a) of LKS01 and
determination of absolute stereochemistry of epoxide utilizing single crystal X-ray.
Reagents and conditions: (a) N,O-dimethylhydroxylamine hydrochloride (2 equiv),
HBTU, DIPEA, DCM, rt, 15 hr, 98%; (b) Isopropenyl magnesium bromide, THF, 0°C, 3
hr, 84%; (c) DMDO (2 equiv), rt, 15 hr, 98%, ratio 4a:4b (3:1); (d) PhSH, Et3N, MeOH,
rt, overnite, 90%.

(X-ray analysis was performed by Dr. Sean Parkin at Department

of Chemistry, University of Kentucky)
34

Scheme 2.6 Final coupling of compound 25 and 36a to synthesis LKS01.
Reagents and conditions: (a) TFA (90% in DCM), 1 hr; (b) TFA-DCM (1:1), 30 min., rt;
(c) TBTU (1.5 equiv), rt, 3 hr, 70% for 3 steps.
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2.3.3. Binding Selectivity of LKS01
Before coupling LKS01 (20) with a fluorescent residue, we wanted to ensure that LKS01
still maintains the β5i/LMP7 binding selectivity of IPSI (19). To examine this, we choose
EL4 mouse thymoma cells to perform a mobility shift assay. These cells abundantly
express all the catalytic subunits of both the immunoproteasome and the constitutive. The
EL4 cells were incubated with LKS01 at varying concentrations, subsequently the cells
were lysed and subjected to immunoblotting analyses using antibodies specific for
different proteasome subunits. As shown in Figure 2.5, there is an upward shift of the
LMP7 band due to the increased molecular weight of LMP7:LKS01 complex. This
suggests that LKS01 maintains the ability to bind and modify LMP7. While LKS01 did
not modify another immunoproteasome-specific subunit LMP2 at the tested
concentrations, we observed that LKS01 has the ability to modify the X subunit at higher
concentrations, similar to IPSI (Figure 2.4). Overall, these results indicated that LKS01
has the ability to modify and bind to LMP7, but the subunit selectivity can be
concentration-dependent. Similar results were obtained using PANC-1 cells which are
derived from human pancreatic ductal adenocarcinoma (Figure 2.6A).
IPSI (PM)
1

5

LKS01 (PM)

10

1

LMP7 (E5i)

5

10

Modified
Free
Modified
Free
Modified
Free

X(E5)
LMP2 (E1i)
E-actin

Figure 2.5 Characterization of binding selectivity of LKS01 and IPSI toward the
proteasome catalytic subunits in EL4 cells. EL4 cells were treated with DMSO
(vehicle control), epoxomicin (positive control for the shift of LMP7, X and LMP2),
YU102 (positive control for the LMP2 shift) or increasing concentrations of IPSI or
LKS01 for 1.5 hr and cell lysates were analyzed by western blotting using antibodies of
proteasome subunits. An upward shift of a band with respect to the DMSO control
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indicates an increase in molecular weight due to covalent modifications. (ChemBioChem
2012, 13, 1899)
2.3.4. Synthesis and Characterization of fluorescently labeled compound
After investigating the binding pattern of LKS01 towards β5i/LMP7, a cbz-deprotection
of LKS01 was performed utilizing H2/Pd-C, which also resulted in the reduction of
double bond of indene group at N-terminal. We did not expect any change in binding
pattern because of the reduction of double bond, so we went ahead and coupled
BODIPY® 650/665 to dihydro-LKS01 (24) using BODIPY® 650/665-X succinimidyl
ester to yield LKS01-B650 (39) (Scheme 3). Here, BODIPY® 650/665 was chosen
because of its near-infrared (NIR) spectral range. NIR-fluorescent probes are known to be
very effective for non-invasive imaging studies in living cells.

Scheme 2.7 Synthesis of LKS01-B650, a fluorescently labeled LMP7 probe. Reagents
and conditions: (a) H2-Pd/C, MeOH, rt, 2 hr; (b) 6-(((4,4-difluoro-5-(2-pyrrolyl)-4-bora3a,4a-diaza-s-indacene-3-yl)styryloxy)acetyl)aminohexanoic acid, succinimidyl ester,
THF, rt, 2 hr, 90% for 2 steps.
Next, we compared the binding pattern of our fluorescently labeled compound
LKS01-B650 (39) and its precursor LKS01 (20) towards β5i/LMP7. We performed
mobility shift assay using Panc-1 human pancreatic cancer cells. The results revealed that
LKS01-B650 still maintained the ability to modify LMP7 (Figure 2.6). To our surprise,
the introduction of a large fluorescent residue (BODIPY® 650/665-X) actually improved
the binding selectivity toward β5i/LMP7. As shown in Figure 2.6B, LKS01-B650 (39)
modified β5i/LMP7 at 5-10 μM, but not other proteasome subunits including X upto 10
μM. These results were further confirmed by molecular modeling studies of LKS0137

B650 (39) with LMP7 (Figure 2.13 in supporting information). Collectively, these results
suggest that the S2 pocket of LMP7 can accommodate the large BODIPY residue at P3
without disrupting the interactions of LKS01-B650 with LMP7.

Figure 2.6 Selective modification of LMP7 by LKS01-B650. Panc-1 cells were
incubated with 5, 10 or 15 μM of LKS01-B650 for 1.5 hr and lysed. The resulting cell
extracts were electrophoresed and subjected to immunoblotting. LKS01-B650 selectively
modified LMP7, but not other proteasome catalytic subunits at the concentrations tested.
(This figure is taken from the supporting information of our published work L. K. Sharma
et al. ChemBioChem 2012, 13, 1899)
2.3.5. Direct In-Gel Visualization of LKS01-B650-bound Subunits‡
To verify that LKS01-B650 (39) does not label any other catalytic subunits (except
β5i/LMP7) of proteasome and does not target any other non-proteasomal proteins, we
explored in-gel fluorescence assay. This assay was performed using immunoproteasomeexpressing parental T1 cells and T1-derived T2 lymphoblast cells which lack
immunoproteasomes. Extracts from T1 cells pretreated with LKS01-B650 (39) were
subjected to gel-electrophoresis, and the gel was imaged using Typhoon imaging system.
To our delight, no significant fluorescent bands except a strong band around 23kD band
were observed, which corresponds to the proteolytically active proteasomal β-subunits.
(Figure 2.7, left panel). When the cells were pre-treated with LKS01 (β5i/LMP7
____________________
‡ The in-gel fluorescent assay was performed by Na-Ra Lee.
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selective inhibitor) or epoxomicin (a broadly acting proteasome inhibitor), this signal at
23 kD was completely abolished (Figure 2.7, left panel). However, the fluorescent signal
was not affected by the pre-treatment of cells with YU-102, an LMP2 selective inhibitor
(Suppl. Figure 2.17), suggesting that the LKS01-B650-labeled protein is most likely
β5i/LMP7. Importantly, when T2 cell lysates (lacking immunoproteasome-subunits) were
treated with LKS01-B650 (39), no fluorescent bands were observed (Figure 2.7, right
panel), indicating that LKS01-B650 does not target catalytic subunits (β1/Y, β2/Z and
β5/X) of constitutive proteasome. Taken together, all these results strongly support that
the major target of LKS01-B650 (39) in the concentration range tested is β5i/LMP7subunit of immunoproteasome.

Figure 2.7 Visualization of LMP7 bound to LKS01-B650 in T1 & T2 lymphoblast
cell lysate. Cell lysate was pretreated with DMSO, LKS01, YU102, or epoxomicin (epx)
for 1 hr, followed by incubation of LKS01-B650 for 1 hr at room temperature. LKS01B650 binding was then visualized using a Typhoon FLA 9000 imaging system.
Pretreatment of LKS01, a parent compound of LKS01-B650, or epoxomicin, a general
proteasome inhibitor, effectively competed away fluorescent signals. In T2 lysates, no
fluorescent signals were observed at the molecular weights consistent with LMP7. (This
figure is taken from our published work L. K. Sharma et al. ChemBioChem 2012, 13,
1899)
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2.3.6. Visualization of LMP7-subunits in Living Cells¶
We next addressed whether LKS01-B650 (39) is able to label selectively β5i/LMP7catalytic subunit of immunoproteasome in living cells. Panc-1 cells were treated with
LKS01-B650 (39) and fluorescent images were captured. As shown in Figure 2.8,
sensitive and specific labeling of β5i/LMP7-subunit was observed in Panc-1 cells. When
the cells were pretreated with LKS01 fluorescent signals were effectively abolished. This
competition assay is consistent with the results obtained from the in-gel fluorescence
assay (Figure 2.8). Collectively, these results suggest that LKS01-B650 (39) can be used
as

an

imaging

probe

to

visualize

catalytic

active

β5i/LMP7-subunit

of

immunoproteasome in living cells.

Figure 2.8 Visualization of LMP7 using LKS01-B650 in Panc-1 cells. Cells were
pretreated with DMSO or LKS01 (5 μM) for 1.5 hr, followed by incubation of LKS01B650 (10 μM) for 1.5 hr. LKS01-B650 binding was then visualized via fluorescence
microscopy. Pretreatment of LKS01, a parent compound of LKS01-B650, effectively
competed away fluorescent signals. LKS01-B650 (Red, λex = 635 nm, λem = 665 nm),
DAPI (Blue) = Nucleus. This experiment was performed by Na-Ra Lee. (This figure is
taken from our published work L. K. Sharma et al. ChemBioChem 2012, 13, 1899)
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2.3.7. Localization Studies of catalytically active LMP7†
Next, we investigated the utility of our imaging probe LKS01-B650 to carry out the
localization studies of immunoproteasome in living cells. At first, we decided to compare
the localization pattern of immunoproteasome using LKS01-B650 with β5i/LMP7antibody. As shown in Figure 2.9A, a diffused localization pattern was observed
throughout the cell when β5i/LMP7 antibodies were used. While fluorescent signals
derived from fluorescent probe LKS01-B650 showed a punctate localization. These
results can be explained based on the fact that the cell contains both active form (mature)
and inactive form (pre-β5i) of catalytic subunits. Given that LKS01-B650 is an activity
based probe, therefore it can detect only active form of β5i/LMP7 which is a part of
immunoproteasome complex. On the other hand, since β5i/LMP7 antibody binds to nonactive site of subunits, it can detect both mature (active) and immature (inactive)
β5i/LMP7 and thereby showed diffuse fluorescent signals.
To confirm that the β5i/LMP7 detected by the LKS01-B650 is a part of the fully
assembled immunoproteasome, we performed a co-localization study with LKS01-B650
and UK101-Fluor, a fluorescent probe targeting catalytic active β2i/LMP2 (Carmony et
al. 2011). As shown in Figure 2.9B, the catalytically active β5i/LMP7 detected by red
fluorescent signals from LKS01-B650 is colocalized with the green fluorescent signals
derived from UK101-Fluorescein β2i/LMP2, indicating that LKS01-B650-bound
β5i/LMP7 is a component of the fully assembled immunoproteasome.
Additionally, we examined whether active β5i/LMP7 is colocalized with the
endoplasmic reticulum (ER), where the assembled immunoproteasome is known to be
localized (Brooks et al. 2000). As expected, red fluorescent signals derived from LKS01B650 (39) appeared to be mostly colocalized with green fluorescent signals derived from
the calnexin antibody (a marker for ER) (Figure 2.9C).

_________________________________________________________________________

†

These experiments were performed by Eun-Ryoung Jang of Dr. Wooin Lee’s group.
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Figure 2.9 Localization Studies of LKS01-B650-bound β5i/LMP7. Panc-1 cells were
incubated with LKS01-B650 (10 μM) for 1.5 hr, and subsequently stained with (A)
antibodies recognizing LMP7 or (B) calnexin (an endoplasmic reticulum marker) or (C)
treated with UK101-Fluor, a LMP2-specific fluorescent imaging probe. Fluorescent
signals derived from an anti-LMP7 antibody appear to diffuse throughout the cytoplasm,
while fluorescent signals from LKS01-B650 appear to be confined to rather limited areas.
Overlapping signals of LKS01-B650 and calnexin immunofluorescence indicate that
immunoproteasomes containing LMP7 are mostly localized around the ER. LMP7
signals are colocalized with signals from LMP2, indicating LKS01-B650-bound-LMP7 is
found in fully assembled immunoproteasomes. (Portion of figure is taken from:
ChemBioChem 2012, 13, 1899)
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2.3.8. FRET-Based Pair
After successfully showing the application of structure-based design to develop
fluorescently-labeled ABPs for β5i/LMP7-subunit of immunoproteasome, we next
focused on developing the imaging agents suitable for FRET studies (Chapter 1, Section
1.8.1). FRET based energy transfer requires the overlap of the emission spectra of the
donor to the absorption spectra of acceptor. Greater is the spectral overlap; more efficient
is the FRET process. In case of Bodipy compounds this spectrum overlap is low and the
most commonly used fluorophore pair for FRET study is Cy3-Cy5 (Figure 2.10). So, we
synthesized cyanine derivatives of LKS01 compounds (Figure 2.11), utilizing the same
synthetic scheme as previously described in this chapter.

Figure 2.10 Spectral overlap of Bodipy dyes and Cyanine dyes

Figure 2.11 Cyanine based LKS01 derivatives.
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To achieve our objective of exploring FRET studies, utilizing these imaging
agents, we needed fluorescently labeled ABP selective for β1i/LMP2-subunits of
immunoproteasome. We decided to use YU102, a LMP2-selective inhibitor in a dose
dependent manner (Figure 2.15). Utilizing the structure-based design as described in this
chapter (Sec 2.3), we designed and synthesized YU102-Cy3 and YU102-Cy5 which
show selectivity towards LMP2-subunits of immunoproteasome (Figure 2.12). These
compounds were also characterized by mobility shift assay and competition assays as
described in Sec 2.3.4 and 2.3.6.

Figure 2.12 LMP2 selective cyanine dye based fluorescent probes.
2.4 Summary
The immunoproteasome, an alternative form of the constitutive proteasome, has been
implicated in a number of pathological states such as cancer and autoimmune diseases.
However, the detailed function of the immunoproteasome remains poorly understood. We
have developed an immunoproteasome-specific near infra-red (NIR) fluorescent probe
targeting the immunoproteasome catalytic subunit β5i/LMP7. We demonstrated that this
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peptide epoxyketone-based compound LKS01-B650 (39), selectively binds to
catalytically active β5i/LMP7, but not inactive or pre-β5i/LMP7. Our results show that
our probe can be used to visualize the catalytically active β5i/LMP7 in living cells
providing an ability to monitor, in real-time, the expression/activity of the
immunoproteasome in living cells. Given the reported implications of the
immunoproteasome in cancer and other neurodegenerative diseases, this imaging agent
can be further explored as a potential diagnostic tool for early detection of tumor. We are
also able to develop cyanine dye-labeled derivatives of LKS01 (β5i/LMP7-selective) and
YU102 (β1i/LMP2-selecive), that can be further used in FRET-based studies to identify
intermediate proteasomes as discussed in chapter 1, section 1.8.1.
2.5 Experimental Procedures
This section of the chapter is taken in parts from the supporting info of our
published paper: L. K. Sharma et. al. ChemBioChem 2012, 13, 1899.
2.5.1. Synthesis of compounds
A. General Methods and Materials
Unless stated otherwise, all reactions were carried out in flame-dried glassware under
nitrogen atmosphere at room temperature and with anhydrous solvent. All commercial
reagents were obtained from commercial available sources and used without further
purification. All reactions were magnetically stirred and monitored by thin-layer
chromatography (TLC). TLC plates were visualized by exposure to ultraviolet light (254
nm) and/or by immersion in a staining solution of phosphomolybdic acid (PMA),
followed by heating on a hot plate. Column or flash chromatography (silica) was
performed with the indicated solvents using silica gel (particle size 0.032-0.063 mm)
purchased from Dynamic Adsorbents or MP Biomedicals. All fluorescently labeled
compounds are purified on a Biotage SP-1 chromatography system.
Dimethyldioxirane (DMDO) was prepared as described by Murray et al. (1998)
and generally concentrations in the range of 0.04-0.10 M were obtained. 1H and

13

C

spectra were recorded using 300 or 400 or 500 MHz, using CDCl3 or acetone-d6 as a
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solvent. The chemical shifts are reported in parts per million (ppm) relative to internal
CHCl3 (δ 7.26 ppm for proton NMR and δ 77.23 ppm for carbon NMR) or relative to
acetone-d6 (δ 2.05 ppm for proton NMR and δ 29.92 ppm for carbon NMR). Coupling
constants are reported in hertz (Hz). The following abbreviations are used to designate
the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet.
X-ray crystallographic structures were obtained by Dr. Sean Parkin of
Department of Chemistry, University of Kentucky.
B. Experimental Procedures for Reactions and Characterization Data
Synthesis of Weinreb Amide (ChemBioChem 2012, 13, 1899)
To a solution of Boc-Phe-OH 33 (5.0 mmol, 1.33 g) in
methylene

chloride

(25

ml)

was

added

dry
N,O-

dimethylhydroxylamine hydrochloride (6.0 mmol, 0.585 g) and
HBTU (5.2 mmol, 1.991 g). After stirring for 5 min at room
temperature, DIPEA (25.0 mmol, 4.2 ml) was added dropwise at
0°C and the reaction mixture was stirred for 15 hr at room temperature. The entire
contents of the reaction mixture was concentrated under reduced pressure and the
residue was purified by flash column chromatography (10-50% ethyl acetate/hexane
gradient) to obtain 1.50 g (97%) Weinreb amide 34; 1H NMR (500 MHz, CDCl 3): δ
7.28 (m, 2H), 7.20 (m, 1H), 7.18 (m, 2H), 5.14 (d, J=4.0 Hz, 1H), 4.95 (m, 1H), 3.65
(s, 3H), 3.16 (s, 3H), 3.04 (dd, J=14.0 Hz, 5Hz, 1H), 2.90 (dd, J=14.0 Hz, 8Hz, 1H),
1.39 (s, 9H); 13C NMR (75 MHz, CDCl 3): δ 172.2, 155.2, 136.6, 129.5, 128.4, 126.8,
79.7, 61.7, 51.7, 39.0, 32.3, 28.5.
Preparation of α,β-unsaturated ketone (ChemBioChem 2012, 13, 1899)
To a solution of the Weinreb amide 34 (1.0 mmol, 0.308 g) in
THF (5.0 ml) was added dropwise a solution of isopropenyl
magnesium bromide in THF (2.5 mmol, 0.5 M, 5.0 ml) under
nitrogen atmosphere at -30°C. After being stirring at 0°C for
3hr, the reaction was quenched by the addition of sat. aq. NH4Cl solution and was
diluted with ethyl acetate. The organic layer was separated and wahed with brine,
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dried over MgSO4 and concentrated under reduced pressure. The resulting residue
was purified by flash column chromatography on Biotage SP-1 chromatography
system using a 5-10% ethyl acetate/hexane gradient to afford 0.243 g (84%) of enone
35; 1H NMR (500 MHz, CDCl 3): δ 7.24 (m, 3H), 7.65 (d, J=7.5 Hz, 2H), 6.01 (d,
J=4.0 Hz, 1H), 5.85 (m, 1H), 5.26 (m, 2H), 3.04 (m, 1H), 2.90 (m, 1H), 1.86 (s, 3H),
1.41 (s, 9H);

13

C NMR (75 MHz, CDCl 3): δ 200.0, 155.1, 142.5, 136.2, 129.5, 128.4,

126.9, 126.7, 79.8, 55.1, 40.1, 28.6, 18.0.
Epoxidation of enone (ChemBioChem 2012, 13, 1899)
A DMDO solution (1.06 mmol, 0.06 M, 18 ml)
was added to enone 35 (0.71 mmol, 0.204 g)
and the reaction mixture was stirred for 15 hr
at room temperature. The entire contents were
concentrated under reduced pressure and the resulting mixture of diasteromers (0.207
g, 96%) was separated by flash column

chromatography on a Biotage SP-1

chromatography system using a 0-5% ethyl acetate/hexane gradient. Data for the
epoxyketone 36a (0.147 g): 1H NMR (500 MHz, CDCl 3): δ 7.31-7.22 (m, 3H), 7.15
(d, J=7.5 Hz, 2H), 4.97 (d, J=8.0 Hz, 1H), 4.57 (m, 1H), 3.28 (d, J=5.0 Hz, 1H), 3.09
(dd, J=14.0, 5.0 Hz, 1H), 2.89 (d, J=5.0 Hz, 1H), 2.72 (dd, J=14.0 Hz, 8 Hz, 1H),
1.49 (s, 3H), 1.36 (s, 9H);

13

C NMR (125 MHz, CDCl 3): δ 208.5, 155.3, 136.0, 129.5,

128.6, 127.1, 79.9, 59.3, 53.8, 52.5, 37.5, 28.4, 16.7; epoxyketone 36b (0.059 g): 1H
NMR (500 MHz, CDCl 3): δ 7.26 (m, 2H), 7.25 (m, 1H), 7.13 (d, J=7.0 Hz, 2H), 4.89
(d, J=5.0 Hz, 1H), 4.60 (m, 1H), 3.0 (m, 1H), 2.83 (m, 1H), 2.67 (d, J=4.5 Hz, 1H),
2.57 (d, J=5.0 Hz, 1H), 1.49 (s, 1H), 1.39 (s, 9H);

13

C NMR (100 MHz, CDCl 3): δ

207.8, 155.0, 136.3, 129.6, 128.9, 127.2, 80.3, 59.2, 54.4, 52.0, 38.4, 28.4, 17.4.
Syntheis of Fmoc-D-Ala-Lys(Z)-OtBu (24) (ChemBioChem 2012, 13, 1899)
Fmoc-D-Ala-OH (0.5 mmol, 0.156 g), H-Lys(Z)OtBu.HCl (0.5 mmol, 0.186 g), HBTU (1.5 equiv)
and HOBt (1.5 equiv) were dissolved in dry DCM
(7 ml) and DIPEA (2.5 mmol, 0.41 ml) was added
dropwise at 0°C. After stirring at room temperature
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for 3 hr, the reaction mixture was concentrated under reduced pressure and the residue
was purified by flash column chromatography on a Biotage SP-1 chromatography
system using a 10-50% ethyl acetate/hexane gradient. to give 0.302 g (96%) of
compound 24; 1H NMR (500 MHz, CDCl 3): δ 7.74 (d, J=7.5 Hz, 2H), 7.57 (d, J=7.25
Hz, 2H), 7.38 (t, J=7.5 Hz, 2H), 7.30 (m, 7H), 6.74 (bs, 1H), 5.53 (d, J=7 Hz, 1H),
5.05 (m ,3H), 4.52 (q, J=7 Hz, 1H), 4.38 (m ,2H), 4.29 (m ,1H), 4.18 (m, 1H), 3.14 (s,
2H), 2.79 (s, 2H), 1.83 (m, 1H), 1.64 (m, 1H), 1.49 (m, 2H), 1.43 (s, 9H), 1.38 (d,
J=6.5 Hz, 3H);

13

C NMR (75 MHz, CDCl 3): δ 172.1, 171.2, 163.8, 156.5, 155.9,

143.8, 143.7, 141.2, 136.6, 128.5, 128.1. 127.7. 127.1, 125.1, 120.0, 82.3, 67.2, 66.7,
52.5, 50.8, 47.2, 40.7, 38.8, 32.2, 29.4, 28.2, 22.3, 19.1.
Synthesis of Ind-D-Ala-Lys(Z)-OtBu (25) (ChemBioChem 2012, 13, 1899)
A

solution

of

piperidine

(20%

solution

in

piperidine, 3 ml) was added to 24 (0.35 mmol,
0.220 g) and stirred for 2 hr at room temperature.
The reaction mixture was concentrated under
reduced pressure and used for the next reaction without further purification. The 3methylindene-2-carboxylic acid (0.35 mmol, 0.061 g), HBTU (0.52 mmol, 0.199 g)
and HOBt (0.52 mmol, 0.071 g) were then added to a solution of previous crude in
DCM (5 ml). After stirring for 15 min at room temperature, DIPEA was added
dropwise at 0°C and the reaction mixture was stirred for 3 hr at room temperature.
The reaction mixture was concentrated under reduced pressure and the crude product
was purified by flash column chromatography on a Biotage SP-1 chromatography
system using a 10-50% ethyl acetate/hexane gradient to obtain 0.142 g (95% for 2
steps) of compound 25; 1H NMR (500 MHz, CDCl 3): δ 7.42 (t, J=7.0 Hz, 2H), 7.367.24 (m, 7H), 7.02 (d, J=8.0 Hz, 1H), 6.60 (d, J=7.0 Hz, 1H), 5.11 (m, 1H), 5.07 (s,
2H), 4.72 (m, 1H), 4.46 (m, 1H), 3.58 (s, 2H), 3.18 (m, 2H), 2.49 (s, 3H), 1.85 (m,
1H), 1.68 (m, 1H), 1.54 (m, 2H), 1.47 (d, J=7 Hz, 3H), 1.42 (s, 9H), 1.3 (m, 3H);

13

C

NMR (75 MHz, CDCl 3): δ 172.4, 171.2, 165.8, 156.6, 147.7, 145.6, 142.2, 136.6,
131.8, 128.5, 128.1, 127.3, 126.8, 123.9, 120.8, 88.4, 66.7, 52.7, 48.9, 40.8, 38.5,
32.2, 29.5, 28.2, 22.4, 19.1, 12.6.
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Synthesis of LKS01 (ChemBioChem 2012, 13, 1899)

A solution of TFA-DCM (9:1, 4 ml) was added to compound 25 (0.05 mmol, 0.028 g)
and stirred for 1h. The reaction mixture was concentrated under reduced pressure and
purified using flash chromatography to obtain compound 21. Similarly, Bocdeprotection of 36a (0.05 mmol, 0.015 g) was performed using TFA-DCM (1:1, 3 ml)
to obtain compound 22. To a solution of compounds 21 and 22 in DCM (2 ml) was
added HBTU (0.06 mmol, 0.016 g) and HOBt (0.06 mmol, 0.008 g). After stirring for
15 min DIPEA (0.20 mmol, 0.03 ml) was added dropwise at 0°C. The reaction was
stirred for 3 hr, after which the entire contents were concentrated under reduced
pressure. The residue was purified by flash column chromatography on a Biotage SP1 chromatography system using a 20-100% EtOAc/hexane gradient to give 0.023 g
(82%) of LKS01 (20); 1H NMR (500 MHz, CDCl 3): δ 7.43 (m, 2H), 7.38-7.28 (m,
8H), 7.19 (m, 2H), 7.13 (m, 4H), 6.98 (d, J= 7.5 Hz, 1H), 6.59 (d, J= 7.0 Hz, 1H),
5.17 (t, J= 11.5 Hz, 1H), 5.08 (s, 2H), 5.05 (d, J= 3.5 Hz, 1H), 4.74 (m, 1H), 4.62 (m,
1H), 4.39 (m, 1H), 3.61 (dq, J= 16.0, 2.0 Hz, 2H), 3.28 (d, J= 5.0 Hz, 1H), 3.12 (m,
2H), 3.04 (dd, J= 14.0, 4.5 Hz, 1H), 2.79 (d, J= 5.0 Hz, 1H), 2.71 (dd, J= 14.0, 8.5
Hz, 1H), 2.51 (t, J= 2.0 Hz, 1H), 1.74 (m, 1H), 1.59 (m, 1H), 1.40 (m, 3H), 1.36 (s,
3H), 1.25 (m, 2H);

13

C NMR (125 MHz, CDCl 3): δ 207.8, 172.9, 171.5, 166.4, 156.8,

145.6, 142.4, 136.8, 136.2, 131.8, 129.4, 128.6, 128.2, 127.5, 127.2, 126.9, 124.0,
121.0, 66.8, 59.5, 53.2, 53.2, 53.0, 52.6, 49.2, 40.4, 38.4, 36.9, 31.5, 29.3, 22.1, 18.5,
16.6, 12.6, 12.5.

49

Attachement of Bodipy-650 (ChemBioChem 2012, 13, 1899)
The compound LKS01 (20) (2x10-3
mmol, 1.4 mg) and Pd-C (5%) were
dissolved in MeOH (3 ml) in a vessel
capped with rubber septum. The solution
was then stirred for 2 hr under a
hydrogen atmosphere. After the reaction,
the mixture was filtered using selite and
the filtered solution was concentrated
under reduced pressure and used for the following step without further purification.
The above residue was dissolved in DMF (1 ml) and 6-(((4,4-difluoro-5-(2-pyrrolyl)4-bora-3a,4a-diaza-s-indacene-3-yl)styryloxy)acetyl)amino-hexanoic

acid,

succinimidyl ester (2x10-3 mmol, 1.2 mg) was added to the solution. The mixture was
then stirred for 2 hr at room temperature and concentrated under reduced pressure.
The remaining residue was purifed by flash column chromatography on Biotage SP-1
chromatography system using a 5-100% methanol/ethyl acetate gradient to give 1.8
mg (86%) of LKS01-B650 (39); the compound 39 was confirmed by mass analysis
(MALDI):

molecular

M++Na=1113(observed),

ion

peak,

M +=1090

1113(calculated);

(calculated).
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(observed),
M+K=1129

1090

(calculated);

(obsereved),

1129

2.5.2. Molecular Modeling Studies (ChemBioChem 2012, 13, 1899)
The molecular dynamics (MD) simulation was performed by using the Sander module of
Amber (version 8). The ligand parameters were prepared with the Antechamber module
of the Amber using the AM1-BCC method. The protein-ligand binding complex was
neutralized by adding counter-ions and was solvated in a rectangular box of TIP3P water
molecules with a minimum solute wall distance of 10 Å. The solvated system was then
carefully equilibrated and fully energy-minimized. The solvated system was gradually
heated from T = 10 K to T = 298.15 K in 60 ps before a production MD simulation run
for 3 ns, making sure that we obtained a stable MD trajectory for the simulated system.
The time step used for the MD simulation was 2 fs. Periodic boundary condition in the
NPT ensemble at T = 298.15 K with Berendsen temperature coupling and P = 1 atm with
isotropic molecule-based scaling was applied. The SHAKE algorithm was used to fix all
covalent bonds containing hydrogen atoms. The non-bonded pair list was updated every
10 steps. The particle mesh Ewald (PME) method was used to treat long-range
electrostatic interactions. A residue-based cutoff of 12 Å was utilized for the noncovalent interactions. The time-dependent geometric parameters were carefully examined
to make sure that we obtained a stable MD trajectory for the simulated protein-ligand
binding system. The coordinates of the simulated system were collected every 1 ps during
the simulation.
(A) Modeling Studies of LKS01-B650 with LMP7 (ChemBioChem 2012, 13, 1899)
We modeled the binding mode of LKS01-B650 with β5i/LMP7 from the X-ray
crystal structure (PDB CODE: 3UNF) Huber et al. (2012), by docking with GOLD
software. The study indicates that the S2 pocket of LMP7 can accommodate the large
side chain of LKS01-B650 (Figure 2.13). To investigate how far our structure
predication is in agreement with the effective immnuproteasome structure reported by
Huber et al (2012), we aligned our previous homology model to the X-ray crystal
structure of LMP7 (Figure 2.14). The root-mean-square deviation (RMSD) of the atomic
positions of the homology model from the X-ray crystal structure is 1.41 Å which is very
small compared to the resolution of the X-ray crystal structure (2.9 Å). The small RMSD
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value suggests that our previous homology model was reasonable. In fact, both the
homology model and X-ray crystal structures lead to the same conclusion in the present
study.

Figure 2.13 Binding mode of LKS01-B650 with LMP7 from the X-ray crystal
structure (PDB CODE: 3UNF). (Molecular modeling was performed by Beilei Lee
from Zhang’s group in the Department of Pharmaceutical Sciences, University of
Kentucky) (ChemBioChem 2012, 13, 1899)

Active site
Figure 2.14 Alignment of homology model (gray) with the X-ray crystal structure
(green) of LMP7, the active site was circled with a red line. (Molecular modeling was
performed by Beilei Lee from Zhang’s group in the Department of Pharmaceutical
Sciences, University of Kentucky) (ChemBioChem 2012, 13, 1899)
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2.5.3. Biological Methods (ChemBioChem 2012, 13, 1899)
Cell Culture (ChemBioChem 2012, 13, 1899)
EL4 and Panc-1 cells were maintained in DMEM (Dulbecco’s modified Eagle’s medium,
Invitrogen) supplemented with 10% horse serum and in DMEM supplemented with 10%
fetal bovine serum, respectively. T1 and T2 cells were cultured at 5% CO2 and 37˚C in
IMDM (Iscove's Modified Dulbecco's Media, Invitrogen) supplemented with 10% fetal
bovine serum and 20% fetal bovine serum, respectively. All cell lines were kept under an
atmosphere of 5% CO2 in a humidified 37°C incubator.
Inhibitor Treatment (ChemBioChem 2012, 13, 1899)
All the compounds (proteasome inhibitors) were dissolved in DMSO and stored at -20 °C
before use. EL4 cells were plated on a 12-well plate at a density of 8.0 X 104 cells/well, 1
hr prior to the compound treatment. Panc-1 cells were plated on a 24-well plate at a
density of 1.0 X 105 cells/well one day prior to the compound treatment. EL4 and Panc-1
cells were then treated with DMSO (vehicle control), LKS01, IPSI and LKS01-B650 at
varying concentrations for 1.5 hr. In addition, cells were treated with the following
compounds to serve as controls for proteasome subunit binding activities; epoxomicin (1
μM, a non-selective inhibitor which covalently modifies β1i, β5i and β5 subunits) or
YU102 (10 μM, a proteasome inhibitor which covalently modifies β1i and β1 subunits).
In order to verify whether the fluorescent signals associated with LKS01-B650 can be
effectively competed away by other specific and non-specific proteasome inhibitors;
LKS01, epoxomicin and YU102 were used as pre-treatments for in-gel fluorescence
experiments and for experiments in which LKS-B650 fluorescence was detected in living
cells. For the in-gel fluorescence competition experiment, T1 and T2 cell lysates were
prepared as described in section 3.4. Cell lysates were pretreated with DMSO, 0.5, 1, 5
μM of LKS01, 0.1 μM of YU102, or 10 μM of epoxomicin for 1 hr before treatment with
LKS01-B650 (10 μM) for 1 hr. Samples were then loaded and separated by
polyacrylamide gel electrophoresis. After separation, gels were imaged using a Typhoon
FLA 9000 imaging system (λex = 635 nm, λem = 665) to detect LKS-B650 bound to
proteins. For the competition assay in live cells, 5 μM of LKS01 was used to treat Panc-1
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cells for 1.5 hr, followed by treatment with LKS01-B650 (10 μM) for 1.5 hr prior to
fluorescence microscopy as described in section 3.5.
Immunoblotting (ChemBioChem 2012, 13, 1899)
Cells were lysed by incubation in ice-cold lysis buffer (50 mM Tris-Cl, 150 mM NaCl,
1% NP-40, 1% Triton X-100, and 1% protease inhibitor cocktail, Sigma-Aldrich) for 1
hr. The resulting cell extracts were then cleared by centrifugation (14,000 rpm) at 4°C for
10 min and supernatants were collected. The protein concentration of the cleared lysates
were measured using a Bradford protein assay kit (Bio-Rad). The lysates were mixed
with 2X Laemmli sample buffer (Sigma-Aldrich) and were boiled for 10 min to denature
protein. Equivalent amounts of total protein were loaded on to 12% (β1i & β1 subunits)
or 14% (β5i & β5 subunits) polyacrylamide gel and protein were separated by
electrophoresis. After electrophoresis, proteins were transferred onto PVDF membranes
(Bio-Rad). The membranes were blocked by incubating with TBST containing 5% w/v
non-fat milk powder in TBST at room temperature for 1 hr. All primary antibodies were
diluted in 3% BSA (Fisher) in TBST except for the β5i antibody which was diluted in 3%
non-fat milk powder in TBST. Membranes were incubated with primary antibodies with
membranes at room temperature for 2 hrs or at 4°C for overnight. All of the secondary
antibodies were diluted in 3% non-fat milk in TBST. The membranes were incubated
with secondary antibodies at room temperature for 1 hr. Polyclonal β1i or β5i antibodies
were purchased from Abcam; β5 and β1 antibodies were purchased from Affinity
Bioreagents; monoclonal β-actin antibody was purchased from Novus Biological. Mouse
or rabbit secondary antibodies conjugated with horseradish peroxidase were purchased
from GE Healthcare. Protein bands were visualized using enhanced chemiluminescence
substrates (ECL).
In-Gel Fluorescence Study (ChemBioChem 2012, 13, 1899)
Appropriate concentrations of YU102, LKS01-B650 and epoxomicin (Epx) for in these
in-gel studies were determined by Western blot analysis of subunit covalent modification.
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Figure 2.15 Differential modification of β1i (LMP2) and β1 (Y) in T1 cell lysate.
YU102 covalently modifies β1i (LMP2) partially 0.05 μM with complete modification at
0.5 μM, while the β1 (Y) subunit is modified at 0.5 μM. Epoxomicin completely
modified β1i (LMP2), β1 (Y), β5 (X) and β5i (LMP7) at 10 μM. Positive Control for β1i,
β1: 10μM YU102; Positive Control for β5i, β5: 30μM Epx. (This experiment was
performed by Na-Ra Lee from Kyung-Bo’s group in the Department of Pharmaceutical
Sciences, University of Kentucky) (ChemBioChem 2012, 13, 1899)

Figure 2.16 Mobility Shift assay of LKS01-B650 in T1 and T2 cell lysates. In T1 cell
lysate, LKS01-B650 selectively modifies β5i (LMP7) at a concentration of 5μM, but not
β1i (LMP2), β1 (Y) or β5 (X) at concentrations of upto 10μM. In T2 cell lysates, none of
the proteasome subunits were modified at concentrations of 5-10 μM. Positive Control
for β1i (LMP2), β1 (Y): 10μM YU102; Positive Control for β5i (LMP7) and β5(X):
30μM Epx (epoxomicine). (This experiment was performed by Na-Ra Lee from Kyung-
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Bo’s group in the Department of Pharmaceutical Sciences, University of Kentucky)
(ChemBioChem 2012, 13, 1899)

Figure 2.17 Impact of the LKS01, YU102 or epoxomicin pretreatment on in-gel
fluorescence labeling of LK01-B650. T1 and T2 cell lysates were pretreated with
DMSO or LKS01, YU102, or epoxomicin (Epx) for 1 hr, followed by incubation with
10μM LKS01-B650 for 1 hr. LKS01-B650 binding was, then, visualized using a
Typhoon FLA 9000 imaging system (λex = 635 nm, λem = 665). Pretreatment with
LKS01, a parent compound of LKS01-B650, effectively competed away fluorescent
signals consistent with the molecular weight of LMP7 in T1 cell lysate. The non-selecitve
inhibitor epoxomicin also blocked LKS01-B650 binding. The LMP2-selective inhibitor
YU102 did not block LKS01-B650 binidng to the major band. Diffuse fluorescent signal
above 40 kDa is likely due to free LKS-01-B650 which was not removed from samples
before separation. No fluorescently-labelled bands were observed at the molecular
weights consistent with non-LMP7 proteasome catalytic subunits. (This experiment was
performed by Na-Ra Lee from Kyung-Bo’s group in the Department of Pharmaceutical
Sciences, University of Kentucky) (ChemBioChem 2012, 13, 1899)
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Figure 2.18 Immunoblotting analysis. The LMP7 antibody detects a specific band (with
a slight shift following pre-incubation and treatment with LKS01-B650) only in T1 cells,
but not in T2 cells. T1 and T2 cells were plated onto 6-well plate (2 x 105 cells/well), 24
h prior to the experiment. The cells were pre-incubated with LKS01 (1 or 5 μM), Epx (5
μM), YU102 (10 μM) or DMSO (control) for 1.5 hr at 37 °C. Subsequently, cells were
treated with 15 μM of LKS01-B650 or DMSO (control) for 1.5 hr at 37 °C and cell
extracts were analyzed by immunoblotting. Pre-incubation of T1 cell lysates with LKS01
and Epx as well as incubation with LKS01-B650 resulted in an upward shift in the LMP7
band. (This experiment was performed by Na-Ra Lee from Kyung-Bo’s group in the
Department of Pharmaceutical Sciences, University of Kentucky) (ChemBioChem 2012,
13, 1899)
Preparation of T1 and T2 cell lysates (ChemBioChem 2012, 13, 1899)
T1 and T2 cells were harvested and cell pellets were washed once with Hank’s Buffered
Salt Solution (HBSS). The pellets were lysed by incubation in 1X Passive lysis buffer
(Promega) at room temperature for 15 min with continuous slow inversion of the
samples. Each of the supernatant was then collected by centrifugation at 14000 rpm at 4
o

C for 10 min. Protein concentrations were determined by the Bradford Assay (Bio-Rad).

The lysates were then diluted to a total protein concentration 1 μg/μL for pretreatments
and treatments with proteasome inhibitors.
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In-Gel Fluorescence Detection (ChemBioChem 2012, 13, 1899)
Compound-treated cell lysates were denatured as described for immunoblotting and
electrophoresed on 12% polyacrlyamide gels. In-gel fluorescence signals were recorded
for gels prepared with lysates from T1 and T2 cells which had been treated with LKS01B650 alone or with LKS01-B650 following pretreatment with LKS01, YU102,
epoxomicin (Epx), or DMSO (vehicle control). Pretreatment with LKS01 or epoxomicin
competed away a fluorescent signal from LKS01-B650 which was consistent with the
molecular weight for LMP7. YU102 pretreatment did not have this effect. Again in-gel
fluorescent signals were captured using a Typhoon FLA 9000 imaging system (λex = 635
nm, λem = 665).
Fluorescence Microscopy (ChemBioChem 2012, 13, 1899)
Panc-1 cells were plated at a density of 1.0 x 105 cells on 4-well chamber slides, 24-48
hrs prior to treatment of compounds. Following compound treatment, the cells were fixed
with 4% paraformaldehyde in PBS for 7 min at 37oC and washed extensively with PBST
to remove unbound compounds. Slides were mounted with coverslips using Prolong Gold
antifade reagent with DAPI (Invitrogen). For co-localization experiments, fixed cells
were subjected to permeablization (incubation with 0.2% Triton-X in PBS for 30 min),
blocking (10% goat serum and 1% BSA for 1 hr), and subsequent incubation with
primary antibodies (β5i or calnexin). Primary antibodies against β5i (Abcam) or calnexin
(Cell Signaling) were diluted with DakoCytomation Antibody Dilutant with Background
Reducing Components and incubated with cells for 1 hr at 37oC. Following washing in
PBST and incubation with secondary antibody conjugated with a green fluorophore
Alex488 (Invitrogen), slides were mounted with coverslips. Cells were then visualized
using an inverted Nikon-Ti-U fluorescence microscope and NIS Element Research image
analysis software.
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2.5.4. Copies of NMR and mass spectra (ChemBioChem 2012, 13, 1899)
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M+ = 694
M+Na = 717
M+K = 733

M+ = 1090.5
M+Na =
1113.5
M+K = 1129.5

Copyright © Lalit Kumar 2012
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Chapter 3: Development of Bifunctional Cross-linking Agents
3.1. Overview of the study
To identify different proteasome subtypes, we decided to use a more traditional
chemical cross-linking approach to complement the FRET-based method. We therefore
sought to develop new bifunctional cross-linking agents that are capable of cross-linking
Thr1Oγ of two catalytic β-subunits within the same proteasome complex (Chapter 1,
Figure 1.8). The ability of the synthesized bifunctional agents to cross-link catalytic
subunits can be easily tested by mobility shift assays, which may serve as a direct and
convincing method to determine the subunit composition of intermediate proteasomes.
3.2. Introduction
3.2.1. The chemical crosslinking approach
A chemical crosslinking approach has been successfully applied to the design of small
bifunctional molecules, capable of interacting with two or more proteins simultaneously,
for enhanced or novel biological effects (Uy et al. 1977; Kluger et al. 2004; Agou et al.
2004; Corson et al. 2008). This approach involves the chemical joining of two different
proteins in close proximity by a covalent bond. It utilizes cross-linking agents that have at
least two chemical groups (such as primary amines, sulfhydryls etc.) that react with
specific functional groups on proteins. If these two reactive groups are identical (homobifunctional), the molecule can crosslink two identical protein monomers; but if two
reactive groups are non-identical (hetero-bifunctional), two different proteins can be
cross-linked. This bifunctional cross-linking approach has proved to be useful for
stabilizing proteins, targeting them to specific sites and for the functional analysis of
proteins (DeSantis et al. 1999; Veronese et al. 2001; Kluger et al. 2004). Additionally,
cross-linking agents have been used to study the tertiary and quaternary structure of
proteins and to identify the spatial arrangements of the subunits in oligomeric proteins
(Kluger et al. 2004; Sinz et al. 2006; Corson et al. 2008).
_________________________________________________________________________

* Kinetic assay and mobility shift assays reported in this chapter were performed by
Kimberly Carmony.
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3.2.2. Chemical crosslinking in proteasome biology
The unique arrangement of proteasome and immunoproteasome catalytic subunits makes
them ideal targets for specific chemical crosslinking. To the best of my knowledge, there
are only three reports in the literature describing the use of crosslinking agents in the
context of proteasome biology. In all of these studies, bifunctional compounds were
developed in attempt to gain to more potent and selective proteasome inhibition. Loidl et.
al. (1999a) designed a bifunctional inhibitor (Mal-βAla-Val-Arg-H) to inhibit the trypsinlike (T-L) activity of proteasome. As shown in Figure 3.1, the C-terminal aldehyde group
of the compound reacts with the N-terminal Thr1 of the β2-subunit, and a maleinimide
moiety at N-terminus reacts with the thiol group of Cys118 in the S3 binding pocket of
the trypsin-like (T-L) site. Because of this unique bifunctional nature of Mal-βAla-ValArg-H, it showed high selectivity towards inhibiting the T-L activity of the eukaryotic
proteasome (IC50 = 0.5μM, T-L activity; IC50 > 100μM, CT-L activity).

Figure 3.1 The hetero-bifunctional structure of Mal-βAla-Val-Arg-H. The aldehyde
group (blue) reacts with the N-terminal Thr1 and maleinimide group (red) reacts
with the Cys118 thiol.
The same research group reported a few peptide aldehyde-based bifunctional inhibitors
and found them to be twice as potent as the parent peptide aldehyde (Loidl et. al. 1999b;
Loidl et. al. 2000). For example, the IC50 (T-L) for compound 45 (Figure 3.2) was
6.4μM, but when the N-termini of two peptide aldehydes were linked with a
polyoxyethylene (PEG) spacer, the IC50 (T-L) for the resulting compound 46 (Figure 3.2)
was reduced to 0.071μM. More recently, Maréchal et al. (2012) reported a non-covalent
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bifunctional proteasome inhibitor that inhibited chymotrypsin like (CT-L) activity 800
times more efficiently compared to the parent compound (TMC-95A).

Figure 3.2 Peptide aldehyde-based bifunctional proteasome inhibitor 46 and the
parent compound 45.

Figure 3.3 Non-covalent homo-bifunctional proteasome inhibitor.
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All previous reports on bifunctional proteasome inhibitors were focused on
developing more potent inhibitors of CT-L and T-L activities of proteasomes, but none of
the compounds reported were designed to target specific catalytic subunits of
constitutive- and immuno-proteasomes. These previous reports encouraged us to develop
new bifunctional crosslinking agents that can be used to identify different intermediate
proteasomes (Chapter 1, Scheme 1.8.2). As peptide epoxyketones react with Thr1Oγ in a
very specific manner by forming a morpholino ring (Chapter 1, Scheme 1.2E), we
decided to develop the required bifunctional agents with epoxyketone pharmacophores.
By choosing the appropriate length of the linkers between the two peptide epoxyketones,
we should be able to cross-link two nearby catalytic subunits (such as β1i and β2i), as
well as distant subunits (such as β1i and β5i). Mobility shift assays could provide a direct
and rapid method to analyze the reaction products of the proteasome and bifunctional
reagents. Therefore, this cross-linking approach may serve as a more convincing method
to determine the subunit composition of intermediate proteasomes.
The overall goal of the study in this chapter is to develop a few homo- and
hetero-bifunctional agents for a proof-of-concept of crosslinking approach and show
their ability to crosslink different catalytic subunits of the proteasome by western
blotting analysis (mobility shift assays).
3.3. Results and Discussion
3.3.1. Design and synthesis of bifunctional agents
To develop the required crosslinking agents, we planned to derivatize the following three
compounds: LKS01 (20), YU102 (48) and epoxomicin (49) (Figure 3.4). The ability of
LKS01 (20) to selectively targeting the β5i/LMP7 subunit has already been discussed in
detail in chapter 2 (Figure 2.5). Dr. Kim’s lab group has also identified YU102 (48) as a
selective inhibitor of the β1i/LMP2 subunit (Chapter 2, Figure 2.15); while on the other
hand epoxomicin (49) has been reported to bind to almost all of the catalytic subunit of
constitutive- and immuno-proteasome (β2, β5, β1i, β2i and β5i).
LKS01 (20) already has a lysine group which can be deprotected easily for further
derivatization. Also, a Boc-derivative (20B) of LKS01 was developed. For YU102 and
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epoxomicin derivatization, compounds 50, 51 and 52 were synthesized (Figure 3.5) by
using a similar synthetic approach as described for LKS01 (20) in chapter 2.

Figure 3.4 Chemical structure of the compounds used for design of bifunctional
agents.

Figure 3.5 Derivatives of YU102: 50, 51; derivative of epoxomicin: 52; and
derivative of LKS01: 20B.
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Scheme 3.1 shows the general synthetic scheme used to synthesize all the
bifunctional crosslinking agents reported in this chapter. The N-hydroxysuccinimide ester
(NHS) groups of the linkers are reacted with the primary/secondary amine in the side
chain of the polypeptide compounds to form an amide bond. The resulting intermediate
can be reacted with the same polypeptide to form homo-bifunctional agents or it can be
reacted with a different polypeptide compound to develop hetero-bifunctional agents.

Scheme 3.1 General synthetic scheme used to synthesize bifunctional compounds.

Figure 3.6 LKS01 and YU102 based hetero-bifunctional agents (53 and 54) with
short linkers.
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3.3.2. Bifunctional agents with short linkers
For our initial studies we synthesized two hetero-bifunctional molecules LKS-7YU (53) and LK-6-YU (54) that consist of LKS01 (β5i-targeting) on one end and YU102
(β1i-targeting) the other end (Figure 3.6). To investigate the ability of these bifunctional
agents to cross-link two catalytic subunits within the same proteasome complex, mobility
shift assays were performed using the U266 cell lines, which expresses all of the catalytic
subunits of both the constitutive proteasome and immunoproteasome.

Figure 3.7 Western blot analysis of bifunctional agents LKS-7-YU (53) using (A)
β1i-antibody; (B) β5i-antibody and (C) β1i-antibody (competition assay). (D)
Cartoon showing the cross-linking ability of LKS-7-YU (53). U266 cell lysates were
treated with DMSO, 5 μM epoxomicin, or 10 μM of each bifunctional compound for 4
hrs at room temperature and subjected to western blot analysis using a β1i-antibody or a
β5i-antibody. For the compettion assay cell lysates were pre-incubated with DMSO, 3
μM NC-012, or 0.1 μM IPSI for 1 hr at room temperature prior to treatment with 5 μM
epoxomicin, or 10 μM of LKS-7-YU. (Mobility shift assays were performed by Kimberly
Carmony)
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As shown in Figure 3.7A and B, both LK-7-YU and LK-6-YU were found to
maintain the ability to modify both β1i and β5i subunits, detected by the increased
molecular sizes of bifunctional agent (53 and 54)-conjugated β1i and β5i subunits
observed between 20-25 kDa. Interestingly, for LK-7-YU a band around 50 kDa was
detected using the LMP2 antibody (Figure 3.7A) which suggests that LK-7-YU (54) is
able to covalently cross-link β1i-bound LK7YU with another catalytic subunit (Figure
3.7A). However, no band around 50 kDa was observed on a western blot for β5i, which
suggests that β1i is not crosslinked with β5i. Next, we performed a competition assay
using NC-012 (Ac-Arg-Leu-Arg-ketoepoxide) which is known to be a selective inhibitor
of β2/β2i (trypsin like) activity (Kisselev et al. 2012). To our delight, the bands at 50 kDa
completely disappeared in the β1i immunoblot when the cells were pre-treated with NC012 (Figure 3.7C), demonstrating that LKS-7-YU cross-linked β1i and β2/β2i subunits
(Figure 3.7D). This also suggests the presence of intermediate proteasomes containing
β1i and β2 in U266 cells. This contradicts the assumption that cells that abundantly
express

all

immunoproteasome

subunits

prefer

to

cooperatively

assemble

immunoproteasomes as opposed to intermediate proteasomes.
3.3.3. Bifunctional agents with longer linkers
The initial data obtained with the bifunctional agent LKS-7-YU proved encouraging, and
we decided to develop a few more bifunctional agents with longer linkers. We selected
polyoxyethylene glycol (PEG) as linker because of its interesting properties such as water
solubility, non-toxicity and resistance to proteolysis. Based on the nature of the
polypeptide at each end, the bifunctional agents developed by us can be characterized as:
homo-bifunctional agents, hetero-bifunctional agents and cleavable bifunctional
agents. First, we synthesized homo-bifunctional agents (YU)2-PEG (55), (LKS)2-PEG
(56), (Epx)2-PEG (57) that are homo-dimers of YU102, LKS01 and epoxomicin,
respectively (Figure 3.8). In addition to these bifunctional agents that contain PEG as
linker, we also synthesized a linear alkyl linker-based epoxomicin homo-dimer, (12-AdoEpx)2-C10 (58). One hetero-bifunctional agent, LKS-PEG-YU (59), was also synthesized
that contains LKS01 (β5i-targeting) on one end and YU102 (β1i-targeting) on the other
end. Two bifunctional agents (YU)2-SS (60) and LKS-SS-YU (61) were also developed
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that contain disulfide (S-S) cleavable linkers. The disulfide (S-S) bond can be easily
cleaved by 10-50 mM DTT or TCEP at pH 8.5. The incorporation of cleavable linkers
into our bifunctional agents might provide additional proof of the ability of bifunctional
agents to crosslink catalytic subunits of the proteasome. Of note, when coupling of
compounds 62 and 63 with PEG-linker was investigated, no reaction was observed
(Scheme 3.2). This suggests that a free amine with a long alkyl chain is not suited for
coupling with the PEG-linker, and only a free N-terminal amine or the free amine of εlysine can be used to couple the PEG-linker. However, a free amine with a long alkyl
chain can be reacted easily with the acid group of another alkyl chain; as observed for the
synthesis of compound 58.
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Figure 3.8 Homo-bifunctional agents with PEG-linker and alkyl-linker.
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Figure 3.9 Hetero-bifunctional agent with a PEG-linker.

Figure 3.10 Cleavable Homo- and Hetero-bifunctional agents with a PEG-linkers
containing disulfide (S-S) bonds (red).
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Scheme 3.2 Failed homo-dimerization reaction of compounds 62 and 63.

3.3.4. Proteasome Activity Assay
To confirm that bifunctional agents inhibit proteasome activity, we performed an activity
assay using fluorogenic peptide substrates. This assay measures the ability of inhibitors to
block the hydrolysis of fluorogenic substrates by the proteasome. Several fluorogenic
substrates have been reported in the literature that can be used to measure proteasome
activity. For example, the substrate Suc-LLVY-AMC is generally used to measure the
CT-L activity of the proteasome (i.e. β5 and β5i activity) (Orlowski et al. 2000).
Similarly, fluorogenic substrates Ac-PAL-AMC and Ac-ANW-AMC have been reported
as selective substrates for the subunits β1i and β5i,respectively (Blackburn et al. 2010).
As explained earlier, the bifunctional agent LKS-7-YU (53) was shown to crosslink β1i with another proteasome subunit (Figure 3.7). Therefore, we first compared the
ability of LKS-7-YU (53) and its PEG derivative LKS-PEG-YU (59) to inhibit
proteasome activity. As reported in Table 3.1, both compounds inhibited most β1/β1i and
β5/β5i activity at 1 μM. Additionally, LK-7-YU (53) was found to be a more potent
inhibitor of β2/β2i than LKS-PEG-YU (59) as suggested by Boc-LRR-AMC hydrolysis,
which was inhibited to 68% with 10 μM of LK-7-YU (53) as compared to 81% with 10
μM of LKS-PEG-YU (59).
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Next we investigated the inhibition of proteasome activity by the homobifunctional agents: (YU)2-PEG (55), (LK)2-PEG (56) and (12-Ado-Epx)2-C10 (58)
(Table 3.1). The bifunctional agent (YU)2-PEG (55), which is a homo-dimer of YU102,
was found to be more potent at inhibiting β1/β1i over other subunits. However, it did not
inhibit β2/β2i activity significantly at concentrations up to 10 μM. Similarly, LKS01
homo-dimer (LK)2-PEG (56) more potently inhibited β5i/β5 over other subunits and did
not inhibit β2/β2i activity until 10 μM. Compound (12-Ado-Epx)2-C10 (58) was found to
be least potent bifunctional compound. It displayed some selectivity for β5/β5i over other
subunits. Interestingly, it appeared to have a slight preference for β1 over β2/β2i, unlike
epoxomicin (Epx).
Table 3.1 Proteasome Activity Assay
Relative Rate of Hydrolysis (% control)
Concentration
(μM)

DMSO
Epx

(YU)2-PEG

LKS-PEGYU

LKS-7-YU

Compound
Used

Suc-LLVYAMC
(β5/β5i)

Ac-nLPnLDAMC
(β1)

Ac-PALAMC
(β1i)

Ac-ANWAMC
(β5i)

Boc-LRRAMC
(β2/ β2i)

-

100%

100%

100%

100%

100%

20

1%

14%

3%

0%

39%

1

4%

3%

1%

4%

95%

5

0%

-1%

0%

0%

82%

10

0%

0%

1%

1%

68%

1

3%

13%

5%

4%

105%

5

0%

0%

0%

0%

98%

10

0%

-1%

0%

0%

81%

1

34%

-1%

1%

44%

103%

5

3%

-1%

0%

18%

98%

10

1%

-2%

0%

15%

95%
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(LKS)2-PEG
(12-Ado-Epx)-C10

0.5

25%

89%

92%

5%

103%

1

5%

90%

95%

5%

105%

5

1%

73%

57%

0%

92%

10

1%

45%

37%

0%

76%

0.5

101%

98%

95%

86%

101%

1

59%

82%

85%

63%

93%

5

23%

84%

68%

40%

90%

10

13%

80%

51%

18%

84%

3.3.5. Mobility Shift Assay
To analyze the ability of our synthesized bifunctional agents to crosslink proteasome
subunits, we performed a mobility shift assay using U266 multiple myeloma cells, since
these cells abundantly express both the immunoproteasome and the constitutive
proteasome. Specifically, U266 cell lysates were treated with 10μM of LK-7-YU (53),
LKS-PEG-YU (59), (YU)2-PEG (55), (LKS)2-PEG (56) and (12-Ado-Epx)2-C10 (58).
The cell lysates were then subjected to immunoblotting analyses using antibodies specific
for the β1i/LMP2 proteasome catalytic subunit. Interestingly, bands around 45-50 kDa
were observed for LK-7-YU (53), LKS-PEG-YU (59), (YU)2-PEG (55) and (LKS)2-PEG
(56) which suggests that these bifunctional agents cross-link β1i/LMP2 with another
proteasome subunit.
Next, we performed a mobility shift assay using antibodies specific for β5i/LMP7
subunits and observed the same band around 45kDa for (YU)2-PEG (55), (LKS)2-PEG
(56) (Figure 3.11, B), indicating that both homo-bifunctional agents (55, 56) were able to
cross-link β5i/LMP7-subunit with other proteasome subunit. Of note, no cross-linked
dimers were observed on the immunoblot using antibodies specific for β2/Z (Figure
3.11, C). This is consistent with the activity assay results, which showed that these
bifunctional agents with longer linkers were not potent inhibitors of trypsin-like (T-L)
activity (Table 3.1).
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(C)

Figure 3.11 Mobility shift assay of selected longer linker bifunctional agents using
(A) β1i/LMP2-antibody (B) β5i/LMP7-antibody and (C) β2/Z-antibody. U266 cell
lysates were treated with DMSO, 5 μM epoxomicin, or 10 μM of each bifunctional
compound for 4 hrs at room temperature and subjected to western blot analysis using a
β1i-antibody, a β5i-antibody or a β2-antibody. (Mobility shift assays were performed by
Kimberly Carmony)
3.4. Summary
We have successfully synthesized epoxyketone-based bifunctional compounds by
utilizing homo- or hetero-dimerization of LKS01, YU102 and epoxomicin. The ability of
these bifunctional agents to inhibit proteasome activity was demonstrated by blocking the
proteasome-mediated hydrolysis of polypeptide fluorogenic substrates in activity assays.
Furthermore, mobility shift and competition assays demonstrated that LKS-7-YU (53)
cross-linked β1i and β2/β2i subunits within the same proteasome complex, which
provided the proof-of-concept of crosslinking proteasome catalytic subunits by
epoxyketone-based bifunctional agents. These new bifunctional tools will be helpful in
identifying the subunit composition of different proteasome subtypes and will lead to new
insights into fundamental proteasome biology may lead to the development of novel
proteasome inhibitors that more effectively target specific proteasome subtypes.
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3.5. Experimental Procedures
3.5.1. Synthesis and Characterization of compounds
(A) General Procedure
All reactions were carried out under a nitrogen atmosphere. All commercial reagents
were obtained from commercially available sources and used without further purification.
All reactions were magnetically stirred and monitored by thin-layer chromatography
(TLC). TLC plates were visualized by exposure to ultraviolet light (254 nm) and/or by
immersion in a staining solution of phosphomolybdic acid (PMA), followed by heating
on a hot plate. Column or flash chromatography (silica) was performed with the indicated
solvents using silica gel (particle size 0.032-0.063 mm) purchased from Dynamic
Adsorbents or MP Biomedicals. 1H and

13

C spectra were recorded using 300 or 400 or

500 MHz, using CDCl3 or acetone-d6 as a solvent. The chemical shifts are reported in
parts per million (ppm) relative to internal CHCl3 (δ 7.26 ppm for proton NMR and δ
77.23 ppm for carbon NMR) or relative to acetone-d6 (δ 2.05 ppm for proton NMR and δ
29.92 ppm for carbon NMR). Coupling constants are reported in hertz (Hz). The
following abbreviations are used to designate the multiplicities: s = singlet, d = doublet, t
= triplet, q = quartet, m = multiplet.
Identity of all bifunctional compounds was confirmed by mass analysis (Bruker Daltonics
MALDI-TOFMS).
Synthesis of compound 52

To a solution of compound A (0.1 mmol, 55 mg) and compound B (0.12 mmol, 18
mg) in methylene chloride was added HOBt (1.0 equiv) and HBTU (1.0 eq). After
stirring the reaction mixture for 5 minutes DIPEA was added dropwise. The reaction
mixture was further stirred for overnite at room temperature. The reaction mixture
was concentrated and directly loaded to the column. The purification was performed
with Ethyl acetate/hexane solvent system (25% to 50%), to obtain 53 mg of pure 52
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(76%) yield; 1H NMR (500 MHz, CDCl 3): δ 7.32 (m, 5H), 7.07 (d, J= 8.0 Hz, 1H),
6.87 (d, J= 6.4 Hz, 1H), 6.65 (d, J= 7.0 Hz, 1H), 4.66 (d, J= 11.6Hz, 1H), 4.51 (m,
3H), 4.28 (t, J= 6.5 Hz, 1H), 4.15 (m, 2H), 3.34 (d, J= 4.8 Hz, 1H), 2.88 (d, J= 4.8
Hz, 1H), 2.77 (m, 1H), 2.75 (s, 3H), 2.05 (m, 2H), 1.70 (m, 3H), 1.50 (s, 3H), 1.45 (s,
9H), 1.16 (d, J= 6.8 Hz, 3H), 0.92-0.82 (m, 18H), 0.78 (d, J= 6 Hz, 3H); 13C NMR (75
MHz, CDCl3): δ 208.3, 171.6, 171.1, 169.7, 157.2, 138.0, 128.6, 128.1, 128.1, 80.7,
74.0, 71.7, 63.2, 59.4, 58.6, 56.2, 52.7, 52.6, 50.6, 39.8, 36.3, 31.4, 30.3, 29.9, 28.6,
25.2, 24.6, 24.4, 23.6, 21.3, 16.9, 16.0, 15.9, 15.1, 11.6, 10.5.
Synthesis of compound 50

HBTU/HOBt/DIPEA mediated peptide coupling was performed to synthesize compound
50 in 82% yield; 1H NMR (500 MHz, CDCl3): δ 7.21 (m, 5H), 6.93 (d, J= 8.0 Hz, 1H),
6.57 (d, J= 8.0 Hz, 1H), 5.22 (t, 1H), 4.55 (m, 2H), 4.67 (m, 1H), 4.09 (dd, J= 7.2 Hz, 6.8
Hz, 1H), 3.80 (dd, J= 5.2 Hz, 5.2 Hz, 1H), 3.68 (dd, J= 4.0 Hz, 3.6 Hz, 1H), 3.29 (m,
3H), 3.12 (dd, J= 5.2 Hz, 5.2 Hz, 1H), 3.00 (dd, J= 8.8 Hz, 8.2 Hz, 1H), 2.86 (d, J= 4.4
Hz, 1H), 2.2 (m, 1H), 1.82 (m, 5H), 1.47 (s, 3H), 1.43 (s, 9H), 1.22 (t, J=7.6 Hz, 6H); 13C
NMR (75 MHz, CDCl3): 208.4, 171.1, 170.9, 169.2, 156.0, 136.9, 129.3, 128.6, 127.2,
80.2, 60.6, 59.3, 54.1, 54.1, 52.6, 50.5, 50.5, 46.6, 43.2, 40.0, 37.2, 28.6, 27.8, 25.2, 24.8,
23.6, 21.5, 16.9, 16.9, 14.4.
(B) General Procedure for the synthesis of Homo-bifunctional Compounds
To a solution of polypeptide (1 equiv) in THF, BS(PEG)9 (0.5 equiv) or DT(PEG)16 was
added which was followed by dropwise addition of DIPEA (1.5 equiv). The reaction
mixture was stirred overnite at room temperature and then it was concentrated to dryness.
The resulting crude was loaded on column and purification was performed using
methylene chloride/methanol solvent system.
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Synthesis of (YU)2-PEG (55)

A solution of compound 51 in methylene chloride was treated with TFA. After stirring
the reaction mixture for 1hr, it was concentrated and put on high vaccum for 3hr. The
crude product was taken forward for next reaction of coupling with BS(PEG)9 as
described in general procedure A. The 5 mg of bifunctional compound 55 was obtained
in overall 80% yield. The identity of compound 55 was confirmed by mass analysis
(MALDI-TOFMS): molecular ion peak, M+= (not observed), 1649 (calculated); M+Na =
1672 (observed), 1672 (calculated); M+K = 1688 (observed), 1688 (calculated).
Synthesis of (LKS)2-PEG (56)
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To a solution of LKS01 (20) in methylene chloride, 1ml TFA was added. The reaction
mixture was stirred for 1hr at room temperature and then concentrated to dryness. The
crude then reacted with BS(PEG)9 as described in general procedure A. The 2.0 mg of
bifunctional compound 56 was obtained in overall 62% yield. The identity of compound
56 was confirmed by mass analysis (MALDI-TOFMS): M+Na = 1622 (observed), 1622
(calculated); M+K=1638 (observed), 1639 (calculated).
Synthesis of (LKS)2-PEG (56)

By following the procedure A as described earlier, 4 mg of bifunctional compound 57
was obtained in overall 74% yield. The identity of compound 56 was confirmed by mass
analysis (MALDI-TOFMS): M+Na = 1706 (observed), 1706 (calculated); M+K= 1722
(observed), 1722 (calculated).
Synthesis of (12-Ado-Epx)2-C10 (58)

Compound 52B was treated with TFA to deprotect Boc group. After treating the reaction
mixture for 1hr, it was concentrated and the crude was taken forward directly without
purification.

The

crude

was

treated

with

sebacic

acid

(0.5

equiv)

under

HBTU/HOBt/DIPEA coupling condition and the reaction mixture was stirred at room
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temperature for overnite. The purification was done using methylene chloride/methanol
solvent system to obtain 58 (1 mg, 46% yield). The identity of compound 58 was
confirmed by mass analysis (MALDI-TOFMS): M+Na = 1788 (observed), 1788
(calculated).
Synthesis of (YU)2-SS (60)

By following the procedure A, 5 mg of bifunctional compound 57 was obtained in overall
85% yield. The identity of compound 57 was confirmed by mass analysis (MALDITOFMS): M+Na = 2073 (observed), 2073 (calculated); M+K= 2090 (observed), 2090
(calculated).

(C) Synthesis of Hetero-bifunctional Compounds
Synthesis of LKS-PEG-YU (59)

To a solution of LKS01 (20) (1.0 equiv) in ethyl-acetate/methanol (1:1), 10% Pd/C was
added and reaction mixture was stirred under bubbling hydrogen atmosphere. After 5hr
the reaction mixture was filtered and concentrated to dryness. The crude was diluted with
1.0 ml THF and BS(PEG)9 (1equiv) was added which was followed by addition of
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DIPEA (1.5 equiv). After stirring the reaction mixture for overnite, it was concentrated.
The resulting crude was purified using methylene-chloride/methanol solvent system to
obtain LKS-PEG9. The LKS-PEG9 was then dissolved in 1ml THF and reacted with
deprotected compound 20 (1.0 equiv) and DIPEA (1.5 equiv). The reaction mixture was
concentrated after overnite stirring and the crude was purified with methylenechloride/methanol solvent system to obtain compound 59 (3.0 mg, 64% yield).
LKS-PEG9: Mass analysis (MALDI-TOFMS): M+Na = 1180 (observed), 1180
(calculated); M+K = 1196 (observed), 1196 (calculated).
LKS-PEG-YU (59): Mass analysis (MALDI-TOFMS): M+Na = 1647 (observed), 1647
(calculated); M+K = 1663 (observed), 1663 (calculated).
Synthesis of LKS-SS-YU (61)
The same procedure was followed as described above for the synthesis of 59, except that
cleavable linker DT(PEG)16 was used instead of BS(PEG)9. The identity of compound 58
was confirmed by mass analysis (MALDI-TOFMS): Molecular ion peak M+ = 2026
(observed), 2026 (calculated); M+Na = 2049 (observed), 2049 (calculated); M+K = 2065
(observed), 2065 (calculated).
Synthesis of LKS-7-YU (53) and LKS-6-YU (54)
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To synthesize compounds 53 and 54, same procedure was followed with disuccinimidyl
suberate (DSS) linker.
LKS-7-YU (53): Mass analysis (MALDI-TOFMS): M+Na = 1309(observed),
1309(calculated).
LKS-6-YU (54): Mass analysis (MALDI-TOFMS): M+Na = 1196(observed),
1196(calculated).
3.5.2. Biology methods
Cell Lysate Preparation:
x

Cells were lysed in Passive Lysis Buffer (Promega, cat. # E194A) according to
manufacturer’s instructions.

x

Protein assays were performed by the method of Bradford using the Protein Assay
Dye Reagent Concentrate (Bio-Rad, cat. # 500-0006) and Bovine Serum Albumin
Standard (Bio-Rad, cat. # 500-0007). Protein concentrations were measured
using a GENESYS 10 spectrophotometer.

Proteasome Activity Assays:
x

Incubation with bifunctional compounds:
o Each well (96-well plate) contained 5 μg of U266 lysate in assay buffer
(total volume per well = 90 μL).


Assay Buffer: 20 mM Tris/Cl pH 8.0, 0.5 mM EDTA
x

For all substrates except Boc-LRR-AMC, 0.035% SDS was
also included in the assay buffer.

o Lysates were incubated with DMSO, 20 μM epoxomicin, or increasing
concentrations of bifunctional compounds (0.5, 1, 5, 10 μM) for 1 hr at
room temperature.
x

Addition of substrates:
o Suc-LLVY-AMC (CT-L activity), Ac-nLPnLD-AMC (C-L activity, Yselective), Ac-PAL-AMC (LMP7-selective), Ac-ANW-AMC (LMP7-
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selective), and Boc-LRR-AMC (T-L activity) were added to obtain a final
substrate concentration of 100 μM in a final volume/well of 100 μL.
x

Fluorescence was monitored (excitation = 360 nm, emission = 460 nm) over 90
min using a SpectraMax M5 plate reader and SoftMax Pro software.

x

Reaction velocities were determined using linear regression (GraphPad Prism)
and normalized to DMSO-treated control.

Western Blotting
x

U266 lysate was diluted to a concentration of 1 μg/μL in passive lysis buffer
(Promega, cat. # E194A).

x

Lysates were treated with DMSO, 5 μM epoxomicin, or 10 μM of each
bifunctional compound for 4 hrs at room temperature.

x

Samples were denatured in 2X Laemmli sample buffer (Sigma-Aldrich, cat. #
S3401) at 100°C for 20 min.

x

For LMP2, LMP7, X, and Y western blots: Proteins (5 μg/well) were resolved by
14% SDS-PAGE.

x

Proteins were transferred onto PVDF membranes (Bio-Rad, cat. # 162-0177).

x

Membranes were blocked in 5% milk in tris-buffered saline with 0.05% Tween20 (TBST) for 1 hr at room temperature.

x

Membranes were incubated in primary antibody solutions overnight at 4°C.
o LMP2 antibody: Abcam, cat. # ab3328, diluted 1:1,000 in 3% BSA
(Sigma-Aldrich, cat. # A3059) in TBST
o LMP7 antibody: Abcam, cat. # ab3329, diluted 1:1,000 in 3% milk (BioRad, cat. # 170-6404) in TBST
o X antibody: Thermo Scientific, cat. # PA1-977, diluted 1:1,000 in 3%
BSA in TBST
o Y antibody: Thermo Scientific, cat. # PA1-978, diluted 1:1,000 in 3%
BSA in TBST
o β-Actin: Novus Biologicals, cat. # NB600-501 in TBST

x

Membranes were incubated in secondary antibody solutions for 1 hr at room
temperature.
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o For LMP2, LMP7, X, and Y: anti-rabbit IgG horseradish peroxidase (GE
Healthcare, cat. # NA934), diluted 1:20,000 in 3% milk in TBST
o For β-Actin: anti-mouse IgG horseradish peroxidase (GE Healthcare, cat.
# NA931), diluted 1:5,000 in 3% milk in TBST
x

Proteins were visualized using SuperSignal West Femto Chemiluminescent
Substrate (Thermo Scientific, cat. # 34095) and X-ray film (Thermo Scientific,
cat. # 34090).

x

Competition Assay:
o U266 lysate was diluted to a concentration of 1 μg/μL in passive lysis
buffer (Promega, cat. # E194A).
o Lysates were pre-incubated with DMSO, 3 μM NC-012, or 0.1 μM IPSI
for 1 hr at room temperature.
o Lysates were then treated with DMSO, 5 μM epoxomicin, or 10 μM of
each bifunctional compound for 4 hrs at room temperature.
o Samples were then denatured and western blotting was performed to
detect LMP2, as described above.
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3.5.3. Copies of NMR and mass spectra
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Compound 53
M+ = 1286
M+Na = 1309

Compound 54
M+ = 1173
M+Na = 1196
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Compound 55
M+ = 1649
M+Na = 1672
M+K = 1688

Compound 55
M+ = 1649
M+Na = 1672
M+K = 1688
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Compound 56
M+ = 1599
M+Na = 1622
M+K = 1638

Compound 56
M+ = 1599
M+Na = 1622
M+K = 1638
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Compound 57
M+ = 1683
M+Na = 1706
M+K = 1722

Compound
57
M+ = 1683
M+Na =
1706
M+K = 1722
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Compound 58
M+ = 1765
M+Na = 1788

Compound 58
M+ = 1765
M+Na = 1788
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Compound 60
M+ = 2050
M+Na = 2073
M+K = 2090

Compound 60
M+ = 2050
M+Na = 2073
M+K = 2090
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Compound 61
M+ = 2026
M+Na = 2049
M+K = 2065

Compound 61
M+ = 2026
M+Na = 2049
M+K = 2065
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Compound 59
M+ = 1624
M+Na = 1647
M+K = 1663

LKS-PEG9
M+ = 1157
M+Na = 1180
M+K = 1196
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YU102-DSS
M+ = 838
M+Na = 861

Copyright © Lalit Kumar 2012
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Chapter 4: Studies towards a selective β5i/LMP7-inhibitor: Understanding the
binding pattern*
4.1. Overview of the study
Recent studies have associated the β5i/LMP7-subunit of the immunoproteasome with
autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease (IBD)
(Muchamuel et al. 2009; Basler et al. 2010). The treatment of autoimmune diseases with
proteasome inhibitors represents a large potential market with possibilities for significant
improvement in patient wellbeing. However, the current proteasome inhibitors in clinical
use are designed to target both β5 and β5i subunits, which provide the proteasome with
its chymotrypsin-like activity. As described previously, non-specific inhibition of the
chymotrpysin-like activity of the proteasome causes cytotoxic effects which would be
undesirable in the treatment of autoimmune disease. Aside from therapeutic applications,
the lack of subunit specific inhibitors also limits our understanding of the functional role
of individual active subunits in cells. The overall goal of the study in this chapter focuses
on developing a small library of tripeptide compounds to understand the structural
determinants for binding to and inhibiting catalytic proteasome subunits. This knowledge
may lead to a more selective inhibitor of the β5i/LMP7 subunit.
4.2. Introduction: β5i/LMP7-subunit and Human Diseases
The approval of bortezomib and carfilzomib by the FDA for the treatment of multiple
myeloma and mantle cell lymphoma has encouraged scientists to investigate the role of
constitutive- and immuno-proteasomes in other diseases as well. Several studies have
recently linked the β5i/LMP7 subunit of the immunoproteasome to diseases including
autoimmune disorders and cancers.
Autoimmune diseases
The upregulation of immunoproteasome subunits (β5i and β1i) has been observed in
_________________________________________________________________________

* Kinetic assay and mobility shift assays reported in this chapter were performed by Zach
Miller.
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several autoimmune diseases such as rheumatoid arthritis and inflammatory bowel
disease. A study utilizing two mouse models of rheumatoid arthritis showed that
administration of PR-957 (a β5i selective inhibitor) resulted in a significant reduction of
inflammatory infiltration, pro-inflammatory cytokine production and autoantibody
production (Muchamuel et al. 2009; Ichikawa et al. 2012). Other studies have
demonstrated that β5i inhibition by PR-957 or deletion of β5i prevents the progression of
experimental colitis and systemic lupus erythematosus (Basler et al. 2010). These
findings provide a rational for targeting the β5i-subunit of immunoproteasome in
autoimmune diseases.
Cancer
Several studies have demonstrated high expression level of immunoproteasome subunits
in various cancer cells lines. In 2009, Parlati et al. showed that neither the selective
inhibition of β5 nor β5i can cause antitumor activity. However, another study
demonstrated that a β5i selective inhibitor PR-924 can provoke apoptosis in human
multiple myeloma cell lines (Singh et al. 2011). These two contradicting reports warrant
further investigation to validate β5i-subunit as anti-cancer target.

Figure 4.1 Chemical Structure of PR-924 (IPSI) and PR-957.
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Figure 4.2 Binding pattern of PR-924 and PR-957 in EL4 cell lines.
Even though PR-957 and PR-924 have been reported as selective inhibitors of the
β5i/LMP7 subunit in a dose dependent manner, our mobility shift assays in EL4 cell lines
have shown that both PR-957 and PR-924 bind to and covalently modify the β1i/LMP2immunosubunit at low concentrations as well (Figure 4.2). Additionally, the study in
chapter 2 outlined the modifications of PR-924 (IPSI) which produced the inhibitor
LKS01 and its fluorescent derivative LKS01-B650. Interestingly, the introduction of the
BODIPY® 650/665 fluorescent group at the P2 position appeared to significantly
improve the binding specificity of LKS01 towards β5i/LMP7 (Figure 2.6). Taken
together, our western blot analysis of PR-924, PR-957 and LKS01-B650 suggest that
there is still room for improvement in the effort to develop a more selective β5i/LMP7subunit inhibitor.
To understand the binding pattern of proteasome inhibitors with constitutive- and
immuno-subunits, we decided to carry out a systematic SAR study. A scheme was chosen
in which each amino acid residue of the β5i/LMP7-targeing tripeptide inhibitor PR-924
would be modified individually by replacement with other natural and unnatural amino
acids in order to generate a series of analogs at each position (Figure 4.3B). These
analogs would then be tested for their ability to inhibit the activity β5i/LMP7 and β5/X
subunits in purified proteasomes. Our overall goal in this combinatorial positional
scanning study was to gain insights that will help advance our efforts to develop a more
selective inhibitor targeting the β5i/LMP7-subunit of the immunoproteasome.
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Figure 4.3 (A) Interaction of the side chains of IPSI with specificity (S) pockets of
proteasomal substrate binding channel; (B) Tripeptide epoxyketone.
4.3. Results and Discussion
4.3.1. P2 modification
Our medicinal chemistry efforts began with the development of a series of analogs of
lead compound, IPSI (PR-924). This initial series of compounds was designed with
different amino acids at the P2 position while maintaining the parent compound’s 3Methylindene-D-Ala-P2-Phe-Ketoepoxide backbone (Figure 4.4). This small library
contained P2 amino acids with small hydrophobic side chain such as Gly, Ala, Abu, Ile
and compounds with larger hydrophobic side chains such as Nle, Met and Lys(Boc).
Compounds with aromatic functionality like Phe, Trp and Lys(Z) were also synthesized.
First, the ability of these compounds to inhibit the β5i/LMP7-subunit was
analyzed by measuring the hydrolysis of the selective fluorogenic substrate Ac-ANWAMC (Blackburn et al. 2010). Compounds with an aromatic ring in the P2 side chain
(Phe, Lys(Z) and Trp) were found to inhibit the β5i/LMP7 subunit more potently than
other compounds. Compounds containing small and large hydrophobic resides (Gly, Ala,
Abu, Ile, Nle and Lys(Boc)) generally did not produce potent activity (Figure 4.5).

99

Figure 4.4 P2 modification with a 3-Methylindene-D-Ala-P2-Phe-Ketoepoxide
backbone.
Interestingly, the compound containing Met at P2 (65F) was found to be more
potent inhibitor of β5i/LMP7 as compared to the carbon analog Nle at P2 (65E)
suggesting a role for the sulfur heteroatom in β5i/LMP7 inhibition. Additionally, the
compound containing the D-Lys(Z) side chain (65I) was found to be nearly inactive
against the β5i/LMP7-subunit, clearly indicating the importance of L-amino acid
stereochemistry at the P2 position. In addition to monitoring the β5i inhibitory potency of
these P2-derivative compounds, we also assessed these compounds for inhibition of the
β5/X-subunit by using the selective substrate Ac-WLA-AMC. Compounds containing
small hydrophobic residue such as Gly, Ala and Abu at P2 position were found to be
much more potent inhibitors of the β5/X-subunit as compared to Nle, Ile and Met P2
derivatives. Interestingly the inhibitor containing Phe at the P2 position was a potent
β5/X inhibitor whereas the analog containing Trp at this position had minimal activity at
this subunit. This suggests that the size or properties of the tryptophan bicycle somehow
influence selectivity for β5i/LMP7 over β5/X.
Taken together, these initial assays utilizing selective fluorogenic substrates
and a series of P2 analogs suggest that amino acids with an aromatic residue at the
P2 position are more suitable for the development of highly selective β5i/LMP7
inhibitor.
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Figure 4.5 Inhibition of β5i/LMP7- and β5/X-specific fluorogenic substrate
hydrolysis by treatment with 0.3 and 1.0 PM of P2-series analogs respectively. (This
assay was performed by Zachary C. Miller of Kyung-Bo’s group)
4.3.2. P3 modification
The known β5i/LMP7-selective ketoepoxide inhibitor IPSI (Parlati et al. 2010) contains a
small methyl chain at its P3 position. Another known β5i/LMP7-selective inhibitor, PR957, has similarities with IPSI and also contains a methyl side chain at its P3 position.
Specifically, PR-957 contains L-Ala while both IPSI and LKS01-B650 contain D-Ala at
their P3 positions. To investigate the impact of P3 position stereochemistry on
proteasome inhibition, we synthesized inhibitors containing stereoisomers of the
hydrophobic amino acids alanine, 2-aminobutyric acid (Abu), and norleucine (Nle) at P3
position with backbone of 3-Methylindene-P3-Nle-Phe-Ketoepoxide (Figure 4.6). An
analog containing D-Phenylalanine was also synthesized to investigate the size of the P3
pockets of the β5i/LMP7 subunit as it has been reported to be quite restrictive based upon
X-ray crystallography (Huber et. al. 2012).
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Figure 4.6 P3 modification with a 3-Methylindene-R3-Nle-Phe-Ketoepoxide
backbone.
Fluorogenic substrate hydrolysis assays using purified proteasomes treated with
these compounds revealed that both D-Ala (65E) and D-Abu (66A) were more potent
inhibitors of β5i/LMP7 as compared to their L-isomers. This pattern was reversed with
the larger hydrophobic residue norleucine. The difference in potency due to
stereochemistry appeared smallest with the Abu-containing inhibitors. We could imagine
that the D and L stereochemistry allow our side chains to access two different portions of
the P3 pocket which have different requirements. This could perhaps explain the lack of a
clear structure-activity relationship (SAR) in this data set. Notably the larger and
aromatic D-Phe analog actually showed better activity that the D-Ala compound
suggesting that the P3 pocket of the β5i/LMP7 is sufficiently spacious to accommodate a
benzyl group. Interestingly, a large difference in the β5/X potency of these P3- derivative
inhibitors was observed. Importantly, L-Ala at P2 was found to be many times more
potent inhibitor of β5/X compared with the D-isomer. This suggests that replacing the
proteinogenic L-alanine with its D-isomer has a very large impact on selectivity. The Lisomers of both Abu and Nle were also found to be slightly more potent inhibitors of
β5/X as compared to D-isomers. Intriguingly, increasing the side chain’s length from that
of Ala to that of Abu greatly increased β5/X inhibition but increasing from Abu to Nle
decreased activity. As with β5i/LMP7, we find evidence of an unexpectedly complex
structure activity-relationship.
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Collectively, the analysis of in vitro β5i/LMP7 and β5/X inhibition by P3
derivatives suggests that small amino acid with D-isomer will be more suitable for
the design of β5i/LMP7-slective inhibitors.
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Figure 4.7 Inhibition of β5i/LMP7- and β5/X-specific fluorogenic substrate
hydrolysis by treatment with 0.3 and 1.0 PM of P3-series analogs. (This assay was
performed by Zachary C. Miller of Kyung-Bo’s group)
4.3.3. P1 and N-cap modification
Next, we investigated the effect of amino acid choice at the P1 position utilizing a
backbone of 3-Methylindene-D-Ala-Lys(Z)-P1-Ketoepoxide. Previous studies have
indicated that both the β5i/LMP7 and β5/X subunits prefer to bind peptides with large
hydrophobic amino acids in their P1 positions. A derivative with a homophenylalanine
(hPhe) group in its P1 side chain (67A) was synthesized as a slightly larger analog of the
existing Phe-containing compound (20) to see what influence a slight increase in size
would have on activity. The branched amino acid side chain leucine has been reported as
being a preferred substrate for both β5/X and β1i/LMP2 but may also be suitable for
binding to β5i/LMP7 (Huber et al. 2012). In addition the presence of OTBDMS ether at
the C1 carbon has been reported to decrease β5/X-binding by steric hindrance (Beilei et
al. 2010). For this reason we synthesized compounds containing leucine (67B) and
leucine with the OTBMDS ether at the P1 position (67C).
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Figure 4.8 P1 modification with a 3-Methylindene-D-Ala-Lys(Z)-R1-Ketoepoxide
backbone
As shown in Figure 4.9, compound 67B containing the amino acid Leu at P1
position showed less ability to inhibit substrate hydrolysis by the β5i/LMP7 as compared
to the Phe-P1 derivative (20). Additionally, Leu-P1 (67B) showed higher potency to
inhibit β5/X activity; which is consistent with the previous crystallographic studies
(Huber et al. 2012). The TBDMS-containing compound (67C) had weaker activity
against both β5/X and β5i/LMP7 suggesting that binding to both β5/X and its homologue
β5i/LMP7 is impeded by the bulky silyl ether. Interestingly, Homo-Phe at the P1 position
(compound 67A) afforded very weak inhibition of both β5i/LMP7 and β5/X activity,
suggesting that S1 pocket of both of these subunits is too small to accommodate homoPhe.
Together, the above results further suggest that a P1 Phe group confers
β5i/LMP7-specificity to peptide-based ketoepoxide inhibitors.
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Figure 4.9 Inhibition of β5/X and β5i/LMP7 by 1.0 and 0.3 PM of P1- and N-CapModified Compounds. (This assay was performed by Zachary C. Miller of Kyung-Bo’s
group)

Figure 4.10 N-cap modification with N-Cap-D-Ala-Trp-Phe-Ketoepoxide Backbone.
Three compounds with N-terminal modifications from the 3-methylindenecontaining inhibitor IPSI (19) were synthesized (Figure 4.10). Notably, the
carbobenzyloxy-containing compound 68C inhibited β5i/LMP7 with a potency similar to
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that of the parent compound (Figure 4.9) Despite this, β5/X activity was increased by a
large factor. This result seems suspect because of the similarity of these two compounds
but perhaps the protruding methyl side chain of 3-methylindene provides steric
hinderance in a key location needed to block binding to β5/X. Alternatively it is possible
that the additional oxygen heteroatom found in compound 68C interacts favorable with a
residue lining the β5/X pocket. Additional analogs of these two seemingly similar
compounds should be made to explore the determinants for selectivity in the N-cap. Two
heterocycle-containing N-cap compounds were also made, one containing the 5-methyl3-isoxazole group which has been successfully incorporated into several proteasome
inhibitors designed at Proteolix, Inc. (Huber et al. 2012), and the pyrazinoic acid group
found in the potent β5/X and β5i/LMP7 inhibitor bortezomib (add a reference).
Interestingly, both heterocyclic N-cap compounds (68A and 68B) demonstrated poor
β5i/LMP7 activity as well as poor selectivity. Again, further compounds are additional
tests are needed to understand the N-terminal structural requirements for potent and
selective β5i/LMP7 inhibition.
4.4. Summary
Recent studies have indicated the therapeutic potential of β5i/LMP7-subunit of
immunoproteasome as a drug target in the treatment of autoimmune diseases. In our
efforts to develop a more selective inhibitor of β5i/LMP7-subunit, we have developed a
small library of compounds based on combinatorial positional scanning approach. The
synthesized proteasome inhibitors were characterized for their potency and specificity by
fluorogenic substrate hydrolysis assays. Although in some cases a clear structure-activity
relationship was not forthcoming, enzyme inhibition assays have shed light on some of
the factors needed for to generate a selective inhibitor of the β5i/LMP7 subunit.
Specifically, we have identified the following structural requirements:
x

P1 position: Phe or a smaller aromatic residues (no extended phenylalanine
analogs)

x

P2 position: A larger, aromatic ring-containing residue

x

P3 position: small D-amino acid
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4.5. Supporting Info
4.5.1. Kinetic assay protocol
The hydrolysis of the X, LMP7, and LMP2-specific substrates Ac-WLA-AMC, AcANW-AMC, and Ac-PAL-AMC respectively, was measured at room temperature in the
presence of 0.5 ug/mL purified 20S human constitutive or immunoproteasome.
Experiments were carried out in 96-well polystyrene microplates with a 100 uL reaction
volume containing 20 mM Tris-HCl, 0.5 mM EDTA, 0.035% w/v SDS, and ≤3% v/v
DMSO. Substrates were present at 20 PM for Ac-WLA-AMC and 100 PM each for AcANW-AMC and Ac-PAL-AMC. 20S proteasomes were exposed to various
concentrations of inhibitors for sixty minutes before the addition of substrate. After
substrate addition, the fluorescence of the liberated AMC was measured using an
excitation wavelength of 360 nm and an emission wavelength of 460 nm. Each well was
read once per minute over a 90 minute time period. A linear regression was then
performed to quantify the rate of substrate hydrolysis. These rates were normalized to
positive control wells to obtain “percent activity remaining” values which represent the
percentage of proteasome active sites not inhibited by 60 minute exposure to an
irreversible inhibitor.
4.5.2. General Procedure, Synthetic Scheme and Characterization data
All the reactions are performed as mentioned in chapter 2, supporting information. After
purification, all the compounds are characterized using 1H NMR,

13

C NMR and mass

analysis.
The general synthetic scheme used to synthesize the compounds reported in chapter 4 is
following:

The tripeptide A is prepared by HBTU/HOBt mediated peptide coupling as reported in
chapter 2, supporting information. Synthesis of epoxyketone B is also reported in chapter
2, supporting information.
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Characterization Data (1H NMR, 13C NMR and mass analysis):

1

H NMR (400 MHz, CDCl3): δ 7.40 (m, 2H), 7.32 (m, 2H), 7.22 (m, 3H), 7.13 (m, 3H),

6.96 (t, J= 7.2 Hz, 1H), 6.51 (d, J= 8.5 Hz, 1H), 4.77 (m, 1H), 4.57 (m, 1H), 3.85 (d, J=
7.0 Hz, 1H), 3.57 (m, 3H), 3.25 (d, J= 6.5 Hz, 1H), 3.08 (dd, J= 13.5, 5.5 Hz, 1H), 2.80
(m, 2H), 2.49 (s, 3H), 1.43 (d, J= 7.2 Hz, 3H), 1.41 (s, 3H).
13

C NMR (100 MHz, CDCl3): δ 208.0, 173.4, 169.1, 166.6, 145.5, 142.3, 136.0, 131.3,

131.2, 129.5, 128.7, 127.6, 127.3, 126.9, 124.0, 121.1, 59.5, 53.4, 52.7, 49.4, 38.3, 37.0,
21.3, 18.2, 16.7, 12.6.
Mass analysis (MALDI): M++Na = 512.2 (observed), 512.23 (calculated); M+K =
528.2 (observed), 528.23 (calculated).

1

H NMR (400 MHz, CDCl 3): δ 7.45 (m, 2H), 7.34 (m, 2H), 7.24 (m, 3H), 7.16 (m,

4H), 6.81 (d, J= 9.5 Hz, 1H), 4.78 (m, 1H), 4.60 (m, 1H), 3.56 (d, J= 3 Hz, 1H), 3.49
(dd, J= 7.5, 4.0 Hz, 1H), 3.32 (dd, J= 10.5, 6.0 Hz, 1H), 3.14 (m, 1H), 2.90 (m, 1H),
2.76 (m, 2H), 2.51 (t, J= 3.0 Hz, 3H), 1.50 (d, J= 10.0 Hz, 3H), 1.36 (d, J= 8.5 Hz,
1H), 1.27 (d, J= 9.0 Hz, 3H), 1.22 (m, 2H).
13

C NMR (100 MHz, CDCl 3): δ 207.6, 172.5, 166.0, 148.5, 148.2, 145.7, 142.3,

135.9, 131.6, 131.4, 129.6, 129.5, 128.7, 127.3, 124.1, 121.1, 59.5, 53.1, 52.9, 48.5,
48.3, 38.5, 38.3, 18.4, 18.1, 16.8, 12.6.
Mass analysis (MALDI): M++Na=526.24 (observed), 526.24 (calculated).
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1

H NMR (400 MHz, CDCl 3): δ 7.47 (m, 2H), 7.35 (m, 2H), 7.22 (m, 3H), 7.13 (m,

2H), 6.99 (d, J= 8.0 Hz, 1H), 6.97 (d, J= 7.2 Hz, 1H), 6.56 (d, J= 7.2 Hz, 1H), 4.78
(m, 1H), 4.63 (m, 1H), 4.32 (m, 1H), 3.70 (m, 1H), 3.63 (m, 1H), 3.28 (d, J= 5.2 Hz,
1H), 3.13 (m, 1H), 3.06 (dd, J= 14, 4.8 Hz, 1H), 2.87 (m, 1H), 2.78 (m, 1H), 2.53 (t,
J= 1.8 Hz, 3H), 1.81 (m, 1H), 1.56 (m, 1H), 1.47 (m, 8H).
13

C NMR (100 MHz, CDCl3): δ 207.7, 172.8, 171.5, 166.4, 148.4, 145.6, 142.4,

136.2, 131.6, 129.5, 128.6, 127.6, 127.2, 126.9, 124.0, 121.0, 59.4, 54.6, 52.9, 49.2,
43.4, 38.4, 37.2, 25.4, 18.8, 17.4, 16.6, 12.7.
Mass analysis (MALDI): M++Na = 540.3 (observed), 540.26 (calculated); M+K =
556.3 (observed), 556.26 (calculated).

30% racemization was observed during the final reaction.
1

H NMR (400 MHz, CDCl 3): δ 7.47 (m, 2H), 7.36 (m, 2H), 7.29 (m, 2H), 7.21 (m,

3H), 6.93 (d, J= 8.5 Hz, 1H), 6.72 (d, J= 7.5 Hz, 1H), 6.42 (d, J= 7.0 Hz, 1H), 4.80
(m, 1H), 4.63 (m, 1H), 4.39 (dd, J= 8.5, 4.5 Hz, 1H), 3.61 (s, 2H), 3.36 (d, J= 5.0 Hz,
1H), 3.16 (dd, J= 14, 5 Hz, 1H), 2.88 (d, J= 5Hz, 1H), 2.76 (dd, J=10.5, 3.5 Hz, 1H),
2.54 (t, J= 3 Hz, 3H), 1.84 (m, 1H), 1.45 (s, 3H), 0.83 (t, J= 6.5, 3H), 0.71 (d, J= 7
Hz, 3H).
13

C NMR (100 MHz, CDCl 3): δ 207.8, 172.6, 171.3, 166.5, 148.8, 145.7, 142.4,
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136.1, 131.7, 129.5, 128.8, 127.7, 127.3, 127.1, 124.0, 121.0, 59.5, 58.0, 56.7, 53.2,
52.6, 49.2, 38.8, 37.1, 26.4, 18.3, 16.8, 15.6, 12.6 11.8.
Mass analysis (MALDI): M++Na = 568.03 (observed), 568.29 (calculated); M+K =
584.3 (observed), 584.29 (calculated).

1

H NMR (400 MHz, CDCl 3): δ 7.47 (m, 2H), 7.36 (m, 2H), 7.20 (m, 2H), 7.12 (m,

3H), 6.70 (d, J= 7.5 Hz, 1H), 6.61 (d, J= 7.6 Hz, 1H), 6.34 (d, J= 6.8 Hz, 1H), 4.77
(m, 1H), 4.58 (m, 1H), 4.32 (m, 1H), 3.64 (m, 2H), 3.28 (d, J=5.2 Hz, 1H), 3.05 (dd,
J= 14.0, 4.8 Hz, 1H), 2.85 (s, 2H), 2.54 (t, J= 2.8 Hz, 3H), 1.71 (m, 2H), 1.44 (d, J=
6.8 Hz, 3H), 1.40 (s, 3H), 1.25 (m, 7H).
13

C NMR (100 MHz, CDCl3): δ 207.6, 172.5, 171.5, 166.5, 148.6, 145.7, 142.4, 136.0,

131.5, 129.5, 128.6, 127.6, 127.2, 127.0, 124.0, 121.1, 59.4, 53.5, 52.8, 52.6, 49.1, 38.4,
37.3, 31.7, 27.6, 22.5, 18.1, 16.7, 14.1, 12.6.
Mass analysis (MALDI): M++Na = 568.03 (observed), 568.29 (calculated); M+K =
584.3 (observed), 584.29 (calculated).

1

H NMR (400 MHz, CDCl 3): δ 7.44 (m, 2H), 7.34 (m, 3H), 7.21 (m, 2H), 7.15 (m,

3H), 7.07 (d, J= 7.5 Hz, 1H), 6.56 (d, J= 7.0 Hz, 1H), 4.74 (m, 1H), 4.59 (m, 2H),
3.60 (m, 2H), 3.29 (d, J=4.5, 1H), 3.07 (dd, J= 14.0, 4.5 Hz, 1H), 2.85 (d, J= 4.5 Hz,
1H), 2.72 (dd, J= 13.5, 8.5 Hz, 1H), 2.50 (m, 5H), 2.04 (s, 3H), 1.94 (m, 2H), 1.43 (d,
J= 7.0 Hz, 3H), 1.41 (s, 3H).
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13

C NMR (100 MHz, CDCl 3): δ 207.7, 173.0, 171.2, 166.4, 148.6, 145.6, 142.4,

135.9, 131.5, 129.4, 128.7, 127.6, 127.2, 126.9, 124.0, 121.0, 59.5, 53.4, 52.7, 52.3,
49.2, 38.8, 38.8, 36.9, 30.9, 30.1, 18.4, 16.6, 12.5.
Mass analysis (MALDI): M++Na=586.2 (observed), 568.25 (calculated); M+K=
602.2 (observed), 602.25 (calculated).

1

H NMR (400 MHz, CDCl 3): δ 7.43 (m, 2H), 7.♥32 (m, 3H), 7.19 (m, 2H), 7.12 (m,

3H), 6.98 (d, J= 7.6 Hz, 1H), 6.85 (d, J= 7.2 Hz, 1H), 6.47 (d, J= 7.5 Hz, 1H), 4.72
(m, 2H), 4.56 (m, 1H), 4.31 (m, 1H), 3.68 (m, 1H), 3.62 (m, 1H), 3.28 (d, J= 5.5 Hz,
1H), 3.13 (m, 1H), 3.04 (m, 3H), 2.83 (d, J= 6 Hz, 1H), 2.72 (m, 1H), 2.50 (t, J=2 Hz,
3H), 1.72 (m, 1H), 1.58 (m, 1H), 1.417 (m, 14H), 1.37 (s, 3H).
13

C NMR (100 MHz, CDCl 3): δ 207.8, 172.9, 171.6, 166.5, 156.4, 145.6, 142.4,

136.2, 131.6, 129.5, 128.8, 128.6 ,127.6, 127.2, 126.9, 124.0, 121.0, 79.4, 59.5, 55.7,
53.2, 52.7, 49.3, 43.7, 40.0, 38.8, 38.4, 36.9, 31.4, 29.6, 28.6, 22.4, 18.2, 16.6, 12.7.
Mass analysis (MALDI): M++Na = 683.4 (observed), 683.35 (calculated); M+K =
699.4 (observed), 699.35 (calculated).

1

H NMR (500 MHz, acetone-d6): δ 7.08 (d, J = 7.5Hz, 1H), 7.60 (d, J = 8.5 Hz, 1H),

7.49 (m, 2H), 7.36-7.28 (m, 5H), 7.235 (m, 3H), 7.20 (m, 3H), 7.14 (m, 2H), 4.72 (m,
1H), 4.67 (m, 1H), 4.44 (m, 1H), 3.67 (s, 2H), 3.35 (d, J = 5.5 Hz, 1H), 3.20 (dd, J=
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14.0, 4.5 Hz, 1H), 3.06 (dd, J= 14.0, 4.0 Hz, 1H), 2.94 (d, J=5.5 Hz, 1H), 2.80 (m,
2H), 2.47 (t, J= 3.0 Hz, 3H), 1.39 (s, 3H), 1.30 (d, J= 6.5 Hz, 3H).
13

C NMR (125 MHz, acetone-d6): δ 208.1, 173.4, 172.1, 166.7, 147.5, 146.6, 143.5,

138.7, 138.4, 133.6, 130.3, 130.2, 130.2, 129.2, 129.0, 128.9, 127.8, 127.5, 127.5,
127.2, 124.7, 121.4, 59.9, 54.7, 52.7, 50.5, 39.0, 38.8, 38.0, 36.9, 18.0, 16.8, 12.5.
Mass analysis (MALDI): M++Na = 602.3 (observed), 602.3 (calculated); M+K =
618.3 (observed), 618.27 (calculated).

1

H NMR (400 MHz, CDCl 3): δ 7.38 (m, 2H), 7.33 (m, 2H), 7.20 (m, 3H), 7.15 (m,

2H), 6.76 (d, J= 7.6 Hz, 1H), 6.54 (d, J= 7.2 Hz, 1H), 6.32 (d, J= 7.6 Hz, 1H), 4.81
(m, 1H), 4.57 (m, 1H), 4.27 (m, 1H), 3.71 (m, 2H), 3.31 (d, J= 4.8 Hz, 1H), 3.16 (m,
2H), 2.90 (d, J= 5.2 Hz, 1H), 2.53 (t, J = 2.4, 3H), 1.48 (d, J = 6.0 Hz, 3H), 1.45 (m,
5H), 1.26 (m, 4H), 0.78 (t, J = 7.2 Hz, 3H).
13

C NMR (100 MHz, CDCl 3): δ 207.6, 172.7, 171.5, 166.3, 148.7, 145.6, 142.3,

135.8, 131.3, 129.5, 128.8, 127.7, 127.4, 127.1, 124.1, 121.1, 59.5, 53.6, 48.9, 43.9,
38.8, 37.3, 31.7, 27.6, 22.5, 18.8, 18.1, 16.7, 13.9, 12.7.
Mass analysis (MALDI): M++Na = 644 (observed), 568.29 (calculated); M+K = 660
(observed), 584.29 (calculated).

1

H NMR (400 MHz, CDCl 3): δ 7.46 (m, 2H), 7.35 (m, 2H), 7.19 (m, 2H), 7.13 (m,

3H), 6.88 (d, J= 8.5 Hz, 1H), 6.85 (d, J= 8..5 Hz, 1H), 6.54 (d, J= 7.5 Hz, 1H), 4.77
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(m, 1H), 4.53 (m, 1H), 4.40 (m, 1H), 3.64 (m, 2H), 3.29 (d, J= 5.0 Hz, 1H), 3.05 (dd,
J= 14.0, 4.5 Hz, 1H), 2.84 (d, J= 5.0 Hz, 1H), 2.73 (dd, J= 13.0, 8.5 Hz, 1H), 2.54 (t,
J=2.0 Hz, 3H), 1.97 (m, 1H), 1.75 (m, 2H), 1.52 (m, 1H), 1.38 (s, 3H), 1.24 (m, 4H),
0.96 (t, J= 7.0 Hz, 3H), 0.85 (t, J=7.0 Hz, 3H).
13

C NMR (100 MHz, CDCl 3): δ 207.6, 171.9, 171.5, 166.6, 148.2, 145.7, 142.4,

136.0, 131.8, 129.5, 128.6, 127.5, 127.2, 126.9, 124.0, 121.0, 59.5, 54.8, 53.4, 52.9,
52.6, 38.5, 37.2, 31.8, 27.6, 25.6, 22.6, 16.6, 14.0, 12.1, 10.2.
Mass analysis (MALDI): M+Na = 582.3 (observed), 582.30 (calculated); M+K =
598.3 (observed), 598.30 (calculated).

1

H NMR (400 MHz, CDCl 3): δ 7.46 (t, J= 6.0 Hz, 2H), 7.35 (m, 2H), 7.22 (m, 3H),

7.15 (d, J = 7.5 Hz, 2H), 6.75 (d, J = 7.5 Hz, 1H), 6.61 (d, J = 7.5 Hz, 1H), 6.38 (d, J
= 7.5 Hz, 1H), 4.84 (m, 1H), 4.50 (m, 1H), 4.34 (m, 1H), 3.62 (s, 2H), 3.30 (d, J = 5.0
Hz, 1H), 3.13 (dd, J = 9.0, 5.5 Hz, 1H), 2.90 (d, J = 4.5 Hz, 1H), 2.81 (dd, J = 14.0,
8.0 Hz, 1H), 2.53 (t, J = 2.0 Hz, 3H), 1.90 (m, 1H), 1.73 (m, 2H), 1.54 (m, 1H), 1.48
(s, 3H), 1.2 (m, 4H), 0.91 (t, J = 7.5 Hz, 3H), 0.85 (t, J = 7.5 Hz, 3H).
13

C NMR (100 MHz, CDCl 3): δ 207.6, 172.0, 171.5, 166.4, 148.2, 145.7, 142.3,

135.8, 131.7, 129.5, 128.8, 127.5, 127.3, 127.0, 124.0, 121.0, 59.4, 54.4, 53.5, 52.7,
52.7, 38.5, 37.3, 31.9, 27.6, 25.7, 22.5, 16.7, 14.0, 12.5, 10.2.
Mass analysis (MALDI): M+Na=582.3 (observed), 582.30 (calculated); M+K=598.3
(observed), 598.30 (calculated).
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1

H NMR (400 MHz, CDCl 3): δ 7.47 (m, 2H), 7.36 (m, 2H), 7.20 (m, 3H), 7.13 (m,

2H), 6.67 (d, J = 7.6 Hz, 1H), 6.58 (d, J = 8.0 Hz, 1H), 6.32 (d, J = 7.6 Hz, 1H), 4.77
(m, 1H), 4.46 (m, 1H), 4.35 (m, 1H), 3.64 (m, 2H), 3.28 (t, J = 2.8 Hz, 1H), 3.05 (dd,
J = 13.6, 5.2 Hz, 1H), 2.85 (d, J = 4.8 Hz, 1H), 2.73 (dd, J = 13.6, 8.0 Hz, 1H), 2.54
(t, J = 2.0 Hz, 3H), 1.94 (m, 1H), 1.73 (m, 2H), 1.47 (m, 1H), 1.38 (s, 3H), 1.30 (m,
2H), 1.25 (m, 6H), 0.90 (m, 3H), 0.85 (t, J = 7.5 Hz, 3H).
13

C NMR (100 MHz, CDCl 3): δ 207.6, 172.0, 171.5, 166.4, 148.2, 145.7, 142.3,

135.7, 131.7, 129.5, 128.8, 127.5, 127.3, 127.0, 124.0, 121.0, 59.4, 53.7, 53.5, 52.9,
52.6, 38.5, 37.2, 31.9, 31.7, 27.9, 27.6, 22.7, 22.5, 16.6, 14.1, 14.1, 12.6.
Mass analysis (MALDI): M+Na = 610.3 (observed), 610.34 (calculated); M+K =
626.3 (observed), 626.34 (calculated).

1

H NMR (400 MHz, CDCl 3): δ 7.47 (m, 2H), 7.34 (m, 2H), 7.22 (m, 3H), 7.14 (m,

2H), 6.76 (d, J = 7.0 Hz, 1H), 6.72 (d, J = 8.0 Hz, 1H), 6.41 (d, J = 7.5 Hz, 1H), 4.78
(m, 1H), 4.51 (m, 1H), 4.36 (m, 1H), 3.66 (m, 2H), 3.29 (t, J = 4.5 Hz, 1H), 3.05 (dd,
J = 14, 4.5 Hz, 1H), 2.84 (d, J = 5.0 Hz, 1H), 2.75 (dd, J = 14, 8.5 Hz, 1H), 2.54 (t, J
= 2.0 Hz, 3H), 1.95 (m, 1H), 1.73 (m, 2H), 1.53 (m, 1H), 1.38 (s, 3H), 1.33 (m, 2H),
1.26 (m, 6H), 0.89 (m, 3H), 0.85 (t, J = 7.5 Hz, 3H).
13

C NMR (100 MHz, CDCl 3): δ 207.6, 172.1, 171.5, 166.6, 148.3, 145.7, 142.4,

136.1, 131.7, 129.5, 128.6, 127.6, 127.2, 126.9, 124.0, 121.0, 59.4, 53.7, 53.4, 52.9,
52.6, 38.5, 37.2, 32.0, 31.8, 27.9, 27.6, 22.7, 22.5, 16.6, 14.1, 14.0, 12.5.
Mass analysis (MALDI): M+Na = 610.3 (observed), 610.34 (calculated); M+K =
626.3 (observed), 626.34 (calculated).
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1

H NMR (400 MHz, CDCl 3): δ 7.41 (m, 1H), 7.36-7.14 (m, 10H), 7.11 (m, 3H), 6.76

(d, J = 7.5 Hz, 1H), 6.52 (d, J = 7.6 Hz, 1H), 4.75 (m, 2H), 4.24 (m, 1H), 3.56 (m,
2H), 3.26 (d, J = 5.2 Hz, 1H), 3.12 (d, J = 7.6 Hz, 2H), 3.01 (dd, J = 14.0, 4.8 Hz,
1H), 2.82 (d, J = 4.8 Hz, 1H), 2.74 (m, 1H), 2.46 (s, 3H), 2.09 (t, J = 12.4 Hz, 3H),
1.36 (s, 3H), 1.16 (m, 2H), 0.95 (m, 2H), 0.79 (t, J = 7.2 Hz, 3H).
13

C NMR (100 MHz, CDCl 3): δ 172.9, 165.5, 147.4, 145.8, 142.3, 132.1, 127.3,

126.8, 123.9, 123.9, 120.9, 120.8, 82.3, 65.2, 54.5, 48.7, 48.7, 38.5, 38.3, 28.2, 19.2,
19.1, 17.8, 17.4, 12.4, 12.3.
Mass analysis (MALDI): M++Na = 644 (observed), 644.32 (calculated); M+K = 660
(observed), 660.32 (calculated).

1

H NMR (400 MHz, CDCl 3): δ 7.41 (m, 3H), 7.32 (m, 6H), 7.18 (m, 3H), 7.10 (m,

4H), 6.92 (d, J = 7.6 Hz, 1H), 6.45 (d, J = 6.8 Hz, 1H), 5.14 (m, 1H), 5.07 (m, 3H),
4.63 (m, 1H), 4.51 (m, 1H), 4.41 (m, 1H), 3.49 (m, 2H), 3.20 (m, 3H), 2.64 (m, 1H),
2.55 (m, 1H), 2.46 (t, J = 2.4 Hz, 3H), 2.06 (m, 1H), 1.88 (m, 1H), 1.70 (m, 1H), 1.52
(d, J = 6.4, 1H), 1.47 (m, 4H), 1.42 (m, 1H), 1.38 (m, 4H).
13

C NMR (100 MHz, CDCl 3): δ 208.1, 173.2, 171.8, 166.5, 156.9, 145.6, 142.4,

140.7, 136.7, 131.4, 128.6, 128.6, 128.3, 127.6, 126.9, 126.4, 124.0, 121.0, 99.7, 66.8,
59.4, 53.2, 52.4, 49.3, 40.4, 38.8, 38.3, 32.6, 31.3, 29.3, 22.4, 18.4, 17.6, 16.7, 12.6.
Mass analysis (MALDI): M++Na = 731 (observed), 731.35 (calculated); M+K = 747
115

(observed), 747.35 (calculated).

1

H NMR (400 MHz, CDCl 3): δ 7.41 (m, 2H), 7.33-7.29 (m, 8H), 7.19 (d, J = 8.0 Hz,

1H), 6.80 (d, J = 7.6 Hz, 1H), 6.59 (d, J = 7.2 Hz, 1H), 5.20 (m, 1H), 5.05 (s, 2H),
4.64 (m, 1H), 4.47 (m, 2H), 3.60 (m, 2H), 3.25 (d, J = 5.2 Hz, 1H), 3.15 (m, 2H), 2.48
(t, J = 2.0 Hz, 3H), 1.82 (m, 1H), 1.62 (m, 3H), 1.46 (m, 1H), 1.44 (m, 4H), 1.39 (m,
4H), 1.34 (m, 1H), 1.24 (m, 1H), 0.84 (t, J = 6.4Hz, 6H).
13

C NMR (100 MHz, CDCl 3): δ 208.7, 173.0, 171.9, 166.3, 156.9, 148.4, 145.6,

142.4, 136.7, 131.4, 128.7, 128.3, 127.5, 126.9, 124.0, 121.0, 66.8, 59.4, 53.0, 50.8,
49.2, 40.4, 39.6, 38.4, 31.6, 29.3, 25.4, 23.4, 22.3, 21.3, 21.3, 18.6, 16.8, 12.5.
Mass analysis (MALDI): M++Na = 683 (observed), 683.35 (calculated); M+K = 699
(observed), 699.35 (calculated).

Mass analysis (MALDI): M++Na = 813.4 (observed), 813.43 (calculated); M+K =
829.4 (observed), 829.43 (calculated).
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Mass analysis (MALDI): M++Na = 591 (observed), 591.24 (calculated); M+K = 607
(observed), 607.24 (calculated).

Mass analysis (MALDI): M++Na = 619 (observed), 619.29 (calculated); M+K = 635
(observed), 635.29 (calculated).

Mass analysis (MALDI): M++Na = 594 (observed), 594.23 (calculated); M+K = 610
(observed), 610.24 (calculated).
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4.5.3. Copies of Mass Spectra
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Chapter 5: A Concise Synthetic Approach to 1-Azaspirocyclic Compounds†
5.1. Overview of the Study
In drug-discovery research, structural modification is an important tool that facilitates the
understanding and enhancement of the specific biological activity of small molecules.
The development of a concise and flexible synthetic route is a fundamental prerequisite
for said structural modification. The study in this chapter focuses on the development of a
concise approach towards the synthesis of 1-azaspirocyclic ring systems. These structural
motifs have captivated the synthetic community for many years, as a result of their
presence as structural subunits in biologically active and structurally diverse natural
products. We have developed a new and step-economical approach to 1-azaspirocyclic
ring system formation via an efficient tandem semi-pinacol/Beckmann rearrangement.
The reaction constructs a tertiary carbon center adjacent to the nitrogen functionality and
a spirocyclic ring system in a single synthetic operation. During this endeavour, an
environmentally benign, microwave-assisted, and solvent-free self-condensation of
carbonyl compounds has also been developed.
5.2. Introduction
5.2.1. 1-Azaspirocyclic Ring System in Natural Products

Figure 5.1 1-Azaspirocyclic Ring Systems
1-azaspirocyclic systems comprise two rings fused in spiro fashion that contain a
nitrogen atom adjacent to ring the junction. 1-azaspiro[4.4]-nonane (69), 1azaspiro[4.5]decane (70), and 6-azaspiro[4.5]decane (71) ring systems are some
____________________

† The studies reported in this chapter are started under the supervision of Dr. Gregory I.
Elliott.
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representative examples of 1-azaspirocyclic systems (Figure 1). The 1-azaspirobicyclic
core has been observed in a variety of alkaloid natural products. Notable examples
include (–)-histrionicotoxin (72), lepadiformine (73), halichlorine (74), pinnaic acid (75),
tauropinnanic acid (76) as well as many others (Figure 5.2).

Figure 5.2 Alkaloids that contain 1-azaspirocycle motifs
The histrionicotoxins are a group of alkaloids isolated from the skin extracts of
the Colombian “poison dart” frog Dendrobates histrionicus (Daly et al. 1971). They
differ primarily in the degree and nature of unsaturation in the side chains. (–)histrionicotoxin (72a) and its hydrogenated derivative perhistrionicotoxin (72b) were
originally isolated by Witkop and co-workers in 1971. They were among the first
alkaloids shown to act as noncompetitive inhibitors of neuromuscular, ganglionic and
central neuronal nicotinic acetylcholine receptors (Takahashi et al. 1982; Daly et al.
1991). These types of biological activity of this type give these compounds antiarrythmic
properties. Histrionicotoxin and perhistrionicotoxin are both useful biochemical tools for
probing the mechanism of transynaptic transmission of neuromuscular impulses. The
parent compound’s low abundance in nature (>200 μg/frog), interesting biological
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activity and unique spiropiperidine structure make histrionicotoxins attractive synthetic
targets.
In 1994, Lepadiformine (73) was isolated from Clavelina lepadiformis and
exhibits moderate in vitro cytotoxicity against nasopharynx carcinoma (KB) and nonsmall-cell lung carcinoma (NCSLC-N6) (Biard et al. 1994). When the alkaloid was tested
in rats, it caused induction of bradycardia, prolongation of ECG parameters and a
transient fall in blood pressure (Juge et al. 2001).
Halichlorine (74), a marine alkaloid isolated from the marine sponge
Halichondria okadai Kadota by Uemura and co-workers in 1996 (Kuramoto et al. 1996),
has been shown to inhibit the expression of vascular cell adhesion molecule-1 (VCAM-1)
with an IC50 of 7μg/ml. VCAM-1 is a peptide involved in the recruitment and trafficking
of leukocytes to site of tissue trauma (Chou et al. 1996), making it a potential target for
the treatments of a wide variety of diseases believed to arise from extreme inflammatory
and autoimmune responses such as atherosclerosis, rheumatoid arthritis, organ transplant
rejection and a wide number of autoimmune conditions.
Later, the structurally similar compounds pinnaic acid (75) and tauropinnanic acid
(76), which were isolated from the Okinawan bivalve Pinna muricata, were shown to
exhibit inhibitory activity against cPLA2 (cytosolic phospholipase A2) (Chou et al.
1996), This enzyme cleaves arachidonic acid from phospholipids in the cell membrane,
thus allowing for its conversion into prostaglandins and making these compounds of
potential value for the treatment of inflammatory diseases.
5.2.2. Previous approaches for the construction of 1-azaspirocyclic motifs
In addition to the interesting biological activities of these alkaloids, their complex
structures have attracted synthetic chemists for the development of a number of synthetic
strategies towards the core 1-azaspirocyclic ring systems. An outstanding review by Dake
provides a comprehensive overview of the previous approaches for the construction of 1azaspirocyclic ring system (Dake et al. 2006). Additionally, reviews by Weinreb and
Sinclair provide a good read and highlights various approaches for the synthesis of
histrinicotin and cylindricine/lepadiformine respectively (Weinreb et al. 2006; Sinclair et
al. 2007).
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Most of the previous strategies have proven to be innovative and provide good
yields, but they have also been target-molecule oriented. As Dake noted “In most cases, a
method was developed in order to solve a specific synthetic problem, generally within the
context of a total synthesis exercise” (Dake, G. 2006). So, in the context of my
dissertation, I decided to briefly review only those previous azaspirocyclization
approaches that were shown to have general applicability.
(A) Ring Expansions
In 2001, Dake and co-workers reported a semipinacol-based acid-mediated ring
expansion of cyclobutanols to produce azaspirocyclic ketones (Fenster et al. 2001).
Mechanistically, the reaction of enamines 77 with camphorsulfonic acid (CSA) produced
the transient azacarbenium ion intermediate 78 (Scheme 5.1). Finally, ring expansion of
the adjacent cyclobutane with carbonyl bond formation furnished azaspirocyclic ring
systems 79a and 79b. However, the same ring expansion reaction of cyclopentanols
derivatives was found to be unsuccessful. An alternate strategy was suggested for the ring
expansion of cyclopentanol-derived substrates to their corresponding cyclohexanones.
The reaction required a siloxy-epoxide derivative 81 and treatment with a lewis acid
resulted in epoxide ring opening. The resulting transient intermediate 82 generated the
ring expansion product 83 as single observable diastereomer.

Scheme 5.1 Dake’s ring expansion approach
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(B) Conjugated Diene-Iminium Ion Spirocyclization
Kibayashi’s group efficiently used N-acyliminium ion-based spirocyclizations for the
synthesis of 1-azaspiro[4.4]nonane and 1-azaspiro[4.5]decane ring systems (Abe et al.
2005). These reactions started with the acyclic ketoamide 84 which on treatment with
formic acid initiated the in situ generation of the cyclic N-acyliminium ion 85 (Scheme
5.2). Subsequently, the attack of formate anion on the conjugated diene resulted in
azaspirocyclization to form 87. This methodology was successfully used for the
enantioselective total synthesis of the tricyclic marine alkaloids (-)-lepadiformine (73)
and the structurally similar compounds: (+)-cyclindricine C and (-)-fasicularin.

Scheme 5.2 Kibayashi’s approach via intramolecular conjugate azaspirocyclization
(C) Dearomatization
In 2004, Wardrop’s group expanded the concept of the electrophilic addition process
originally developed by Glover for the synthesis of the (+)-Kishi lactum utilizing
nitrenium ion as electrophile (Glover et al.1987; Wardrop et al. 2004). The
spirocyclisation

was

achieved

by

using

a

hypervalent

iodine

reagent,

phenyliodinebis(trifluoroacetate) (PIFA) to obtained a 9:1 mixture of C6 epimers 89a and
89b (Scheme 5.3). This method was successfully adopted to generate intermediates used
in the synthesis of the natural product fasicularin (Wardrop et al. 2004).
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Scheme 5.3 Electrophilic addition to arenes (Wardrop route)
(D) Cycloaddition
Funk’s research group demonstrated the applicability of the cycloaddition approach for
the synthesis of azaspirocyclic ring systems (Funk et al. 1987). The [3+2] cycloaddition
of the exocyclic nitrone 92 and the unsaturated ester 93 resulted in the formation of the
isoxazolidine intermediate 94 (Scheme 5.4). N-O bond cleavage by hydrogenolysis of 94
initiated the spontaneous lactamization to yield the azaspirocyclic product 95.

Scheme 5.4 [3+2] Cycloaddtion approach

(E) Radical Cyclization
The Ihara group reported the development of a radical cyclization approach for the
synthesis of halichlorine 74 and pinnaic acids 75 (Takasu et al. 2003). The reaction of 96
with tri-n-butyltin hydride and AIBN generated an aryl radical. A 1,5 hydrogen atom
transfer generated radical 97 which cyclized in a 5-exo fashion to produce the
azaspirocycles 98a and 98b.
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Scheme 5.5 The Ihara radical cyclization approach
(F) Intramolecular Aza-Piancatelli Rearrangement
Recently, Palmer and Alaniz demonstrated an Aza-Piancatelli rearrangement of
furylcarbinols 99 for the construction of 1-azaspirocylic ring system (Palmer et al. 2011).
The reaction was catalyzed by dysprosium (III) triflate to form exclusively trans
diastereomer azaspirocyclic framework 101.

Scheme 5.6 Aza-Piancatelli rearrangement approach
5.3. Our Approach to Azaspirocyclic Compounds
The preceding schemes provide clear evidences for the interest of synthetic organic
chemists in architecturally complex 1-azaspirocyclic compounds. Structurally, the 1azaspirocyclic framework contains a carbocyclic ring and a heterocyclic ring joined in a
spiro fashion. The two main synthetic problems associated with this structural motif are:
(1) the construction of a tertiary carbon center adjacent to the nitrogen functionality and
(2) the formation of the spirocyclic ring system. Most of the previous reported syntheses
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first construct the tertiary center adjacent to N-atom, then during the end stages either
close the heterocyclic ring (path a), or close the carbocyclic ring (path b) to form the core
azaspirocyclic ring system. There have been only a few synthetic strategies reported that
combine the generation of tertiary carbon center and spirocyclic ring formation within a
single synthetic step (Dake, G. 2006).

Scheme 5.7 Our approach to 1-azaspirocylic ring system
In developing a conceptually different and concise approach to the 1azaspirocyclic framework, we envisioned a new synthesis of histrionicotoxin (72a) from
lactam 102. The amide group and carbonyl moiety in compound 102 were seen to
provide a perfect platform for further derivatization to launch the total synthesis of
histrionicotoxin (72a) and its perhydroderivative perhistrionicotxin (72b). The
spirocyclic compound 102 was envisioned to obtain from rearrangements of epoxy-oxime
103. Specifically, we intended to use a semipinacol rearrangement of the epoxide to
explore ring expansion reaction for the formation of the spirocyclic ring system. The
amide bond in 102 was envisioned to be synthesized from a Beckmann rearrangement of
corresponding oxime. We planned to synthesize this required epoxy-oxime 103 from
corresponding cyclic enone 104 (Scheme 5.7). Similarly, the 1-azaspirocyclic core of
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other natural products, having different ring sizes, could be synthesized from the
corresponding cyclic enones using the same series of reactions. This approach should
provide a general method that will enable the synthesis of azaspirocyclic compounds with
different heterocycle or carbocycle ring sizes.
5.4. Results and Discussion
Our initial task focused on the synthesis of 2-cyclopentylidene-cyclopentaone (104) from
an aldol condensation of cyclopentanone. The aldol condensation is a classic and wellknown carbon-carbon bond forming reaction. The reaction involves the removal of an
acidic α-hydrogen from an aldehyde or ketone to generate an enolate or enol (donor)
which then reacts with another molecule of same aldehyde or ketone (acceptor). The
resulting β-hydroxycarbonyl compound can then undergo dehydration to produce an α,βunsaturated carbonyl compound.
The aldol condensation of alkyl aldehydes is a very rapid process (Watanabe et al.
2010 and references therein). However, ketones show poor reactivity as aldol acceptors
due to steric hindrance, especially in case of cyclic and higher molecular weight ketones
(Mestres, R. 2004). Additionally, ketones are moderate carbonacids and thus require
strong bases like lithium diisopropylamide (LDA) and sodium hydride for their selfcondensation (Mestres, R. 2004). These strong bases require special reaction conditions
such as aprotic solvents and complete exclusion of moisture and oxygen. Alternative
methods reported for the self-aldol condensation of ketones require two to three
equivalents of strong acids like hydrochloric acid and polyphosphoric acid (Nielsn, A. T.
1968). The cationic rhodium complex [Cp*Rh(η6-C6H6)](BF4)2] (Terai et al. 2006) and
the W(CO)6/CCl4/UV system (Bozkurt et al. 2000) are also known to promote selfcondensation of cyclic ketones. Aldol condensation of aromatic and aliphatic ketones has
been reported using organometallic reagents (Nakano et al. 1987; Danen et al. 1940) and
titanium alkoxide (Yatluck et al. 2004).
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5.4.1 A microwave assisted solvent-free self-condensation of cyclic ketones†
In 2006, Arnold et. al. observed a very slow self-condensation of cyclopentanone while
researching the synthesis of arylidene and alkylidene carbonyl compounds. A decent
conversion of cyclopentanone to the self-condensed product 104 was observed over a
period of 11 days with two molar equivalents of lithium perchlorate and catalytic amount
of triethylamine. When we investigated the same reaction, the dilakylated product 105
was also observed along with required monoalkylated product 104. We decided to further
study the self-condensation of cyclic ketones using cyclopentanone as model substrate.
As microwave irradiation is known to provide an efficient energy source to accelerate
organic transformations, we planned to investigate self-condensation reaction using a
Biotage microwave reactor under solvent-free conditions (Scheme 5.8).

Scheme 5.8 Self-condensation of cyclopentanone
(A) Effect of effect of LiClO4 and Et3N on the ratio of monoalkylated 104) and
dialkylated (105) products.
First, we decided to investigate whether Lewis acid (LiClO4) is required for the reaction
or not. When the self-condensation of cyclopentanone was carried out in the absence of
lithium perchlorate, even an equivalent amount of triethylamine failed to give the
required product. To further investigate the effect of lithium perchlorate, the selfcondensation was carried out at different mol% amounts of lithium perchlorate while
keeping the concentration of Et3N at 20 mol%. It was observed that the increase in the
mol% of lithium perchlorate resulted into the formation of more dialkylated product 105
(Table 5.1, Entry 1-4.).
____________________

† A report of this work has been published. Portions taken in part from: Lalit Kumar Sharma,
Kyung Bo Kim and Gregory I. Elliott: Green Chem. 2011, 13, 1546-1549.
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Table 5.1 Effect of LiClO4 on self-condensation of cyclopentanone

a
b

Entry

LiClO4 (mol%)

Et3N (mol%)

Ratio (104:105)a

Yield of 104 (%)b

1

50

20

5.4:1

68

2

20

20

88:1

66

3

10

20

14.3:1

56

4

5

20

28.6:1

31

5

0

20

-

0

Ratio based on the peak integration of 1H NMR (500 MHz)
Isolated yield.

Next we studied the effect of triethylamine and as we expected no reaction was
observed in the absence of triethylamine (Table 5.2, Entry 5). Next the selfcondensation was carried out at different mol% amount of triethylamine while keeping
the concentration of lithium perchlorate at 10 mol%. Surprisingly, no effect on the yield
or ratio of the two products was observed after addition of extra equivalent of
triethylamine relative to lithium perchlorate (Table 5.2, Entry 1-3).
Table 5.2 Effect of Et3N on self-condensation of cyclopentanone

a

Entry

Et3N (mol%)

LiClO4 (mol%)

Ratio (104:105)a

Yield of 104 (%)b

1

30

10

14.3:1

55

2

20

10

14.3:1

56

3

10

10

14.3:1

52

4

5

10

20.0:1

30

5

0

10

‒

0

Ratio based on the peak integration of 1H NMR (500 MHz)
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b

Isolated yield.

(B) Optimization studies of self-condensation of cyclopentanone
After closely looking at the previous data of Table 5.1 and Table 5.2, we observed that
best yield and selectivity for 2-cyclopentylidene-cyclopentaone (104) was obtained when
equal equivalents of lithium perchlorate and triethylamine were used. So, we further
studied the self-condensation reaction with equal equivalents of lithium perchlorate and
triethylamine (Table 5.3). The best yield (80%) with good selectivity was obtained using
40 mol% of each triethylamine and lithium perchlorate (Table 5.3, Entry 5). To our
delight, the self-condensation of cyclopentanone was also accomplished on
100 mmol scale without any observable loss in yield or selectivity.
Table 5.3 Optimization of self-condensation of cyclopentanone (Green Chem. 2011,
13, 1546-1549)
Entry

Et3N (mol%)

LiClO4 (mol%)

Ratio (104:105)a

Yield of 104 (%)b

1

10

10

93:7

50

2

20

20

88:12

69

3

25

25

86:14

72

4

30

30

86:14

77

5

40

40

90:10

80

6

50

50

88:12

75

7

60

60

86:14

71

8

70

70

85:15

75

9

100

100

88:12

61

Ratio based on the peak integration of 1H NMR (500 MHz)
Isolated yield.
*Entry 2-6 are average of two runs
a
b
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(C) Mechanistic studies
For mechanistic investigation, other additives were also examined for their effect on the
self-condensation

of

cyclopentanone.

The

reactions

with

lithium

trifluoromethanesulfonate and lithium perchlorate trihydrate were found to work
efficiently (Table 5.4, Entry 3 and 4). Interestingly, we also observed that lithium
perchlorate, lithium perchlorate trihydrate, and lithium trifluoromethane-sulfonate are all
soluble in cyclopentanone at 120 °C. While the other additives that were found to be
ineffective for self-condensation reactions are insoluble in cyclopentanone at 120 °C.
Therefore, it can be concluded that mutual solubility of the reactants is a major factor for
the reaction to proceed. This observation was also made previously by Rothenberg et al.
with respect to very similar reactions (Rothenberg, G. 2001).
The role of LiClO4 in the reaction may be realized through coordination of
lithium ion with the carbonyl oxygen, making it more susceptible to nucleophilic attack
by the enolate generated by triethylamine. Also, anhydrous lithium perchlorate acts as a
dehydrating agent, thus helping in aldol dehydration.
Table 5.4 Investigation of other additivesa (Green Chem. 2011, 13, 1546-1549)

a
b

Entry

Additive

Ratio (104:105)b

Yield of 104 (%)c

1

LiSO4

‒

0

2

LiCl

‒

0

3

LiCF3SO3

92:8

71

4

LiClO4.3H2O

94:6

51

5

NaClO4

‒

0

6

KClO4

‒

0

Reactions were carried out with 40 mol% of LiClO4 and 40mol% of Et3N at 120 °C.
Ratio based on the peak integration of 1H NMR (500 MHz).
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c

Isolated yield.
Next we compared the efficiency of microwave irradiation with conventional

heating. To effectively compare these two sets of conditions, all reactions were initiated
after reaching the designated temperature in oil-bath and were carried out in sealed
Biotage microwave vails. When the reaction was carried out with an oil bath held at
120±0.5 °C using 40 mol% each of LiClO4 and Et3N, only 17% of the desired cyclic
enone 104 was obtained (Table 5.5, Entry 1). After performing the reaction for periods
of time, yield of required compound 104 increased but selectivity for compound 104
dropped fourfold with a threefold increase in reaction time (Table 5.5, Entry 2-4).
Table 5.5 Reaction using conventional heating (Green Chem. 2011, 13, 1546-1549)
Entry

Time

Ratio (104:105)b

Yield of 104 (%)c

1

20min

95:5

17

2

1h

85:15

46

3

2h

80:20

68

4

4h

70:30

54

All reactions were started after reaching the designated temperature in oil-bath and were
carried out in sealed Biotage microwave vails with 40 mol% of LiClO4 and 40mol% of Et3N
at 120 °C.
b
Ratio based on the peak integration of 1H NMR (500 MHz).
a

c

Isolated yield.

(D) Substrate Scope (Green Chem. 2011, 13, 1546-1549)
Further studies were conducted to explore the substrate scope of our microwave-assisted
solvent-free reaction (Table 5.6). First, we attempted the solvent-free condensation of 1indanone 109 and 5,6-dimethoxy-1-indanone 113 under optimized conditions. NOE
experiments showed that the reaction exclusively gave the E-isomer (Table 5.6, Entry 2
and 3). The self-condensation of 2-indanone 114 yielded the mono-condensed product
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115 as the major product (Table 5.6, Entry 4). While, the same reaction of 1,3indandione 117 was completed in 5 min giving dione 118 as the major product (Table
5.6, Entry 5). Of note, an increase in the yield of truxenequinone 119 was observed when
the reaction was allowed to run for a longer time. Truxenequinone 119 has been reported
to be useful for the synthesis of fullerenes compounds (Diederich, F. 1992, Rabideau, P.
W. 1996). Interestingly, the reaction of six membered cyclic ketones such as
cyclohexanone 120 and beta-tetralone 121 gave the β,γ-unsaturated isomer (Table 5.6,
Entry 6 and 7). However, the reaction was successfully applied to the six-membered
α,β-unsaturated ketone 125 (Table 5.6, Entry 8). Unfortunately, the self-condensation
reaction of larger ring systems such as cycloheptanone and cyclooctanone (Table 5.6,
Entry 9) failed under our optimized conditions.
We also investigated the implication of our method towards the self-condensation
of various aldehydes. It was found that the method afforded the desired self-condensation
products in excellent yields and with high selectivity towards E-isomers (Table 5.7,
Entries 1-7). It is noteworthy that the self-condensation of aldehydes also does not
proceed in the absence of lithium perchlorate (Table 5.7, Entry 2). For the practical
conversion to the self-condensed products of acyclic ketones, higher temperatures and
longer reaction times were required (Table 5.7, Entry 8-9).
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Table 5.6 Substrate Scope a
Ratiob
(major:
minor)

Yield of
Major (%)c

1

90:10

80

2

99:1

73

NAe

70

75:25

71

99:1

92

98:2

50

NA

61

50:50

40

Entry

Substrate

Major Product

Minor Product

3d

_

4

5f

6

7

_

8

143

9

_

_

NA

No
reaction

Reaction were carried out with 40 mol% of LiClO4 and 40 mol% of Et3N at 120 ˚C.
Ratio based on the peak integration of 1H NMR (500 MHz). c Isolated Yield.
d
Reaction temperature was 150 °C.
e
Not Applicable.
f
Reaction time was 5 min.
a

b

Table 5.7 Self-condensation of acyclic aldehydes and ketones (Green Chem. 2011, 13,
1546-1549)

a

Entry

R1

R2

Yield (%)a

E:Zb

1

C5H11

H

95

98:2

2

C4H9

H

93(0)c

97:3

3

C3H7

H

90

95:5

4

C2H5

H

90

98:2

5

(CH3)2CHCH2

H

85

94:6

6

PhCH2

H

92

98:2

7

PhCH2CH2

H

89

97:3

8

H

4-Me-C6H4

15

>99:1

9

H

4-Me-C6H4

42d

50:50

Isolated Yield.

Ratio based on the peak integration of 1H NMR (500 MHz). c Reaction without LiClO4.
d
Reaction was done at 200 ˚C for 4 hr.
b
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5.4.2. Studies towards the synthetic 1-azaspirocyclic ring system
After achieving our initial goal of synthesizing 2-cyclopentylidenecyclopentanone 104
from cyclopentanone 106, we focused our attention on the development of a concise
synthetic strategy to obtain the 1-azaspiroctyclic ring system.
(A) Sequential Semi-pinacol and Beckmann rearrangements to synthesize 1azaspirocyclic ring system
We began with the investigation of the epoxidation reaction of 2-cyclopentylidenecyclopentaone (104). Several epoxidation reaction conditions using reagents such as
MCPBA, H2O2/NaOH and HBO3 were investigated and the best yield was obtained with
dimethyldioxirane (DMDO) which afforded the corresponding oxide 128 in 98% yield
(Scheme 5.9). DMDO provided a mild and neutral reaction condition and produced easily
removable acetone as the only byproduct. Importantly, no purification was required for
the DMDO-mediated epoxidation reaction. The epoxyketone 128 was then treated with
hydroxylamine hydrochloride to obtain oxime 129 in 97% yield. The oxime formation
reaction selectively produced the E-isomer as revealed by the X-ray analysis of oxime
129 (Figure 5.3). The E-isomer was required for the late stage Beckmann rearrangement.
Next, we investigated the ring expansion reaction required to generate the
spirocyclic ring system. Several Lewis acids such as Bi(OTf)3, In(OTf)3, La(OTf)3 and
BF3.Et2O were investigated for the semipinacol-type ring expansion of epoxy-oxime 129
and the best results were obtained using 10 mol% of Sc(OTf)3 in DCM, affording spiro
keto-oxime 130 in 91% isolated yield. Finally, a PPSE (polyphosphoric acid
trimethylsilyl ester) mediated Beckman rearrangement provided an efficient method for
the isomerization of oxime 130 to amide 131. The structure of this 1-azaspirolactam 131
was confirmed by X-ray crystallography (Figure 5.3).
Overall, our approach in Scheme 5.9 provided 1-azaspirolactam 131 in five
sequential steps starting from the cheap and commercially available precursor
cyclopentanone with high atom efficiency. Since the conversion of 1-azaspirolactam 131
into (±)-perhistrioniocotoxin 72b has already been reported, our synthesis of 1azaspirolactam 131 also constitutes a formal synthesis of (±)-perhistrioniocotoxin.
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Scheme 5.9 Synthesis of azaspiro lactam 10 utilizing sequential semi-pinacol and
Beckmann rearrangements.
Reagents and conditions: (a) LiClO4 (0.4 equiv), Et3N (0.4 equiv), 120°C, 20 min.,
microwave irradiations, 80%; (b) DMDO (1.5 equiv), rt, 15 hr, 98%; (c) NH2OH.HCl
(1.5 equiv), NaOAc (1.5 equiv), MeOH, 30 min, rt, 88%; (d) Sc(OTf)3 (0.1 equiv), DCM,
rt, 4hr, 91%; (e) PPSE, 80°C, 12 hr, 75%.
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Figure 5.3 X-ray crystal structure of 129 (left) and 131 (right). (X-ray analysis was
performed by Dr. Sean Parkin at Department of Chemistry, University of Kentucky)
(B) Tandem Semi-pinacol and Beckmann rearrangements
Scheme 5.9 clearly demonstrated the efficiency of our synthetic strategy for the
construction of the 1-azaspirocyclic ring system. The key sequential reactions in our
approach were a Lewis acid catalyzed semi-pinacol rearrangement and a PPSE-mediated
Beckmann rearrangement. As both of these reactions are known to proceed using acids
also, we envisaged that it might be possible to use both the above reactions in one
synthetic step to construct an azaspirocyclic ring system.
Table 5.8 Tandem Semi-pinacol/Beckmann rearrangements.

a

Entry

Reagents

Temp (°C)

Time (h)

Yield (%)a

1

TiCl4, DCM

-78

0.5

10

2

AlCl3, CH3CN

reflux

2.5

trace

3

SOCl2, rt, 6h

25

6.0

0

4

PPA

130

0.5

84

5

Eaton’s reagent

100

1.0

77

6

PPE

100

2.0

20

7

PPSE

80

12

10

Isolated Yield.
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We started by investigating the feasibility of tandem semi-pinacol/Beckmann
rearrangements. When we attempted use TiCl4 and AlCl3, which are commonly
employed strong Lewis acids in Beckmann rearrangements, for the conversion of epoxy
ketone 129 to required product 131, yields were poor. However, moderate yields were
observed in the case of strong acids such as Eaton’s reagent and PPE (Polyphosphate
Ester). To our delight, a smooth expansion to 1-azaspirocycle 131 was observed when
PPA (polyphosphoric acid) was used. To the best of my knowledge, this reaction
provides the first example of tandem semi-pinacol/Beckmann rearrangements in the
literature. This tandem reaction allows the formation of a tertiary carbon adjacent to the
N functionality and the spirocyclic ring system within one synthetic operation.
(C) One pot synthesis of sterically hindered α,β-dicyclic enone and corresponding
epoxides
After successfully showing the application of the tandem semi-pinacol/Beckmann
rearrangements for the synthesis of 1-azaspirolactam 131, we next focused on the
application of tandem semi-pinacol/Beckmann rearrangements on other systems (Scheme
5.10). For the synthesis of α,β-dicyclic enones having different ring sizes, we decided to
investigate a procedure previously reported by Bach et al. (1985). Initially, thiol 132 was
chosen as a model substrate for our studies. A Lewis acid catalyzed α-thioalkylation of
silyl enol ether resulted in the desired carbon–carbon bond formation of the two cyclic
fragments to obtain thiol 132 (Reetz, M. T. 1981). Bach et al. reported in their paper that
treatment of 132 with sodium periodate at 0 °C produced the required α,β-unsaturated
cyclic enone 134a. However, we were unable to reproduce this oxidative
dehydrosulfenylation reaction. Even a 24 hr reaction at room temperature did not go to
completion and yielded sulfone 133 as major product. After further digging into the
literature we found that heating of β-ketosulfone in CCl4 is known to produce unsaturated
ketones (Paterson, I. 1979). The reaction provided an isomeric mixture of products 134a
and 134b whose separation was difficult and an extensive chromatography was required
to purify the products; thus affording a low yield of the required enone 134a. Hence, we
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turned our attention towards modification of this route to synthesize the cyclic enone
more efficiently.

Scheme 5.10 Investigation of previously reported method to synthesize α,β-dicyclic
enones
First, we decided to investigate the oxidation of thiol 132 to sulfone 133.
Dimethyldioxirane (DMDO) being a powerful electrophilic oxidant is known to oxidize
aliphatic sulfides to sulfinic acids. Also, DMDO provides a mild and neutral reaction
condition for transfer of oxygen atoms; and produces a fairly innocuous and easily
removable acetone as the only byproduct. When we carried out the oxidation of thiol 132
with DMDO, a complete conversion to required product 133 was observed within 30
min. Next, we investigated the selective elimination reaction for the conversion of
compound 133 to enone 134a. Several amine bases such as DMAP, imidazole, Et3N,
DABCO and DIPEA provided unsatisfactory results and 1,8-diazabicyclo[5.4.0]undec-7ene (DBU) was found to be the best one giving enone 134a in 95% yield.
In Scheme 5.9 we showed the application of DMDO for the epoxidation of enone
and for the oxidation of sulphide we used DMDO also. So, we envisioned a one pot
synthesis of epoxy-ketone 135 from thiol 132.
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Scheme 5.11 One pot thiol-oxidation/elimination/epoxidation
The one-pot procedure consists of the reaction of thiol 132 (1 equiv) with DMDO
(2.5 equiv). After complete consumption of starting material, the reaction mixture was
concentrated to remove acetone. The concentrate was diluted with methylene chloride (2
ml) and DBU was added dropwise at 0°C and the reaction was monitored. After
completion of the elimination reaction 1.5 equiv DMDO was added and the reaction
mixture was stirred for 15 hr at room temperature. The reaction mixture was again
concentrated and the product was extracted with ethyl acetate in pure form. The epoxyketone 135 was thus obtained in a one-pot fashion with an overall yield of 95% (Scheme
5.11).
(D) Application of tandem semi-pinacol/Beckmann rearrangements
With the straightforward synthesis of the trispiro epoxyketone in hand, we next
focused on the application of the tandem semi-pinacol/Beckmann rearrangement to
another system. The treatment of hydroxylamine hydrochloride with epoxyketone 141
afforded epoxy-oxime 142 which was further transformed into lactam 143 by a PPA
mediated

tandem

semi-pinacol/Beckmann

rearrangement;

thus

validating

our

straightforward strategy for the rapid construction of the 1-azaspriocyclic ring system
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(Scheme 5.12). The structure of lactam 143 was confirmed by X-ray crystallography
(Figure 5.4).

Scheme 5.12 Substrate Scope of tandem semi-pinacol/Beckmann rearrangement

Figure 5.4 X-ray structure of 1-azaspirocycle 143. (X-ray analysis was performed by
Dr. Sean Parkin at Department of Chemistry, University of Kentucky)
5.5. Summary
A new concise approach for the construction of 1-azaspirocyclic ring system has been
developed via tandem rearrangements of an α,β-epoxy oxime. The synthetic strategy
demonstrated the first example of tandem semi-pinacol/Beckman rearrangements and
generated a tertiary carbon center and a spirocyclic ring within a single synthetic step.
The method also highlighted an efficient one-pot reaction for the construction of highly
strained trispiro epoxyketone epoxides. Additionally, an environmentally benign,
microwave-assisted, and solvent-free self-condensation of carbonyl compounds has also
been developed.

151

5.6. Supporting Information
5.6.1. General Methods (Green Chem. 2011, 13, 1546-1549)
All reactions were carried out in flame-dried glassware under nitrogen atmosphere with
anhydrous solvent. The microwave reactions were carried out in sealed tubes in Biotage
InitiatorTM Microwave Synthesizer. Unless otherwise noted, all commercial reagents
were obtained from commercially available sources and used without purification. Flash
column chromatography was performed on a Biotage SP-1 chromatography system. TLC
plates were visualized by exposure to ultraviolet light (254 nm) and/or by immersion in a
staining solution of vanillin, followed by heating on a hot plate. Dimethyldioxirane
(DMDO) was prepared as described by Murray et al. Generally, concentrations in the
range of 0.04-0.10 M were obtained. 1H and 13C spectra were recorded using 300 or 400
or 500 MHz, using CDCl3 as a solvent. The chemical shifts are reported in parts per
million (ppm) relative to CHCl3 (δ 7.26 ppm for proton NMR and δ 77.23 ppm for carbon
NMR). Coupling constants are reported in hertz (Hz). The following abbreviations are
used to designate the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m =
multiplet.
5.6.2. Synthesis
(A) Self-condensation of ketones
Reaction Procedure A: (Green Chem. 2011, 13, 1546-1549)
To a 0.2-0.5 ml microwave vial containing ketone (1 mmol) was added anhydrous
LiClO4 (0.043 g, 40 mol %) and Et 3N (0.056 mL, 40 mol %). The vial was sealed and
the reaction mixture was stirred for 20 min. at 120 °C (or as specified conditions) in
the microwave reactor. After cooling, the microwave vessel was uncapped and 15mL
of sat. NH4Cl was added. The product was extracted with (2x20 mL) ethyl acetate.
The organic layer was dried over MgSO 4, filtered, and evaporated to dryness under
reduced pressure to obtain the crude. All the liquid products were purified using
distillation while the solid products were purified either by crystallization or by silica
gel column chromatography.
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Self-condensation of cyclopentanone: (Green Chem. 2011, 13, 1546-1549)

Reaction procedure A was followed to obation crude. The crude was distilled to
obtain the enone 104 (80%) as colorless liquid, while the remaining solid was
crystalized using hexane-ethyl acetate (3:1) to yield 105 in pure form.
2-cyclopentylidenecyclopentan-1-one (104): IR (ν, cm-1): 2955, 2870, 1706, 1636,
725;

1

H NMR (500 MHz, CDCl 3): δ 2.77 (m, 2H), 2.51 (m, 2H), 2.29 (m, 4H),

1.90 (m, 2H), 1.76-1.64 (m, 4H);

13

C NMR (125 MHz, CDCl 3): δ 207.6, 158.8, 128.1,

40.0, 34.5, 32.7, 27.2, 26.9, 25.4, 20.3.
2,5-Dicyclopentylidenecyclopentaone (105): White solid; mp=83-84 °C; IR (ν, cm-1):
2952, 2862, 1689, 1637, 1617, 1260, 1173, 767; 1H NMR (500 MHz, CDCl3): δ 2.87 (t, J
= 6.5 Hz, 4H), 2.52 (bs, 4H), 2.28 (t, J = 6.5 Hz, 4H), 1.76-1.64 (m, 8H); 13C NMR (125
MHz, CDCl3): δ 196.06, 157.76, 131.37, 34.31, 32.45, 27.32, 26.16, 25.47.
Self-condensation of 1-indanone: (Green Chem. 2011, 13, 1546-1549)

Reaction procedure A was followed to obtain solid crude. 1H NMR of crude product
showed the formation of very small amount of 110. The crude was crystallized using
hexane-ethyl acetate (3:1) to obtain 110 (73%) in pure form (compound 111 was not
isolated).
trans-2-(1-indanylidene)indan-1-one (110): White solid; mp=143-144 °C; IR (ν, cm-1):
3064, 2918, 1673, 1597, 1325, 733; 1H NMR (500 MHz, CDCl3): δ 7.83 (d, J = 7.5 Hz,
1H), 7.82 (d, J = 7.5 Hz, 1H), 7.60-7.80 (m, 2H), 7.44-7.34 (m, 4H), 4.03 (s, 2H), 3.58 (t,
J = 6.5 Hz, 2H), 3.14 (t, J = 6.5 Hz, 2H); 13C NMR (125 MHz, CDCl3): δ 195.5, 155.3,
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151.9, 148.7, 141.1, 139.8, 133.8, 130.6, 127.5, 127.1, 126.5, 126.2, 126.2, 126.0, 123.8,
33.3, 31.8, 31.2.
Self-condensation of 5,6-dimethoxy-1-indanone: (Green Chem. 2011, 13, 15461549)

Reaction procedure A was followed to obtain solid. Purification of silica gel (50%
EtOAc/hexane) afforded 113 in 70% yield.
Dione 113: Yellow solid; IR (ν, cm-1): 3064, 2918, 1673, 1597, 1325, 733; 1H NMR (500
MHz, CDCl3): δ 7.29 (s, 1H), 7.27 (s, 1H), 7.18 (s, 1H), 7.00 (s, 1H), 4.00 (s, 3H), 3.97
(s, 3H), 3.95 (s, 6H), 3.91 (s, 2H), 3.57 (t, J = 6.0 Hz, 2H), 2.68 (t, J = 6.0 Hz, 2H); 13C
NMR (125 MHz, CDCl3): δ 194.2, 154.5, 154.4, 151.9, 149.5, 148.7, 143.0, 133.4, 108.1,
107.8, 107.7, 107.3, 105.2, 104.7, 104.3, 56.4, 56.3, 56.3, 56.2, 32.5, 32.3, 31.1.
Self-condensation of 2-indanone: (Green Chem. 2011, 13, 1546-1549)

Reaction procedure A was followed to obtain solid crude. Purification by silica gel
(3% EtOAc/hexane) afforded dione 115 in 71% yield and 116 in 8% yield.
Dione (115): Yellow solid; mp=160-162 °C, IR (ν, cm-1): 3027, 2906, 1707, 1625, 1393,
731; 1H NMR (500 MHz, CDCl3): δ 7.63 (d, J = 5.0 Hz, 1H), 7.42-7.38 (m, 4H), 7.33 (d,
J = 10.0 Hz, 1H), 7.28-7.26 (m, 2H), 4.42 (s, 2H), 4.01 (s, 2H), 3.51 (s, 2H);

13

C NMR

(125 MHz, CDCl3): δ 204.3, 154.4, 141.4, 140.4, 139.5, 137.6, 129.9, 127.7, 127.5,
127.3, 126.9, 125.4, 124.9, 124.6, 123.7, 42.6, 41.5, 41.0.
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Compound (116): Green solid; mp=178-180 °C, IR (ν, cm-1): 3022, 2900, 1700,
1625, 1390, 722; 1H NMR (500 MHz, CDCl 3): δ 7.69 (m, 2H), 7.41 (m, 6H), 7.27 (m,
4H), 4.58 (s, 4H), 4.25 (s, 4H).
Self-condensation of 1,3-indandione: (Green Chem. 2011, 13, 1546-1549)

Reaction procedure A was followed for only 5 minutes to obtain solid crude and crude
was crystallized using hexane-ethyl acetate (3:1) to obtain 118 (92%) in pure form.
When the reaction was conducted for 20 min, truxenequinone 119 was obtained in 55%
yield while compound 118 was obtained in 25% yield by column chromatography (5%
Ethyl acetate/hexane).
1-(indan-1,3-dione-2-ylidene)indan-3-one (118): Yellow solid; IR (ν, cm-1): 3020,
2901, 1707, 1680, 1340, 931; 1H NMR (500 MHz, CDCl3): δ 9.64 (d, J=8.0 Hz, 1H),
8.00 (m, 1H), 7.96-7.90 (m, 2H), 7.88-7.74 (m, 3H), 7.72 (1.75, J=6.5Hz, 1H), 4.11 (s,
2H);

13

C NMR (125 MHz, CDCl3): δ 201.1, 191.2, 189.5, 155.5, 146.1, 141.8, 141.4,

140.6, 135.5, 134.3, 131.8, 126.0, 123.7, 123.6, 123.2, 43.6.
Truxenequinone (119): Yellow solid; 1H NMR (500 MHz, CDCl3): δ 9.30 (d, J= 10 Hz,
3H), 7.87 (d, J= 10.0 Hz, 3H), 7.72 (t, J = 10.0 Hz, 3H), 7.85 (t, J = 10.0 Hz, 3H).
Self-condensation of cyclohexanone: (Green Chem. 2011, 13, 1546-1549)

Reaction procedure A was followed to obtain crude as yellow oil. The crude was distilled
to obtain 121 (50%) and 122 (2%) in pure form.
[1,1'-bi(cyclohexylidene)]-2-one (121): Colorless oil; IR (ν, cm-1): 2922, 2851, 1675,
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1639, 1444, 729; 1H NMR (500 MHz, CDCl 3): δ 5.38 (t, J=10 Hz, 1H), 2.88 (dd,
J=11.2 and 5.0Hz, 1H), 2.42-2.36 (m, 1H), 2.34-2.26 (m, 1H), 2.06-1.96 (m, 4H),
1.96-1.80 (m, 4H), 1.74-1.52 (m, 6H);

13

C NMR (125 MHz, CDCl 3): δ 211.8, 136.1,

123.8, 58.9, 42.3, 31.0, 27.8, 27.5, 25.5, 25.1, 23.1, 22.6.
1'-hydroxy-[1,1'-bi(cyclohexan)]-2-one (122): Colorless oil; IR (ν, cm-1): 3300,
1670, 1429; 1H NMR (500 MHz, CDCl3): δ 3.64 (s, 1H), 2.39 (dd, J=12.0 and 5Hz,
1H), 2.36-2.28 (m, 2H), 2.22-2.16 (m, 1H), 2.10-2.04 (m, 1H), 1.96-1.90 (m, 1H),
1.74-1.54 (m, 8H), 1.46-1.38 (m, 3H), 1.30-1.12 (m, 2H);

13

C NMR (125 MHz,

CDCl3): δ 216.6, 72.2, 59.2, 44.1, 36.5, 33.5, 29.2, 28.5, 26.1, 25.7, 21.9, 21.6.
Self-condensation of β-tetralone: (Green Chem. 2011, 13, 1546-1549)

Reaction procedure A was followed to obtain solid crude and crude was crystallized
using hexane-ethyl acetate (3:1) to obtain 19 (61%) in pure form.
1',3,4,4'-tetrahydro-[1,2'-binaphthalen]-2(1H)-one (124): White solid; IR (ν, cm-1):
2918, 2842, 1678, 1629, 1451, 780; 1H NMR (500 MHz, CDCl 3): δ 7.30-7.20 (m, 3
H), 7.15-7.05 (m, 4H), 6.97 (d, J=6.0 Hz, 1H), 6.27 (s, 1H), 3.68 (s, 2H), 3.36-3.26
(m, 2H), 3.13 (dd, J=14.0, 4.5 Hz, 1H), 2.90-2.68 (m, 2H), 2.36-2.18 (m, 2H);

13

C

NMR (125 MHz, CDCl 3): δ 209.6, 138.2, 136.1, 134.9, 134.2, 133.1, 128.2, 127.9,
127.4, 127.2, 127.1, 127.0, 126.6, 126.1, 125.7, 55.4, 45.2, 33.7, 28.2, 26.1.
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Self-condensation of 3,3-dimethylcyclohexenone: (Green Chem. 2011, 13, 15461549)

Reaction procedure A was followed to obtain crude. Purification of silica gel (3%
EtOAc/hexane) afforded a mixture of (126) and (126) as colorless oil (40% yield); 1H
NMR (500 MHz, CDCl 3): δ 7.11 (d, J = 10.0 Hz, 1H), 6.57 (d, J = 2.5 Hz, 1H), 6.55
(d, J = 2.5 Hz, 1H), 6.33 (d, J = 10.0 Hz, 1H), 5.93 (d, J = 10.0 Hz, 1H), 5.89 (d, J =
1.5 Hz, 1H), 5.87 (d, J = 1.5 Hz, 1H), 5.79 (d, J = 10.5 Hz, 1H), 2.86 (t, J = 6.5 Hz, 2
H), 2.60 (s, 2H), 2.57 (s, 2H), 2.44 (t, J = 6.5 Hz, 2H), 1.62 (t, J = 7.0 Hz, 2H), 1.52
(t, J = 7.0 Hz, 2H), 1.13 (s, 6H), 1.12 (s, 6H), 1.04 (s, 6H), 1.03 (s, 6H);

13

C NMR

(125 MHz, CDCl 3): δ 192.2, 191.9, 157.3, 157.2, 147.5, 145.3, 143.0, 142.2, 129.8,
129.6, 127.3, 126.9, 123.9, 122.6, 42.3, 41.5, 36.9, 36.6, 36.2, 35.8, 32.4, 32.2, 28.6,
28.5, 27.9, 27.9, 25.0, 24.2.
Self-condensation of 4-methylacetophenone (Table V, Entry 8):

Reaction procedure A was followed to obtain crude. The condensation product was
isolated by column chromatography on silica gel (3% EtOAc/hexane). 1H NMR (500
MHz, CDCl3): δ 8.01 (d, J=5.0 Hz, 2H), 7.59 (d, J=5.0 Hz, 2H), 7.37 (d, J=8.0 Hz, 2H),
7.33 (d, J=8.0 Hz, 2H), 2.69 (s, 3H), 2.52 (s, 3H), 2.50 (s, 3H);

13

C NMR (75 MHz,

CDCl3): δ 191.6, 163.8, 154.5, 143.2, 139.9, 139.3, 136.9, 129.4, 129.3, 128.5, 126.5,
121.5, 21.9, 21.5, 19.0.
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(B) Self-condensation of aldehydes
Reaction Procedure B: (Green Chem. 2011, 13, 1546-1549)
To a 0.2-0.5 ml microwave vial containing substrate (1mmol) was added anhydrous
LiClO4 (0.043 g, 40 mol %) and Et 3N (0.056 ml, 40 mol %). The vial was sealed and
the reaction mixture was stirred for 20 min. at 120 °C in microwave reactor. After
cooled to ambient temperature, saturated NH 4Cl (10 ml) was added and extraction
was done using ether. The organic layer was dried over MgSO4, filtered, and
evaporated to dryness under reduced pressure to obtain crude. The condensation
product was purified by distillation.
Self-condensation of heptanal (Table V, Entry 1): (Green Chem. 2011, 13, 15461549)
1

H NMR (500 MHz, CDCl 3): δ 9.35 (s, 1H), 6.43 (t, J=7.5 Hz, 1H), 2.36 (m, 2H),

2.22 (t, J=7.4 Hz, 2H), 1.36-1.22 (m, 10H), 0.92-0.84 (m, 6H);

13

C NMR (125 MHz,

CDCl3): δ 195.4, 155.4, 143.9, 31.9, 31.8, 29.1, 29.0, 28.7, 28.6, 24.0, 22.7, 22.4,
14.1, 14.1.
Self-condensation of hexanal (Table V, Entry 2): (Green Chem. 2011, 13, 15461549)
1

H NMR (500 MHz, CDCl 3): δ 9.36 (s, 1H), 6.44 (t, J=7.5 Hz, 1H), 2.40-2.16 (m,

4H), 1.60-1.25 (m, 10 H), 0.92-0.88 (m, 6H);

13

C NMR (125 MHz, CDCl 3): δ 195.5,

155.5, 143.8, 31.7, 31.1, 29.0, 28.5, 23.8, 22.9, 22.5, 14.0, 13.8.
Self-condensation of pentanal (Table V, Entry 3): (Green Chem. 2011, 13, 15461549)
1

H NMR (500 MHz, CDCl 3): δ 9.36 (s, 1H), 6.48 (t, J=7.5 Hz, 1H), 2.35 (m, 2H),

2.21 (t, J=7.5 Hz, 2H), 1.54-1.26 (m, 6H), 0.94-0.88 (m, 6H);

13

C NMR (125 MHz,

CDCl3): δ 195.4, 155.6, 143.7, 31.0, 28.8, 26.1, 22.6, 22.1, 14.2, 14.1.
Self-condensation of butanal (Table V, Entry 4): (Green Chem. 2011, 13, 15461549)
1

H NMR (500 MHz, CDCl 3): δ 9.35 (s, 1H), 6.40 (t, J=7.5 Hz, 1H), 2.35 (t, J=7.5 Hz,
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2H), 2.24 (q, J=7.5 Hz, 2H), 1.54 (m, 2H), 1.0-0.92 (m, 6H);

13

C NMR (125 MHz,

CDCl3): δ 195.1, 154.6, 145.4, 30.7, 22.0, 17.2, 13.9, 13.4.
Self-condensation of isovaleraldehyde (Table V, Entry 5): (Green Chem. 2011, 13,
1546-1549)
1

H NMR (500 MHz, CDCl 3): δ 9.31 (s, 1H), 6.33 (t, J=7.5 Hz, 1H), 2.90-2.80 (m,

1H), 2.5 (t, J=7.5 Hz, 2H), 1.82-1.75 (m, 1H), 1.15 (d, J=7 Hz, 6H), 0.95 (d, J=7 Hz,
6H); 13C NMR (125 MHz, CDCl 3): δ 195.6, 152.9, 137.1, 46.3, 43.7, 41.8, 37.6, 33.5.
Self-condensation of phenylacetaldehyde (Table V, Entry 6): (Green Chem. 2011,
13, 1546-1549)
1

H NMR (500 MHz, CDCl 3): δ 9.45 (s, 1H), 7.30-7.10 (m, 10H), 6.65 (t, J=7.4, 1H),

3.42 (d, J=7 Hz, 2H);

13

C NMR (125 MHz, CDCl 3): δ 195.1, 154.7, 142.6, 140.4,

128.8, 128.5, 128.4, 128.3, 128.2, 128.1, 126.3, 126.0, 35.0.
Self-condensation of 3-phenyl propionaldehyde (Table V, Entry 7): (Green Chem.
2011, 13, 1546-1549)
1

H NMR (500 MHz, CDCl 3): δ 9.45 (s, 1H), 7.32-7.10 (m, 10H), 6.65 (t, J=7.0, 1H),

3.58 (s, 2H), 2.80-2.70 (m, 4H);

13

C NMR (125 MHz, CDCl 3): δ 194.8, 155.1, 142.7,

140.5, 139.0, 128.6, 128.5, 128.5, 128.3, 126.4, 126.2, 34.4, 31.1, 29.6.
Note: All the spectral data of self-condensation of aldehydes are consistent with the
data given in Green Chem., 2010, 12, 384-386.
(C) Synthesis spirocyclic ring systems
Preparation of 2-Cyclopentylidenecyclopentan-1-one Oxide (128)
To a solution of 104 (0.779 g, 5.2 mmol) in CH2Cl2 (5 ml) was added
rapidly a solution of 0.053 M DMDO in acetone (28 ml, 1.5 eq) under
nitrogen. The reaction mixture was stirred at room temperature for 15 h.
The solvent was removed in vacuo and extraction was done using CH2Cl2
to obtain epoxide 128 (0.846 g, 98%) as colorless oil. IR (ν, cm-1): 2962, 2871, 1746,
1406, 1206, 1164, 960; 1H NMR (500 MHz, CDCl3): δ 2.42-2.28 (m, 2H), 2.19-2.02 (3H,
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m, 3H), 1.96-1.50 (m, 9H); 13C NMR (125 MHz, CDCl3): δ 214.5, 76.9, 68.1, 37.3, 32.1,
29.7, 27.5, 25.6, 25.0, 18.1.
Preparation of (1E)-11-oxadispiro[4.0.4.1]undecan-1-one oxime (129)
Epoxide 128 (0.392 g, 2.4 mmol) was treated with NH2OH.HCl (1.1
equiv) and sodium acetate (2.2 equiv) in methanol (10ml/g of
NH2OH.HCl) at 0oC for 1hr. CH2Cl2 was added and aqueous phase was
extracted several times with CH2Cl2. The combined aqueous phases
were washed with brine and dried over MgSO4, filtered, and evaporated to dryness under
reduced pressure to yield 129 (0.421 g, 97%) as white solid. NMR of crude suggested
that no further purification is required. In order to get mp of the compound
recrystallization was done with hot hexane. mp: 115-117 °C; IR (ν, cm-1 ) : 3224, 2960,
1469, 1428, 930, 754; 1H NMR (500 MHz, CDCl3): δ 2.66 ̶ 2.42 (m, 2H), 1.44 ̶ 2.20
(15H, m); 13C NMR (125 MHz, CDCl3): δ 161.4, 76.4, 68.2, 32.3, 30.4, 30.3, 26.8, 25.5,
25.3, 19.9.

Preparation of (1E)-spiro[4.5]decane-1,6-dione 1-oxime (130)
To a solution of oxime 129 (0.181 g, 1.0 mmol) in 5 ml CH2Cl2, Sc(OTf)3
(0.049 g, 0.1 eq) was added. The reaction mixture was stirred for 4h at
room temperature and 20 ml of saturated NaHCO3 solution was added to
quench the reaction. The product was extracted with 2 x 50 ml ethyl ether.
The organic phase was washed with 50 ml brine and dried (MgSO4). The solvent was
then removed, and recrystallization of the crude from a hot solution of hexane-CH2Cl2
(5:1) yielded ketoxime 130 (0.165 g, 91%). mp: 94-95 °C; IR (ν, cm-1): 3284, 2948, 1704,
1451, 1416, 906; 1H NMR (500 MHz, CDCl3): δ 9.20 (bs, 1H), 2.62 ̶ 2.52 (m, 1H), 2.52 ̶
2.28 (m, 3H), 2.08 ̶ 1.98 (m, 1H), 1.98 ̶ 1.84 (m, 1H), 1.84 ̶ 1.70 (m, 2H), 1.70 ̶ 1.44 (m,
6H);

13

C NMR (125 MHz, CDCl3): δ 210.8, 167.8, 60.1, 39.5, 37.2, 36.8, 27.7, 27.0,

21.8, 21.2.
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Preparation of 1-azaspiro[5.5]undecane-2,7-dione (10)
A viscous mixture of 0.050 g (0.28 mmol) of epo-oxime 130 and 1.0 g of
PPA was heated at 130°C for 5 min. The mixture was cooled and the
viscous oil was allowed to stand at room temperature overnight, and then
diluted with ice water. Neutralization was done with 30ml of 50%
sodium hydroxide with cooling. The product was separated with CHCl3 and
recrystallization from CHCl3 gave 1-azaspirolactam 131 (0.042 g, 84%). mp: 152-154 °C;
IR (ν, cm-1): 3183, 2928, 1712, 1650, 1407; 1H NMR (500 MHz, CDCl3): δ 6.35 (bs,
1H), 2.54-2.46 (m, 2H), 2.34-2.24 (m, 2H), 2.18-2.10 (m, 1H), 2.10-2.00 (m, 2H), 1.901.54 (m, 7H); 13C NMR (125 MHz, CDCl3): δ 209.7, 172.4, 65.4, 40.9, 38.7, 30.9, 29.4,
27.4, 21.8, 17.2.

Preparation of 2-(1-(ethylthio)cycloheptyl)cyclopentanone (132a)

To a round bottom flask containing 20 ml of anhydrous CH2Cl2 at -60°C, SnCl4 (10 ml, 1
M in CH2Cl2) was added. A cooled (-60°C) solution of cycloheptane-1,1diylbis(ethylsulfane) (2.18 g, 10.0 mmol) in 5 ml anhydrous CH2Cl2 was added dropwise.
Immediately, a cooled (-60°C) solution of (cyclopent-1-en-1-yloxy)trimethylsilane
(1.56g, 10.0 mmol) in 5.0 ml CH2Cl2. After stirring the reaction mixture at -60°C for 45
min, reaction was quenched with 100 ml ice water. Extraction was done using CH2Cl2
and organic layer was washed with 10% aqueous NaHCO3 (100 ml), water (100 ml) and
dried over MgSO4. The filtrate was concentrated under reduced pressure to obtain
compound 132a (2.1 g, 87% yield); IR (ν, cm-1): 2926, 2864, 1694, 1447; 1H NMR (500
MHz, CDCl3): δ 2.44 (m, 2H), 2.30-2.22 (m, 3H), 2.20-2.12 (m, 3H), 2.00 (m, 1H), 1.92
(m, 1H), 1.85 (m, 1H), 1.72-1.56 (m, 6H), 1.52-1.42 (m, 4H), 1.14 (t, J=7.5 Hz, 3H); 13C
NMR (125 MHz, CDCl3): δ 219.3, 56.5, 54.8, 41.4, 39.2, 36.4, 29.9, 29.5, 27.2, 23.1,
23.1, 22.5, 20.4, 14.5.
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Preparation of 2-cycloheptylidenecyclopentanone (133a)
To a solution of compound 132a (0.24 g, 1 mmol) in MeOH-H2O (9:1,
10 ml), NaIO4 (1.0 mmol) was added. The reaction mixture was stirred
in the dark for 16 h, water (15 ml) was added and extraction was done
with CH2Cl2. The organic phase was dried and concentrated to give a
mixture of sulphoxide and eliminated products. The crude was warmed in CCl4 at 60 °C
for 24h and chromatography on silica gel (99:1 hexane/EtOAc) yielded 133a (0.11 g,
62%). IR (ν, cm-1): 2926, 2854, 1702, 1620, 1447, 1250, 1173, 1083; 1H NMR (500
MHz, CDCl3): δ 2.97 (t, J=5.5 Hz, 2H), 2.59 (t, J=7.5 Hz, 2H), 2.32 (t, J=8 Hz, 4H),
1.86 (m, 2H), 1.68-1.58 (m, 4H), 1.54-1.48 (m, 4H); 13C NMR (125 MHz, CDCl3): 206.6,
156.7, 129.8, 40.2, 35.2, 30.3, 29.3, 29.1, 28.8, 26.8, 25.8, 19.0.
13-oxadispiro[4.0.6.1]tridecan-1-one (141)
A DMDO solution (2.5 equiv, 12.5mmol) was added to a round bottom
flask containing compound 132a (1.2 g, 5.0 mmol). The reaction
mixture was stirred and monitored with TLC using vanillin stain. After
complete consumption of SM (in 1 hr), the reaction mixture was concentrated to remove
acetone. The concentrate was diluted with methylene chloride (2 ml) and DBU (1 equiv)
was added dropwise at 0°C and the reaction was carefully monitored using TLC. After
completion of elimination reaction, 1.5 equiv DMDO solution was added and the reaction
mixture stirred for 15 hr at room temperature. The reaction mixture was concentrated and
product was extracted with methylene chloride. The oxide 141 was obtained in a one-pot
fashion with an overall yield of 92% (0.89 g). IR (ν, cm-1): 2924, 2855, 1740, 1455. 1405,
1168, 997, 751; 1H NMR (500 MHz, CDCl3): 2.44-2.28 (2H, m), 2.22-1.88 (6H, m),
1.82-1.46 (9H, m), 1.34-1.22 (1H, m);

13

C NMR (125 MHz, CDCl3): 214.1, 71.8, 69.8,

36.9, 34.7, 29.8, 29.2, 28.5, 26.6, 24.5, 24.3, 17.8.
(1E)-13-oxadispiro[4.0.6.1]tridecan-1-one oxime (142)
Epoxide 141 (0.246 g, 1.27 mmol) was treated with NH2OH.HCl
(1.1equiv) and sodium acetate (2.2 equiv) in methanol (10ml/g of

162

NH2OH.HCl) at 0°C. After stirring the reaction mixture at 0°C for 30 min, CH2Cl2 was
added and aqueous phase was extracted several times with CH2Cl2. The combined
aqueous phases were washed with brine and dried over MgSO4, filtered, and evaporated
to dryness under reduced pressure to yield 142 (0.252, 95% yield); IR (ν, cm-1): 3120,
2919, 2852, 1448, 960; 1H NMR (500 MHz, CDCl3): 8.45 (1H, bs), 2.74-2.64 (m, 1H),
2.54-2.46 (m, 1H), 2.04-1.34 (16H, m); 13C NMR (125 MHz, CDCl3): 161.6, 70.9, 70.4,
35.0, 30.7, 29.5, 29.4, 28.8, 26.2, 24.7, 24.5, 19.8.
1-azaspiro[5.7]tridecane-2,7-dione (143)
A viscous mixture of 0.037g (0.18 mmol) of epoxy-oxime 142 in 1
g of PPA was heated at 130°C for 5 min with manual stirring. The
mixture was cooled and the viscous oil was allowed to stand at
room temperature overnight, and then diluted with ice water.
Neutralization was done with 30ml of 50% sodium hydroxide with
cooling.

The

product

was

separated

with

CHCl3

and

recrystallization from CHCl3 gave lactam 143 (0.030g, 80% yield); IR (ν, cm-1): 3211,
2932, 1702, 1655, 1403; 1H NMR (500 MHz, CDCl3): δ 6.02 (s, 1H), 2.72 (td, J = 11 Hz,
J = 4 Hz, 1H), 2.44-2.24 (m, 4H), 1.96-1.84 (m, 3H), 1.84-1.68 (m, 4H), 1.68-1.42 (m,
4H), 1.40-1.24 (m, 1H), 1.02-0.88 (m, 1H); 13C NMR (125 MHz, CDCl3): δ 214.7, 172.6,
66.5, 36.7, 34.8, 30.9, 30.8, 30.1, 25.9, 24.4, 22.8, 17.3.
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5.6.3. Copies of 1H and 13C NMR spectra (Green Chem. 2011, 13, 1546-1549)
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